Anti-CD147 antibody

A CD147-specific antibody activates signal transduction to inhibit cancer cell proliferation and metastasis, providing a novel and effective treatment for pancreatic and liver cancers with improved safety.

JP2024160262AInactive Publication Date: 2024-11-13DAIICHI SANKYO CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024122924
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-07-27
Filing Date
2024-07-30
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments for pancreatic and liver cancers, such as pancreatic cancer and liver cancer, are not effective due to high recurrence rates and lack of sensitivity to conventional drugs, necessitating the development of novel antitumor agents with high efficacy and safety.

Method used

Development of a CD147-specific antibody that activates CD147-mediated signal transduction, leading to antitumor effects without relying on effector functions, thereby inhibiting cancer cell proliferation and metastasis.

Benefits of technology

The CD147 antibody exhibits significant antitumor activity in pancreatic and liver cancer cells, outperforming standard treatments like sorafenib and gemcitabine, and is safe due to minimal impact on immune cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160262000009
    Figure 2024160262000009
  • Figure 2024160262000010
    Figure 2024160262000010
  • Figure 2024160262000011
    Figure 2024160262000011
Patent Text Reader

Abstract

To provide a novel anti-CD147 antibody that shows excellent anti-tumor activity and has excellent safety, a medicine containing such an antibody, and a method for treating a tumor using the antibody or the medicine.SOLUTION: Provided are: a CD147-specific antibody that activates CD147 and shows a high anti-tumor effect; an anti-CD147 antibody that shows a high anti-tumor effect without depending on an effector function; a pharmaceutical composition containing such an anti-CD147 antibody; and a method for treating a tumor using such an anti-CD147 antibody and / or pharmaceutical composition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an anti-CD147 antibody that exhibits excellent antitumor activity, and a method for producing the anti-CD147 antibody. It also relates to an antitumor agent containing said anti-CD147 antibody. [Background technology]

[0002] With the advancement of cancer treatments and drugs, cancers that were once considered incurable are now treatable and curable. It has been discovered that the antibody drug has excellent drug stability and specificity. The CTLA4 and PD1 antibodies activate immune cells, including T cells, and inhibit the proliferation of melanoma. It has a high response rate and in some cases a cure for cancer patients, including laminar cancer and some solid tumors. These drugs have been tried to treat many refractory solid tumors. However, most cancers such as pancreatic and liver cancers are not sensitive to drugs and can be cured by surgery. Even with conventional cancer removal or conventional anticancer drug-based treatment, there is a high rate of recurrence, and a cure is urgently needed. There is a need for treatments and medications.

[0003] CD147 is a single-pass transmembrane protein with two to three immunoglobulin-like domains. Interaction between CD147, CD44, integrin family molecules, CD98, V Extracellular factors involved in proliferation, invasion, and inflammation, such as EGFR, CypA / B, and MCT1 / 3 / 4 By interacting with molecules on the cell membrane, downstream signaling-related molecules such as FAK, MEK, and E rk, JAK / STAT, AKT, MAPK family molecules are activated, and MMP and other It is known that the production of proteases, which are involved in the proliferation, metastasis, and invasion of cancer cells, promotes the In patients with liver cancer and pancreatic cancer, high expression of CD147 is associated with short survival and poor prognosis. It has been reported that this is a potential therapeutic target for cancer.

[0004] Antibodies targeting CD147 include ABX-CBL and Licartin, which are in clinical use. ABX-CBL inhibits the binding of CD147 to cyclophilin A. Not only does it inhibit T cell activity by inhibiting T cell proliferation, but it also inhibits CD147-positive T cells in the blood in a complement-dependent manner. It has cytotoxic activity against normal cells, including erythrocytes. Clinical trials are currently being conducted for the treatment of GVHD. However, the efficacy was insufficient and severe muscle pain was observed, so approval as a drug was not possible. This has not yet been achieved (Patent Document 1, Non-Patent Document 1).

[0005] Licartin is a radioisotope that binds iodine to the Fab'2 portion of the HAb18 antibody. It is a biological drug containing I-131 and has been approved in China for use in the treatment of liver cancer. (Non-Patent Document 2, Non-Patent Document 3). Licartin activates immune cells and complement. It lacks the Fc portion of the antibody that controls liver cancer, and no immune-mediated toxicity has been reported. There have been no reported cures.

[0006] Other CD147-targeting antibodies include those that inhibit angiogenesis, VEGF production, and matrix Anti-CD147 monoclonal antibodies that block CD147-associated biological activities such as metalloproteases Clonal antibody (Patent Document 2), anti-CD147 monoclonal antibody that inhibits T cell activation and CD20 characterized by having ADCC activity and CDC activity. An antibody that specifically binds to 147 molecules is known (Patent Document 3). There are no known CD147 antibodies that have no CD147 function and exhibit antitumor effects. The relationship between activation of cell signaling pathways mediated by 7 and antitumor effects is unknown. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] WO1999 / 045031 [Patent Document 2] WO2010 / 036460 [Patent Document 3] WO2017 / 061602 [Non-patent literature]

[0008] [Non-Patent Document 1] Deeg H,et al.,J.Blood.,2052-2058,2001 [Non-Patent Document 2] Chen Z,et al.,Int.J.Radiation Oncology Biol.Phys.,435-444,2006 [Non-Patent Document 3] Xu J,et al.,Hepatology,269-276,2007 [Non-Patent Document 4] Koch C, et al., International Immunology, 777-786, 1999 Summary of the Invention [Problem to be solved by the invention]

[0009] The object of the present invention is to provide a compound having a novel pharmacological action, excellent safety, and high antitumor effect. A novel anti-CD147 antibody, a drug containing said antibody, and a tumor treatment using said antibody or drug. The present invention aims to provide a method for treating the above-mentioned condition. [Means for solving the problem]

[0010] In order to achieve the above object, the present inventors have conducted extensive research and have found that CD147-mediated related signaling The present inventors have found for the first time that activation of IL-1 is associated with antitumor effects. We succeeded in obtaining a CD147-specific antibody that activates CD147 and exhibits high antitumor effects. The antibody of the present invention has the characteristic of exhibiting a high antitumor effect independent of effector function. In addition, no antibodies have been reported to have antitumor effects that depend on effector functions. However, the antibody of the present invention does not act on T cells and PBMCs and has no effector function. It has the characteristic of exhibiting high antitumor effects without relying on cancer cells, and is expected to be safe as a pharmaceutical. The antibody of the present invention inhibits the activity of standard therapeutic drugs for liver cancer in liver cancer cells. The antibody of the present invention exhibits a significantly stronger pharmacological effect than sorafenib, which is one of the antibodies used. In pancreatic cancer cells, it is more potent than gemcitabine, which is one of the standard treatments for pancreatic cancer. Furthermore, the antibody of the present invention shows a markedly stronger efficacy than that of the antibody of the present invention in chronic myeloid leukemia cells. It is significantly more potent than imatinib, which is used as one of the standard treatments for myeloid leukemia. The present inventors have demonstrated that the CD147 antibody of the present invention inhibits p38MAPK and The present inventors also found that the present invention activates the SMAD signaling pathway. We found that CD147 antibody shows excellent antitumor effect on SMAD4-positive cells. .

[0011] The present invention includes the following inventions. [1] At least one antibody selected from the group consisting of the following (A) to (F) and a human It competes for binding to CD147 and activates signaling through CD147. A human CD147 antibody or an antigen-binding fragment thereof, comprising: (A) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 71, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 69 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (B) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 51, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (C) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 61, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 59 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (D) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 81, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 79 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (E) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 8 An antibody comprising a light chain variable region consisting of an amino acid sequence as set forth in claim 1, (F) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 20, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 18 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. [2] At least one antibody selected from the group consisting of the following (A) to (F) is bound to the antibody: The antibody binds to an epitope that activates signal transduction via CD147. A human CD147 antibody or an antigen-binding fragment thereof, (A) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 71, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 69 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (B) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 51, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (C) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 61, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 59 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (D) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 81, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 79 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. (E) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 8 An antibody comprising a light chain variable region consisting of an amino acid sequence as set forth in claim 1, (F) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 20, and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 18 An antibody comprising a light chain variable region consisting of the amino acid sequence shown. [3] The human CD147 antibody according to [1] or [2], which has reduced or no ADCC activity. An antigen-binding fragment of the antibody. [4] The human CD14 according to any one of [1] to [3], which has reduced or absent CDC activity. 7. Antibody or an antigen-binding fragment thereof. [5] The human CD11 having reduced or absent ADCP activity according to any one of [1] to [4]. 47 antibody or an antigen-binding fragment thereof.

[0012] [6] Arginine (Arg) at position 106 to glycine (Gly) at position 165 of SEQ ID NO: 3 The antibody according to any one of [1] to [5], which binds to an epitope containing a residue thereof Antigen-binding fragments of the body. [7] Arginine (Arg) at position 106 and 108 in the amino acid sequence of SEQ ID NO:3 Lysine at position 1, Alanine at position 109, and Valine at position 110 ), lysine (Lys) at position 127, serine (Ser) at position 128, and glutamate (Glu) at position 129. Glu, 130th serine (Ser), 131st valine (Val), Proline at position 132 (Pro), Proline at position 133 (Pro), and Valine at position 134 (Pro). Val, 164th glutamine (Gln) and 165th glycine (Gly) The antibody according to any one of [1] to [6], which binds to an epitope comprising each of the residues An antigen-binding fragment of the antibody. [8] The heavy chain sequence comprises a variable region having CDRH1, CDRH2 and CDRH3, DRH1 consists of the amino acid sequence shown in SEQ ID NO: 75, and said CDRH2 consists of the amino acid sequence shown in SEQ ID NO: 7 6, and said CDRH3 comprises the amino acid sequence shown in SEQ ID NO: 77. consisting of an acid sequence; and The light chain sequence comprises a variable region having CDRL1, CDRL2 and CDRL3, L1 consists of the amino acid sequence shown in SEQ ID NO: 72, and said CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 73. and said CDRL3 comprises the amino acid sequence shown in SEQ ID NO: 74. Consisting of a column; The antibody or antigen-binding fragment thereof according to any one of [1] to [7], [9] The amino acid sequence of SEQ ID NO: 143, or the sequence of SEQ ID NO: 143, Binds to an epitope containing an amino acid sequence in which one or more amino acids have been deleted, substituted, or added, The antibody or antigen-binding fragment of the antibody according to any one of [1] to [5].

[10] The heavy chain sequence comprises a variable region having CDRH1, CDRH2 and CDRH3, DRH1 consists of the amino acid sequence shown in SEQ ID NO:55, and said CDRH2 consists of the amino acid sequence shown in SEQ ID NO:5 6, and said CDRH3 comprises the amino acid sequence shown in SEQ ID NO:57. consisting of an acid sequence; and The light chain sequence comprises a variable region having CDRL1, CDRL2 and CDRL3, L1 consists of the amino acid sequence shown in SEQ ID NO:52, and said CDRL2 consists of the amino acid sequence shown in SEQ ID NO:53. and said CDRL3 comprises the amino acid sequence shown in SEQ ID NO:54. Consisting of a column; 10. The antibody or antigen-binding domain of the antibody according to any one of [1] to [5] or [9], sexual fragment.

[0013]

[11] The heavy chain sequence comprises a variable region having CDRH1, CDRH2 and CDRH3, DRH1 consists of the amino acid sequence shown in SEQ ID NO: 65, and said CDRH2 consists of the amino acid sequence shown in SEQ ID NO: 6 6, and said CDRH3 comprises the amino acid sequence shown in SEQ ID NO:67. consisting of an acid sequence; and The light chain sequence comprises a variable region having CDRL1, CDRL2 and CDRL3, L1 consists of the amino acid sequence shown in SEQ ID NO: 62, and said CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 63. and said CDRL3 comprises the amino acid sequence shown in SEQ ID NO: 64. Consisting of a column; 10. The antibody or antigen-binding domain of the antibody according to any one of [1] to [5] or [9], sexual fragment.

[12] The heavy chain sequence comprises a variable region having CDRH1, CDRH2 and CDRH3, DRH1 consists of the amino acid sequence shown in SEQ ID NO: 85, and said CDRH2 consists of the amino acid sequence shown in SEQ ID NO: 8 6, and said CDRH3 comprises the amino acid sequence shown in SEQ ID NO: 87. consisting of an acid sequence; and The light chain sequence comprises a variable region having CDRL1, CDRL2 and CDRL3, L1 consists of the amino acid sequence shown in SEQ ID NO: 82, and said CDRL2 consists of the amino acid sequence shown in SEQ ID NO: 83. and said CDRL3 comprises the amino acid sequence shown in SEQ ID NO: 84. Consisting of a column; 10. The antibody or antigen-binding domain of the antibody according to any one of [1] to [5] or [9], sexual fragment.

[13] An antigen-binding fragment of the antibody described in any one of [1] to

[0012] , selected from the group consisting of Fab, F(ab')2, Fab' and Fv.

[14] The antibody according to any one of [1] to

[12] , which is an scFv.

[15] The antibody molecule according to any one of [1] to

[12] , which is a chimeric antibody. is an antigen-binding fragment of the antibody.

[0014]

[16] The antibody molecule according to any one of [1] to

[12] , characterized in that it is humanized. is an antigen-binding fragment of the antibody.

[17] The heavy chain is a human immune globulin G1 heavy chain, a human immune globulin G2 heavy chain, or a human immune globulin G3 heavy chain. The heavy chain contains the constant region of the human immunoglobulin G4, and the light chain contains the constant region of the human immunoglobulin κ light chain. The antibody according to any one of claims 1 to 16.

[18] The antibody described in

[17] , wherein the heavy chain contains the constant region of human immunoglobulin G4 heavy chain.

[19] In the constant region of the human immunoglobulin G4 heavy chain, the 2 The 28th serine (Ser) is replaced by proline (Pro), as described in

[18] . antibody.

[20] In the constant region of the human immunoglobulin G4 heavy chain, the 2 The 34th phenylalanine (Phe) is replaced by alanine (Ala), and the 235th An antibody in which leucine (Leu) is replaced by alanine (Ala)

[18] .

[0015] [twenty one] In the constant region of the human immunoglobulin G4 heavy chain, the 2 The 28th serine (Ser) is replaced by proline (Pro), and the 234th phenyl Phe is replaced by alanine (Ala), and leucine (Leu) is replaced by 235th leucine (Leu ) is replaced by alanine (Ala). [twenty two] The antibody described in

[17] , wherein the heavy chain contains the constant region of human immunoglobulin G2 heavy chain. [twenty three] The antibody has the following (c) and (d) and activates signal transduction via CD147. A human CD147 antibody or an antigen-binding fragment thereof, characterized in that: (c) A heavy chain copolymer according to any one of the following (c1) to (c4): Variable area: (c1) amino acid residues 20 to 136 of the amino acid sequence shown in SEQ ID NO: 135 a heavy chain variable region consisting of: (c2) amino acid residues 20 to 136 of the amino acid sequence shown in SEQ ID NO: 147 a heavy chain variable region consisting of: (c3) A framework region other than each CDR sequence in the sequence of (c1) or (c2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (c4) A sequence other than each CDR sequence in any one of (c1) to (c3). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. amino acid sequence, and (d) A light chain variable molecule selected from the group consisting of the following (d1) to (d5): Variable area: (d1) the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO: 137 a light chain variable region consisting of: (d2) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 149 a light chain variable region consisting of: (d3) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 151 a light chain variable region consisting of: (d4) In any one of the sequences (d1) to (d3), a sequence other than each CDR sequence Amino acids with at least 95% sequence identity to the framework region sequences Sequence; and (d5) A sequence other than each CDR sequence in any one of (d1) to (d4). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. Amino acid sequence. [twenty four] A heavy chain consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 135. The chain variable region and the amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO: 137

[23] The antibody or antigen-binding fragment thereof according to

[23] , which contains a light chain variable region consisting of acid residues. .

[0016] [twenty five] A duplicate consisting of the 20th to 463rd amino acid residues of the amino acid sequence shown in SEQ ID NO: 135. and the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 137. The antibody or antigen-binding fragment of the antibody according to

[23] , comprising a light chain consisting of:

[26] A heavy chain consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 147. The chain variable region and the amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO: 149

[23] The antibody or antigen-binding fragment thereof according to

[23] , which contains a light chain variable region consisting of acid residues. .

[27] A duplicate consisting of the 20th to 463rd amino acid residues of the amino acid sequence shown in SEQ ID NO: 147. and the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 149. The antibody or antigen-binding fragment of the antibody according to

[23] , comprising a light chain consisting of:

[28] A heavy chain consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 147. The chain variable region and the amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO: 151

[23] The antibody or antigen-binding fragment thereof according to

[23] , which contains a light chain variable region consisting of acid residues. .

[29] A duplicate consisting of the 20th to 463rd amino acid residues of the amino acid sequence shown in SEQ ID NO: 147. and the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 151. The antibody or antigen-binding fragment of the antibody according to

[23] , comprising a light chain consisting of:

[30] A compound that has the following (a) and (b) and activates signal transduction via CD147: A human CD147 antibody or an antigen-binding fragment thereof, characterized in that: (a) A heavy chain copolymer selected from the group consisting of the following (a1) to (a4): Variable area: (a1) amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 123 a heavy chain variable region consisting of: (a2) amino acid residues 20 to 140 of the amino acid sequence shown in SEQ ID NO: 125 a heavy chain variable region consisting of: (a3) A framework region other than each CDR sequence in the sequence of (a1) or (a2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (a4) A sequence other than each CDR sequence in any one of (a1) to (a3). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. amino acid sequence, and (b) A light chain variable fragment selected from the group consisting of the following (b1) to (b3): Variable area: (b1) the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO: 127 a light chain variable region consisting of: (b2) A sequence of the framework region other than each CDR sequence in the sequence of (b1) an amino acid sequence having at least 95% sequence identity to the (b3) A framework region other than each CDR sequence in the sequence of (b1) or (b2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[0017]

[31] A heavy chain consisting of the 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 123. or the 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 125 a heavy chain variable region consisting of amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO:127;

[30] , or an antibody according to the above item

[30] , which comprises a light chain variable region consisting of amino acid residues 111-113 and 111-114. Proto-associative fragment.

[32] A heavy chain consisting of the 20th to 466th amino acid residues of the amino acid sequence shown in SEQ ID NO: 123. or the amino acid sequence of SEQ ID NO: 125, and a heavy chain having amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 127. The antibody or antigen-binding fragment of the antibody according to

[30] , comprising a light chain consisting of the following group:

[33] Having the following (e) and (f) and activating signal transduction via CD147 A human CD147 antibody or an antigen-binding fragment thereof, characterized in that: (e) A heavy chain variable molecule selected from the group consisting of the following (e1) to (e4): Variable area: (e1) amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 129 a heavy chain variable region consisting of: (e2) amino acid residues 20 to 137 of the amino acid sequence shown in SEQ ID NO: 131 a heavy chain variable region consisting of: (e3) A framework region other than each CDR sequence in the sequence of (e1) or (e2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (e4) A sequence other than each CDR sequence in any one of (e1) to (e3). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. amino acid sequence, and (f) A light chain variant selected from the group consisting of (f1) to (f3) below: Variable area: (f1) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 133 a light chain variable region consisting of: (f2) A sequence of the framework region other than each CDR sequence in the sequence of (f1) an amino acid sequence having at least 95% sequence identity to the (f3) A framework region other than each CDR sequence in the sequence of (f1) or (f2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[34] A heavy chain consisting of the 20th to 137th amino acid residues of the amino acid sequence shown in SEQ ID NO: 129. or the 20th to 137th amino acid residues of the amino acid sequence shown in SEQ ID NO: 131 a heavy chain variable region consisting of 21 to 128 amino acids of the amino acid sequence shown in SEQ ID NO: 133;

[33] , or an antibody according to the above item

[33] , which comprises a light chain variable region consisting of amino acid residues 111-113 and 111-114. Proto-associative fragment.

[35] A duplicate consisting of the 20th to 463rd amino acid residues of the amino acid sequence shown in SEQ ID NO: 129. or the amino acid sequence of SEQ ID NO: 131, and a heavy chain comprising the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 133. The antibody or antigen-binding fragment of the antibody according to

[33] , comprising a light chain consisting of the following group:

[0018]

[36] The antibody has the following (g) and (h) and activates signal transduction via CD147. A human CD147 antibody or an antigen-binding fragment thereof, characterized in that: (g) A heavy chain copolymer according to any one of the following (g1) to (g3): Variable area: (g1) amino acid residues 20 to 138 of the amino acid sequence shown in SEQ ID NO: 139 a heavy chain variable region consisting of: (g2) A sequence of the framework region other than each CDR sequence in the sequence of (g1) an amino acid sequence having at least 95% sequence identity to the (g3) A framework region other than each CDR sequence in the sequence of (g1) or (g2). an amino acid sequence in which one or several amino acids are deleted, substituted or added in the sequence of the region; To, (h) A light chain variable molecule selected from the group consisting of the following (h1) to (h3): Variable area: (h1) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 141 a light chain variable region consisting of: (h2) A sequence of the framework region other than each CDR sequence in the sequence of (h1) an amino acid sequence having at least 95% sequence identity to the (h3) A framework region other than each CDR sequence in the sequence of (h1) or (h2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[37] A duplicate consisting of the 20th to 138th amino acid residues of the amino acid sequence shown in SEQ ID NO: 139. The chain variable region and the amino acids 21 to 128 of the amino acid sequence shown in SEQ ID NO: 141 The antibody or antigen-binding fragment of the antibody according to

[36] , which contains a light chain variable region consisting of acid residues. .

[38] A duplicate consisting of the 20th to 464th amino acid residues of the amino acid sequence shown in SEQ ID NO: 139. and the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 141. The antibody or antigen-binding fragment of the antibody according to

[36] , comprising a light chain consisting of:

[39] The human C according to any one of

[23] to

[38] , which has reduced or absent ADCC activity. D147 antibody or an antigen-binding fragment of said antibody.

[40] The human CD40 according to any one of

[23] to

[39] , which has reduced or absent CDC activity. 147 antibody or an antigen-binding fragment of said antibody.

[0019]

[41] The human C according to any one of

[23] to

[40] , which has reduced or absent ADCP activity. D147 antibody or an antigen-binding fragment of said antibody.

[42]

[41] , wherein the antibody or the antigen-binding fragment thereof is at least one of A pharmaceutical composition comprising any one of the following:

[43] The pharmaceutical composition described in

[42] , which is an antitumor agent.

[44] The pharmaceutical composition described in

[43] , wherein the tumor is a tumor expressing CD147.

[45] Tumors include pancreatic cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, breast cancer, uterine cancer, ovarian cancer, lung cancer, and lymphoma. , thyroid cancer, skin cancer, head and neck cancer, sarcoma, prostate cancer, bladder cancer, brain tumors, gastrointestinal stromal tumors (G IST), leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CL), acute lymphoblastic leukemia (CLL), acute lymphoblastic leukemia (ALL), malignant lymphoma, B-cell lymphoma The pharmaceutical composition according to

[0043] or

[44] , wherein the patient is a B-cell lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL).

[0020]

[46] Tumors include pancreatic cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, leukemia, acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (A LL), malignant lymphoma, B-cell lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma The pharmaceutical composition according to any one of

[43] to

[45] , wherein the composition is a pulmonary lymphoma (DLBCL). thing.

[47] The pharmaceutical composition described in any one of

[0043] to

[46] , wherein the tumor is a SMAD4-positive tumor or a tumor in which KLF5 expression is reduced or absent.

[48] The pharmaceutical composition according to any one of

[42] to

[47] , further comprising another antitumor agent. thing.

[49] A method for treating a patient comprising administering to the patient an antibody or an antigen-binding fragment thereof according to any one of [1] to

[41] , or a pharmaceutical composition according to any one of

[0042] to

[48] . Tumor treatment methods.

[50] The therapeutic method described in

[49] , wherein the tumor is a tumor expressing CD147.

[0021]

[51] Tumors include pancreatic cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, breast cancer, uterine cancer, ovarian cancer, lung cancer, and lymphoma. , thyroid cancer, skin cancer, head and neck cancer, sarcoma, prostate cancer, bladder cancer, brain tumors, gastrointestinal stromal tumors (G IST), leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CL), acute lymphoblastic leukemia (CLL), acute lymphoblastic leukemia (ALL), malignant lymphoma, B-cell lymphoma The method for treating B-cell lymphoma is selected from the group consisting of bronchial asthma, non-Hodgkin's lymphoma and diffuse large B-cell lymphoma (DLBCL).

[52] Tumors include pancreatic cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, leukemia, acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (A LL), malignant lymphoma, B-cell lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma The treatment method according to any one of

[49] to

[51] , wherein the cancer is DLBCL.

[53] The therapeutic method described in any one of

[0049] to

[52] , wherein the tumor is a SMAD4-positive tumor or a tumor in which KLF5 expression is reduced or absent.

[54]

[49] to

[53] , which is administered in combination with another antitumor agent. Treatment method.

[55]

[41] A method for producing a composition comprising: Polynucleotide.

[0022]

[56] The polynucleotide according to any one of the following (j1) to (j3): The polynucleotide according to

[55] , which comprises: (j1) CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 75, and CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 76 CDRH2 consisting of the amino acid sequence and CDR consisting of the amino acid sequence set forth in SEQ ID NO:77 A polynucleotide encoding H3, and the amino acid sequence set forth in SEQ ID NO: 72. CDRL1 having the amino acid sequence set forth in SEQ ID NO: 73, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 74, A polynucleotide encoding CDRL3 having the amino acid sequence set forth in (j2) A nucleic acid sequence having at least 95% sequence identity with the nucleotide sequence described in (j1). rinucleotides; and (j3) The polynucleotide according to (j1) or (j2), A polynucleotide in which a sequence has been substituted, deleted or added.

[57] The polynucleotide according to any one of the following (i1) to (i3): The polynucleotide according to

[55] , which comprises: (i1) CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 55, and CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 56 CDRH2 consisting of the amino acid sequence and CDR consisting of the amino acid sequence set forth in SEQ ID NO:57 A polynucleotide encoding H3, and the amino acid sequence set forth in SEQ ID NO:52. CDRL1 having the amino acid sequence set forth in SEQ ID NO:53, CDRL2 having the amino acid sequence set forth in SEQ ID NO:54, a polynucleotide encoding a CDRL3 consisting of the amino acid sequence set forth in (i2) A polypeptide having at least 95% sequence identity with the nucleotide sequence described in (i1). rinucleotides; and (i3) In the polynucleotide according to (i1) or (i2), one to several nucleotides A polynucleotide in which a sequence has been substituted, deleted or added.

[58] The polynucleotide according to any one of the following (k1) to (k3): The polynucleotide according to

[55] , which comprises: (k1) CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 65, and CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 66 CDRH2 consisting of the amino acid sequence and CDR consisting of the amino acid sequence set forth in SEQ ID NO:67 A polynucleotide encoding H3, and the amino acid sequence set forth in SEQ ID NO:62. CDRL1 having the amino acid sequence set forth in SEQ ID NO:63, and CDRL2 having the amino acid sequence set forth in SEQ ID NO:64. A polynucleotide encoding CDRL3 having the amino acid sequence set forth in (k2) A polypeptide having at least 95% sequence identity with the nucleotide sequence described in (k1). rinucleotides; and (k3) The polynucleotide according to (k1) or (k2) is selected from one to several nucleotides. A polynucleotide in which a sequence has been substituted, deleted or added.

[59] The polynucleotide according to any one of the following (m1) to (m3): The polynucleotide according to

[55] , which comprises: (m1) CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 85, and CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 86 CDRH2 consisting of the amino acid sequence and CDR consisting of the amino acid sequence set forth in SEQ ID NO:87 A polynucleotide encoding H3, and the amino acid sequence set forth in SEQ ID NO:82. CDRL1 having the amino acid sequence set forth in SEQ ID NO: 83, CDRL2 having the amino acid sequence set forth in SEQ ID NO: 84, A polynucleotide encoding CDRL3 having the amino acid sequence set forth in (m2) A polypeptide having at least 95% sequence identity with the nucleotide sequence set forth in (m1). rinucleotides; and (m3) The polynucleotide according to (m1) or (m2) is a polynucleotide having one or several nucleotides. A polynucleotide in which a sequence has been substituted, deleted or added.

[60] An expression vector comprising the polynucleotide according to any one of

[55] to

[59] .

[0023]

[61] A host cell transformed with an expression vector according to

[60] .

[62] Culturing the host cell according to

[61] , and extracting the desired antibody or a functional fragment of the antibody from the culture product.

[41] , comprising a step of collecting a fragment of the antibody or the antibody. Methods for producing functional fragments.

[63] Activation of CD147-mediated signaling leads to activation of p38 and / or SMAD4. The antibody or functional fragment of the antibody according to any one of [1] to

[41] , which is activated. .

[64] Activation of p38MAPK and / or activation of SMAD4 reduces the expression level of p38MAPK. Increase, phosphorylation of p38MAPK, phosphorylation of HSP27, increase in CXCL8 expression, r Increased expression of hoB, decreased expression of KLF5 mRNA, or decreased expression of KLF5 protein.

[63] An antibody or a functional fragment of the antibody described in.

[65]

[63] or

[64] , A method for treating a tumor.

[0024]

[66] Using a biological sample derived from a cancer patient, the expression or Patients in whom KLF5 expression was detected and SMAD4 was detected, or patients in whom KLF5 expression was decreased or A patient in whom a deletion has been detected is treated with the antibody or the antibody according to any one of [1] to

[41] . Treatment of cancer with a functional fragment of the polypeptide or the pharmaceutical composition according to any one of

[42] to

[48] . The present invention relates to a method for predicting responsiveness of a cancer to treatment, the method comprising determining that the cancer is responsive to treatment.

[67] Using biological samples from cancer patients, the presence or absence of SMAD4 expression in the biological samples is examined. or KLF5 expression was detected, and SMAD4 expression was detected or KLF5 expression was decreased or The patient in whom the deletion or deletion has been detected is treated with the antibody or the corresponding antibody according to any one of [1] to

[41] . A method for treating cancer using a functional fragment of the antibody or the pharmaceutical composition according to any one of

[42] to

[48] . 23. A method for selecting a subject for cancer treatment, comprising: selecting a subject for cancer treatment.

[68] Using biological samples derived from cancer patients, the expression of SMAD4 contained in the biological samples was examined. Patients with no or no KLF5 expression and patients with SMAD4 expression or patients with decreased or no KLF5 expression The antibody or the antibody according to any one of [1] to

[41] is administered to a patient in whom a deletion or a deletion has been detected. or a functional fragment of the antibody, or the pharmaceutical composition according to any one of

[42] to

[48] . 23. A method for treating cancer comprising administering

[69]

[0042] -

[48] A kit for detecting SMAD4 expression or KLF5 expression in a biological sample derived from a cancer patient. A kit comprising at least a means for detecting expression.

[70] The antibody or antigen-binding fragment of the antibody according to any one of [1] to

[41] and another drug. Conjugated antibody-drug conjugates.

[0025]

[71]

[41] An antigen-binding fragment of the antibody according to any one of [1] to

[41] and an antigen other than CD147. A bispecific antibody comprising an antigen-binding fragment that binds to the original antigen. Effect of the Invention

[0026] The antibody of the present invention specifically recognizes CD147 and inhibits the interaction mediated by CD147. CD147 activates signaling molecules associated with tumors and has a strong antitumor activity. The antibody of the present invention expresses IL-1 in T cells and PBMCs. Since it does not act on tumor cells and does not depend on effector functions, it is suitable for development as an antitumor agent. In addition, the antibody of the present invention has an extremely high antitumor activity. The antibody of the present invention exhibits antitumor activity in liver cancer cells. The antibody of the present invention shows a significantly stronger pharmacological effect than sorafenib, which is used as an anti-cancer agent. In pancreatic cancer, the effect was more pronounced than that of gemcitabine, which is used as one of the standard treatments for pancreatic cancer. In addition, the antibody of the present invention exhibits strong efficacy against chronic myeloid leukemia cells. The drug showed significantly stronger efficacy than imatinib, which is used as one of the standard treatments for leukemia. vinegar. [Brief description of the drawings]

[0027] [Figure 1] (a)-(c): Changes in tumor volume in the PANC-1 xenograft model. [Figure 2-1] Binding to human CD147 or monkey CD147. [Figure 2-2] Binding to human CD147 or monkey CD147. [Figure 2-3] Binding to human CD147 or monkey CD147. [Diagram 3] Comparison of amino acid sequences between human CD147 and cynomolgus monkey CD147 and positions of mu1 to mu9. [Figure 4-1] Nucleotide and amino acid sequences of the light chain variable region of LN22R8, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of the LN22R8 light chain. [Figure 4-2] Nucleotide and amino acid sequences of the heavy chain variable region of LN22R8, and the amino acid sequences of CDRH1, CDRH2, and CDRH3 of the LN22R8 heavy chain. [Figure 5-1] The nucleotide and amino acid sequences of the light chain variable region of 2P10F2, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of the 2P10F2 light chain. [Figure 5-2] The nucleotide and amino acid sequences of the heavy chain variable region of 2P10F2, and the amino acid sequences of CDRH1, CDRH2, and CDRH3 of the 2P10F2 heavy chain. [Figure 6] ADCC activity of human chimeric antibodies. [Figure 7] CDC activity of human chimeric antibodies. [Figure 8] ADCP activity of human chimeric antibodies. [Figure 9-1] (a) to (d): Antitumor effects of each antibody in a MIA PaCa-2 subcutaneously implanted model in NOD-scid mice. [Figure 9-2] (e) to (g): Antitumor effects of each antibody in a MIA PaCa-2 subcutaneously implanted model in NOD-scid mice. [Figure 10] Antitumor effect of LN22R8chIgG4P in a subcutaneous MIA PaCa-2 tumor model using NOG mice.

[0028] [Figure 11] (a) to (d): Antitumor effects of r#84, r#101, r#110, or r#131 in a subcutaneous MIA PaCa-2 transplantation model using NOD-scid mice. [Figure 12] Competition assay between 2P10F2 and r#84, r#101, r#110 or r#131. [Figure 13-1] (a) to (d): Antitumor effects of each chimeric antibody in a MIA PaCa-2 subcutaneous tumor model. [Figure 13-2] (e) to (h): Antitumor effects of each chimeric antibody in a MIA PaCa-2 subcutaneous tumor model. [Figure 13-3] (i)-(l): Antitumor effects of each chimeric antibody in a MIA PaCa-2 subcutaneous tumor model. [Figure 13-4] (m) and (n): Antitumor effect of each chimeric antibody in a MIA PaCa-2 subcutaneous tumor model. [Figure 14] (a) Design of the variable regions of the humanized antibody heavy chain #84H1h and (b) the humanized antibody light chain #84L2h. [Figure 15] (a) Design of the variable regions of humanized antibody heavy chain #101H1h and (b) humanized antibody light chain #101L2h. [Figure 16] Design of the variable regions of (a) humanized antibody heavy chain #110H1h, (b) humanized antibody heavy chain #110H13h, (c) humanized antibody light chain #110L4h, (d) humanized antibody light chain #110L2h, and (e) humanized antibody light chain #110L12h. [Figure 17] (a) Design of the variable regions of the humanized antibody heavy chain #131H2h and (b) the humanized antibody light chain #131L2h. [Figure 18] (a)-(d): Antitumor effects of each humanized antibody in the MIA PaCa-2 subcutaneous tumor model [Figure 19] p38MAPK phosphorylation by anti-human CD147 human chimeric antibody. [Figure 20] (a) and (b): Phosphorylation of HSP27 by anti-human CD147 human chimeric antibody.

[0029] [Figure 21] (a)-(c): Intratumor p38 MAPK phosphorylation by anti-human CD147 human chimeric antibody. [Figure 22](a) to (c): Expression of cxcl8 and rhoB by anti-human CD147 human chimeric antibody. [Figure 23] (a)~(c): Expression of cxcl8 and rhoB by anti-human CD147 rat antibody and its human chimeric antibody. [Figure 24] The results of evaluating the antitumor effects of anti-CD147 antibody and gemcitabine using SMAD4-negative pancreatic cancer cells BxPC-3. [Diagram 25] (a) to (c): Results of evaluating the antitumor effect of anti-CD147 human chimeric antibody using BxPC-3 cells stably expressing SMAD4. [Figure 26] (a) and (b): Phosphorylation of p38MAPK was evaluated when anti-CD147 human chimeric antibody was administered to pancreatic cancer cells BxPC-3 expressing SMAD4. [Figure 27] Antitumor effect of anti-CD147 human chimeric antibody in a gemcitabine-resistant pancreatic cancer tumor model. [Figure 28] (a) Flow cytometric confirmation of CD147 expression in Hep G2 cells. (b) p38MAPK activation by humanized CD147 antibody in hepatocellular carcinoma cells. [Figure 29] (a)~(d): Comparison of the antitumor effects of CD147 antibody and sorafenib in liver cancer. [Diagram 30] Binding of CD147-APC to CD3, CD4 positive cells and CD3, CD8 positive cells.

[0030] [Diagram 31] Assessment of the effect of anti-human CD147 antibodies in inducing proliferation of human peripheral blood mononuclear cells. [Diagram 32] Evaluation of the effect of anti-human CD147 antibody on cytokine production in human peripheral blood lymphocytes. [Figure 33-1] Nucleotide sequence and amino acid sequence of the light chain variable region of rat_CD147_#84, and amino acid sequences of CDRL1, CDRL2, and CDRL3 of the light chain of rat_CD147_#84. [Figure 33-2]Nucleotide sequence and amino acid sequence of the heavy chain variable region of rat_CD147_#84, and amino acid sequences of CDRH1, CDRH2, and CDRH3 of the heavy chain of rat_CD147_#84. [Figure 34-1] Nucleotide sequence and amino acid sequence of the light chain variable region of rat_CD147_#101, and amino acid sequences of CDRL1, CDRL2, and CDRL3 of the light chain of rat_CD147_#101. [Figure 34-2] Nucleotide sequence and amino acid sequence of the heavy chain variable region of rat_CD147_#101, and amino acid sequences of CDRH1, CDRH2, and CDRH3 of the heavy chain of rat_CD147_#101. [Figure 35-1] Nucleotide sequence and amino acid sequence of the light chain variable region of rat_CD147_#110, and amino acid sequences of CDRL1, CDRL2, and CDRL3 of the light chain of rat_CD147_#110. [Figure 35-2] Nucleotide sequence and amino acid sequence of the heavy chain variable region of rat_CD147_#110, and amino acid sequences of CDRH1, CDRH2, and CDRH3 of the heavy chain of rat_CD147_#110. [Figure 36-1] Nucleotide sequence and amino acid sequence of the light chain variable region of rat_CD147_#131, and amino acid sequences of CDRL1, CDRL2, and CDRL3 of the light chain of rat_CD147_#131. [Figure 36-2] Nucleotide sequence and amino acid sequence of the heavy chain variable region of rat_CD147_#131, and amino acid sequences of CDRH1, CDRH2, and CDRH3 of the heavy chain of rat_CD147_#131. [Figure 37-1] Amino acid and nucleotide sequences of #84H1hIgG2. [Figure 37-2] Amino acid and nucleotide sequences of #84H1hIgG4P. [Figure 37-3] Amino acid and nucleotide sequences of #84L2h. [Figure 38-1] Amino acid and nucleotide sequences of #101H1hIgG2. [Figure 38-2]Amino acid and nucleotide sequences of #101H1hIgG4P. [Figure 38-3] Amino acid and nucleotide sequences of #101L2h. [Figure 39-1] Amino acid and nucleotide sequences of #110H1hIgG4P. [Figure 39-2] Amino acid and nucleotide sequences of #110H13hIgG4P. [Figure 39-3] Amino acid and nucleotide sequences of #110L4h. [Figure 39-4] Amino acid and nucleotide sequences of #110L2h. [Figure 39-5] Amino acid and nucleotide sequences of #110L12h. [Figure 40-1] Amino acid and nucleotide sequences of #131H2hIgG2. [Figure 40-2] Amino acid and nucleotide sequences of #131L2h.

[0031] [Diagram 41] Ribbon diagram showing the two complexes in the asymmetric unit. CD147 is shown in black, and the antibody heavy (H CHAIN) and light (L CHAIN) chains are shown in grey. [Diagram 42] CD147-antibody interaction surface. The amino acids of CD147 in the vicinity of the antibody are represented by stick models and labeled with letters. The rest of CD147 is represented by a black ribbon model. Meanwhile, the amino acids of the antibody in the vicinity of CD147 are represented by thin line models, and the rest of the antibody is represented by a grey ribbon model. [Diagram 43] Antitumor effects of chimeric and humanized CD147 antibodies in gastric cancer models. [Diagram 44] Antitumor effect of humanized CD147 antibody in a chronic myeloid leukemia (CML) model. [Diagram 45] Antitumor effect of humanized CD147 antibody in a colon cancer model. [Figure 46] Antitumor effect of humanized CD147 antibody in a renal cancer model. [Figure 47] Antitumor effect of humanized CD147 antibody in an acute myeloid leukemia (AML) model. [Figure 48] Antitumor effect of humanized CD147 antibody in a pancreatic cancer model. [Figure 49] Competitive ELISA results. [Figure 50] Comparison of the antitumor effects of humanized CD147 antibodies using (a) MIA PaCa-2 cells and (b) MIA PaCa-2 cells expressing KLF5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] Preferred embodiments of the present invention will now be described with reference to the accompanying drawings. The embodiment described below is an example of a typical embodiment of the present invention. This will not narrow the scope of the present invention.

[0033] (Definitions) In this specification, the terms "cancer" and "tumor" are used interchangeably and are not limited to any particular term. Unless otherwise specified, the term is used when referring to solid tumors, non-solid tumors, or both.

[0034] In the present specification, the term "gene" includes not only DNA but also its mRNA, cDNA and The cRNA is also included.

[0035] In this specification, the terms "polynucleotide" and "nucleotide" are used interchangeably with "nucleic acid." This also includes DNA, RNA, probes, oligonucleotides, and primers.

[0036] In this specification, the terms "polypeptide" and "protein" are used interchangeably.

[0037] In this specification, the term "cell" includes cells in an animal body and cultured cells.

[0038] As used herein, "CD147" is used synonymously with CD147 protein.

[0039] As used herein, the term "functional fragment of an antibody" is also referred to as an "antigen-binding fragment of an antibody" and is a fragment that binds to an antigen. These fragments refer to partial fragments of antibodies that have the binding activity of Fab, F(ab')2, Fv, and s This includes cFv, diabodies, linear antibodies, and multispecific antibodies formed from antibody fragments. In addition, Fab, a monovalent fragment of the variable region of an antibody, is obtained by treating F(ab')2 under reducing conditions. However, these fragments are also included in the antigen-binding fragments of antibodies as long as they have the ability to bind to antigens. These antigen-binding fragments are not limited to those described above. In addition, the full-length antibody protein molecule can be fused to an appropriate enzyme. Not only those treated with natural antibodies, but also those genetically engineered to produce antibodies in suitable hosts Proteins produced in cells are also included.

[0040] As used herein, the term "effector activity" refers to antibody-dependent cellular cytotoxicity (ADC). ependent-Cellular-Cytotoxicity (ADCC) Complement-dependent cytotoxicity ity (hereinafter referred to as CDC) activity, or antibody-dependent cell phagocytosis (Antibody-dependent cell phagocytosis). Pendent cellular phagocytosis (ADCP) activity This refers to any one or more of the following:

[0041] As used herein, the term "effector function" refers to the exertion of each "effector activity." say.

[0042] Antibody-dependent cellular cytotoxicity (ADCC) is a process that activates immune cells, antibodies, and Beauty 51 Cr Measure cell death that occurs when labeled target cells are contacted 51 Cr Release The ADCC activity of the human CD147 antibody of the present invention can be measured by an assay method. The ADCC activity of the human CD147 antibody to be evaluated is measured as follows. Human peripheral blood mononuclear cells (PBMCs) were used as donor cells, and CD147 cells were used as ADCC target cells. A positive human cancer cell line (e.g., pancreatic cancer line MIA PaCa-2) is used. 51 Cr-labeled cancer cells and the antibody to be evaluated were incubated at 4°C at a concentration of 0.5 or 5 μg / ml. After 30 minutes of treatment, PBMCs isolated from human peripheral blood were added at a ratio of 20 times that of the cancer cells. The cells were then cultured at 37°C for 4 hours in the presence of 5% CO2. 51 Cr to Top Measure using Count NXT v2.53 to obtain the total release value. 51 Cr-labeled cancer cells were treated with Triton-100 and released 51 Measurement of Cr The values ​​were the maximum release values, and the values ​​were the antibody-treated cells without PBMCs. was released 51 The measured value of Cr is the spontaneous release value. The % specific release was calculated using the formula above. Human IgG (hIgG, ChromPure Human IgG, Jackson ImmunoResearch Laboratories, Cat.009-00 0-003) is used. Measurements are carried out in triplicate, and the average value and standard deviation are calculated.

[0043] % specific release=(Total release-Spont aneous release) / Maximamu release Complement-dependent cytotoxicity (CDC) activity is a mechanism by which complement, antibodies and target cells in blood are reacted with each other to form CDC. The evaluation can be performed by measuring the cell death that occurs when the human CD147 antibody of the present invention is contacted with the cell. The CDC activity of the body is measured as follows: Complement-dependent CDC by the human CD147 antibody being evaluated The specific cell killing activity (CDC activity) was measured using human pancreatic cell line MIA PaCa-2 as the target cell. The complement was evaluated using commercially available rabbit complement (Low Tox-M Rabbit Complement). plement, CEDARLANE LABORATORIES LIMITED, C At.CL3051) was used as a control antibody with negative CDC activity. ,ChromPure Human IgG,Jackson ImmunoResea Rch Laboratories, Cat. 009-000-003) is used. The positive and negative control antibodies were each administered at concentrations of 0, 0.1, 1, or 10 μg / ml. After incubation at 4°C for 1 hour, rabbit complement was added to a final concentration of 7.5%. After heating for 3 hours at ℃ in the presence of 5% CO2, the intracellular ATP in living cells was ter-Glo Lumimescent Cell Viability Assay (Promega, Cat. G7572) was used for the measurement. Using the Io Luminescent Cell Viability Assay The resulting luminescence signal was analyzed using EnVision 2104 Multilabel Quantification was performed using a Reader (Perkin Elmer). Measurements were performed in triplicate. The average value and standard deviation were calculated. The luminescence signal obtained from untreated cells was set as 100%. The antibody- and complement-dependent decrease in luminescence signal is taken as CDC activity.

[0044] Antibody-dependent cellular phagocytosis (ADCP) activity is the binding of phagocytic immune cells, antibodies, and target cells. Phagocytosis by contact of the vesicles can be measured by a dual fluorescent labeling method.

[0045] The ADCP activity of the human CD147 antibody of the present invention is measured as follows. The body induces antibody-dependent transcription of monocytes and macrophages through interaction with mouse Fcγ receptors. It has been reported that it exerts a cytocidal effect on cancer cells by inducing phagocytosis by the adenocarcinoma antigen (ADCP). (Overdijk et al., Journal of Immunolo gy, 1-9, 2012). The ADCP activity of the human chimeric antibody of the present invention was RAW264.7 (ATCC, TIB-71) as target cells, and ADCP The human pancreatic line PANC-1 or MIA PaCa-2 was used for evaluation. een Fluorescent Cell Linker Mini Kit for General Cell Membrane Labeling(SIGMA,Ca t.MINI67-1KIT) labeled ADCP target cells and the antibody to be evaluated, and 20 μg The cells were treated with the antibody to be evaluated at a concentration of / ml at 4℃ for 1 hour, and then PKH26 Red Fluo rescent Cell Linker Lit for General Cell Membrane Labeling(SIGMA,Cat.PKH26GL-1KT )-labeled RAW264.7 cells were added in 5x the amount of ADCP target cells, and incubated at 37°C for 3 hours. The mixture was heated in the presence of 5% CO2. A flow cytometer (BD, CantoII) was used. The percentage of PKH26-positive cells that transitioned to PKH67 signal positivity through phagocytosis was measured. As a negative control sample, human IgG (hIgG, ChromPure Human man IgG,Jackson ImmunoResearch Laborator The same measurement was performed on the sample treated with 100% ethanol (Cat. 009-000-003, ies Co., Ltd.). The measurements are carried out in triplicate, and the average value and standard deviation are calculated.

[0046] As used herein, the terms "substantially free of effector activity" and "having reduced effector activity" are used. "or lacking" means that the antibody has no or little ADCC activity, CDC activity, or ADCP activity. At least one of them is inactive or does not fully function. "Has substantially no effector activity" or "has an activity as low as The term "effector activity is reduced or lost" refers to, for example, the effector activity is reduced or lost in the above-mentioned activity evaluation method. This refers to the activity of a specific antibody being comparable to that of a negative control.

[0047] As used herein, the term "reduced or lost ADCC activity" refers to an antibody that has reduced or lost ADCC activity. They either do not show any activity or their activity is so low that their functions are not fully exerted. The term "ADCC activity is reduced or lost" means that, for example, the ADCC activity is reduced or lost by the above-mentioned activity evaluation method. In this method, the activity of the antibody to be evaluated must be comparable to that of the negative control. say.

[0048] As used herein, the term "CDC activity is reduced or absent" means that the antibody being evaluated has no CDC activity. or their activity is so low that their functions are not fully exerted. The term "CDC activity is reduced or eliminated" refers to, for example, the activity of a protein in the above-mentioned method for evaluating CDC activity. In this case, the activity of the antibody to be evaluated is equivalent to that of the negative control.

[0049] As used herein, the term "ADCP activity is reduced or eliminated" refers to an antibody that has reduced or eliminated ADCP activity. They either do not show any activity or their activity is so low that their functions are not fully exerted. The term "ADCP activity is reduced or lost" means that, for example, In this method, the activity of the antibody to be evaluated must be comparable to that of the negative control. say.

[0050] "Decreased or absent ADCC activity," "Decreased or absent CDC activity," or "AD The term "CP activity is reduced or lost" means, for example, the following in the above-mentioned activity evaluation method: This means that the activity of the antibody to be evaluated is at the same level as that of the negative control.

[0051] As used herein, the terms "activate signal transduction via CD147" and "activate signal transduction via CD147" refer to "Activation of CD147-associated signaling molecules," "activation of CD147," or "activation of CD147" This refers to the activation of cell signaling pathways mediated by CD147, and is related to downstream pathways of CD147. The activation of at least one of the signal molecules via CD147. Activation of signal transduction refers to the increase or decrease in expression of genes downstream of the CD147 signal. The expression of a protein may be increased or decreased, or the phosphorylation of a protein may be decreased. The downstream related signaling molecules of CD147 include For example, FAK, MEK, Erk, JAK / STAT, AKT or MAP kinase (MAP K), or the activation of further downstream signaling molecules. Examples of the target protein include ERK1 / 2, JNK, and p38MAPK. More preferably, p38MAPK. Further downstream signaling molecules of MAPK include HSPs. 27, cxcl8 or SMAD (e.g., SMAD2, SMAD3 and / or SMAD4 Examples of "activation of CD147" include activation of p38MAPK mRNA. Increased expression, increased protein expression of p38MAPK, phosphorylation of p38MAPK, HS Phosphorylation of p27 (e.g., phosphorylation of Ser82 of HSP27 or phosphorylation of Ser 15 phosphorylation), increased expression of CXCL8 mRNA, and increased expression of CXCL8 protein , increased expression of rhoB mRNA or rhoB protein through activation of SMAD signaling Increased expression, or decreased expression of KLF5 mRNA or KLF5 protein Some examples include:

[0052] As used herein, the term "epitope" refers to a portion of CD147 to which a specific anti-CD147 antibody binds. The epitope, which is a partial peptide of CD147, or a partial three-dimensional structure thereof. The group can be determined by methods well known to those skilled in the art, such as immunoassays. First, various partial structures of the antigen are prepared. For example, a nucleotide sequence encoding either the C-terminus or the N-terminus of CD147 can be synthesized using oligonucleotide synthesis techniques. A series of polypeptides shortened in appropriate lengths can be produced by recombinant gene techniques well known to those skilled in the art. After preparing the antibodies using the antibodies, the reactivity of the antibodies against them was examined and the rough recognition sites were determined. After that, shorter peptides were synthesized and the reactivity with these peptides was examined. In addition, epitopes can be determined by using the ELISA kit. If an antibody that binds to a protein has an epitope that is a three-dimensional structure consisting of multiple domains, The amino acid sequence of a specific extracellular domain can be modified to change the three-dimensional structure. The specific domain to which a particular antibody binds can be determined by the The epitope, which is a partial three-dimensional structure of the original, is identified by X-ray structural analysis as the antigen adjacent to the antibody. It can also be determined by specifying the amino acid residues of the sequence.

[0053] If the second antibody binds to the partial peptide or partial three-dimensional structure to which the first antibody binds, It can be determined that the first antibody and the second antibody have a common epitope. A second antibody cross-competes with the antibody for binding to the antigen (i.e., the second antibody binds to the first antibody). By confirming that the specific epitope sequence or Even if the structure has not been determined, it is possible that the first and second antibodies bind to the same epitope. It can be determined that the first antibody and the second antibody bind to the same epitope and the first antibody binds to the same epitope. If the first antibody has a special effect such as antitumor activity, the second antibody also has the same activity. We can expect this.

[0054] The heavy and light chains of an antibody molecule each contain three complementarity determining regions (CDRs). It is known that there is a Complementarity determining regions are also called hypervariable domains. These are called nucleotide sequences and are located in the variable regions of the heavy and light chains of antibodies, and are sites of particularly high variability in the primary structure. In the primary structure of the heavy and light chain polypeptide chains, they are separated into three parts. In the present specification, the complementarity determining region of an antibody is defined as the complementarity determining region of a heavy chain. The heavy chain amino acid sequence is designated CDRH1, CDRH2, and CDRH3 from the amino-terminal side. The complementarity determining regions of the light chain are CDRL1, CDRL2, and CDRL3 from the amino terminal side of the light chain amino acid sequence. These sites are structurally close to each other and act as receptors for the antigens they bind to. The specificity of the antibody is determined.

[0055] In this specification, when there is a description of "one to several" or "one or several", The term "number of" refers to 2 to 10. Preferably, the number of the molecules is 10 or less, and more preferably, 5 or less. or six or less, and even more preferably two or three.

[0056] (CD147) CD147 is a single-pass transmembrane protein with two to three immunoglobulin-like domains. Interaction between CD147, CD44, integrin family molecules, CD98, V Extracellular factors involved in proliferation, invasion, and inflammation, such as EGFR, CypA / B, and MCT1 / 3 / 4 By interacting with molecules on the cell membrane, downstream signaling-related molecules such as FAK, MEK, and E rk, JAK / STAT, AKT, MAPK family molecules are activated, and MMP and other It is known that proteases, which are involved in the production of inflammatory cytokines, promote cancer growth, metastasis, and invasion.

[0057] Human CD147 has three known variants. Variant 1 is retina-specific. Three immunoglobulin-like domains (referred to herein as D0, D1 and D2, respectively) were expressed. ) and variant 2 is a single-pass transmembrane protein that is involved in T cells and various Two immunoglobulins that are expressed in various normal cells and have been reported to be upregulated in various cancer tissues It is a single-pass transmembrane protein with Brin-like domains (D1, D2). Variant 3 is It is a single-pass transmembrane protein with two immunoglobulin-like domains.

[0058] The amino acid and nucleotide sequences of human CD147 variant 1 are available from GenBan. kSee accession numbers NP_001719.2 and NM_001728.3 In the present specification, the amino acid sequence is SEQ ID NO: 1, the nucleotide sequence is SEQ ID NO: Also disclosed as sequence number 2. The three immunoglobulin-like domains of variant 1 are In SEQ ID NO: 1, the amino acid numbers are 22 to 138 (D0) and 1 40 to 218 (D1) and amino acid numbers 223 to 323 (D2) (Redzic, J., J. Mol. Biol., 2011, 68-82)(Grass e t al., Biosol. Rep, 2016, 1-16). In addition, variants The first transmembrane domain corresponds to amino acid numbers 324 to 344 in SEQ ID NO:1.

[0059] The amino acid and nucleotide sequences of human CD147 variant 2 are available from GenBan. kSee accession numbers NP_940991.1 and NM_198589.2 The amino acid sequence is SEQ ID NO:3, the nucleotide sequence is SEQ ID NO:4, and the like. Also disclosed as sequence number 4. The two immunoglobulin-like domains of variant 2 ( D1, D2) are amino acid numbers 24 to 102 (D1) and and amino acid numbers 107 to 207 (D2). The transmembrane region of variant 2 is In column 3, it is amino acid numbers 208 to 228 (Grass et al., Biosol. Rep, 2016, 1-16).

[0060] The amino acid and nucleotide sequences of human CD147 variant 3 are available from GenBan. kSee accession numbers NP_940992.1 and NM_198590.2 The human CD147 gene is also available from commercial sources. It is.

[0061] Cynomolgus monkey CD147 (sometimes referred to as monkey CD147 in this specification) The amino acid and nucleotide sequences are available under GenBank accession number XP_0055. Available by reference to US Pat. No. 6,354,87354.1, XM_005587297.1. The monkey CD147 gene is also available from a commercial source. The amino acid and nucleotide sequences of 7 are identified under GenBank accession number NP_0 Available by reference to NM_01070652.1, NM_001077184.1. The mouse CD147 gene is also available from a commercial source.

[0062] The CD147 used in the present invention can be synthesized in vitro or genetically engineered. Specifically, CD147 c can be produced by inducing it in a host cell. After inserting the DNA into an expression vector, the enzymes, substrates, and energy required for transcription and translation are prepared. They can be synthesized in solutions containing glycerol or in other prokaryotic or eukaryotic host cells. The protein can be obtained by expressing CD147 through transformation of the come.

[0063] The cDNA of CD147 can be, for example, a cDNA library expressing the cDNA of CD147. Using the ribosome as a template, the CD147 cDNA was specifically amplified using primers. Polymerase chain reaction (hereinafter referred to as "PCR") (Saiki, RK, et al., Science, (1988) 239, 487-49), so-called PCR method can be obtained.

[0064] In addition, a nucleotide sequence complementary to the nucleotide sequence encoding human, monkey or mouse CD147 is used. A polynucleotide comprising the nucleotide sequence hybridizes under stringent conditions. and a polynucleotide encoding a protein having a biological activity equivalent to that of CD147 is also disclosed. The CD147 cDNA is also included in the human, monkey or mouse CD147 locus. or a splicing variant transcribed from A polynucleotide that binds to soybean and has a biological activity equivalent to that of CD147 The polynucleotide encoding the protein is also included in the CD147 cDNA.

[0065] In addition, the amino acid sequence of human, monkey or mouse CD147, or a signature derived from these sequences, In the amino acid sequence from which the null sequence has been removed, one or several amino acids have been substituted, deleted, or consists of an additional amino acid sequence, and no proteins with biological activity equivalent to CD147 have been reported in the CD In addition, the CD147 gene is included in the human, monkey, or mouse CD147 locus. or an amino acid sequence encoded by a splicing variant thereof, It consists of an amino acid sequence in which one or several amino acids are substituted, deleted, or added, and CD147 also includes proteins that have biological activity equivalent to that of CD147.

[0066] (Production of anti-CD147 antibody) The antibody against CD147 of the present invention is produced by immunizing a non-human animal with a target antigen, and Lymph, lymphoid tissue, blood cell samples, or bone marrow-derived cells are collected from the subject, and the collected cells are analyzed by a known method (e.g., Kohler and Milstein, Nature (1975) 256, p.495-497, Kennet, R.ed., Monoclonal Antib. odies, p.365-367, Plenum Press, NY (1980) ) Antibody-producing cells that produce antibodies against CD147 were fused with myeloma cells. By this, hybridomas can be established and monoclonal antibodies can be obtained. A specific example of such a method is disclosed in WO2009 / 48072 (published April 16, 2009). and WO2010 / 117011 (published October 14, 2010). Examples of monoclonal antibodies obtained in this manner include LN22R8, 2P1 0F2, rat_CD147_#84, rat_CD147_#101, rat_CD1 47_#110 or rat_CD147_#131. Methods for obtaining clonal antibodies are well established and are not limited to the above specific examples. It is not something that can be done.

[0067] In addition to the above-mentioned monoclonal antibody against CD147, the antibody of the present invention also includes a monoclonal antibody against human CD147. Recombinant antibodies that have been artificially modified for the purpose of reducing heterologous antigenicity, e.g. For example, chimeric antibodies, humanized antibodies, human antibodies, etc. These antibodies can be produced using known methods.

[0068] Chimeric antibodies include antibodies in which the variable and constant regions of the antibody are of different species, such as mouse antibodies. Chimeric antibodies in which the variable regions of a mouse or rat-derived antibody are joined to constant regions of human origin are also included. (Proc. Natl. Acad. Sci. USA, 81, 6851- 6855, (1984). An example of a chimeric antibody derived from LN22R8 is A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 471 of SEQ ID NO: 33; A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 467 of SEQ ID NO:35. or having an amino acid sequence consisting of amino acid residues 20 to 468 of SEQ ID NO:37. A heavy chain having an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:31. An example of a chimeric antibody derived from 2P10F2 is an antibody having a light chain comprising the following sequence: A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO: 43. The amino acid sequence of SEQ ID NO: 45 in the sequence listing is from 20 to 462 amino acid residues. or an amino acid sequence consisting of amino acid residues 20 to 463 of SEQ ID NO:47 and a heavy chain having the sequence: The antibody includes a light chain having the sequence

[0069] An example of a chimeric antibody derived from rat_CD147_#84 is SEQ ID NO: 92 in the sequence listing. A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 470 of the sequence listing, a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 466 of SEQ ID NO:94; a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 467 of SEQ ID NO:96; A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 470 of SEQ ID NO:98, or A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 467 of SEQ ID NO: 100. and an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:90. Examples of antibodies include antibodies consisting of a light chain having a

[0070] As an example of a chimeric antibody derived from rat_CD147_#101, SEQ ID NO: 10 in the sequence listing 4, a heavy chain having an amino acid sequence consisting of the 20th to 463rd amino acid residues of A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 464 of sequence number 106. or an amino acid sequence consisting of amino acid residues 20 to 464 of SEQ ID NO: 108. and a heavy chain having an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO: 102. Examples of antibodies include antibodies consisting of a light chain having a sequence.

[0071] As an example of a chimeric antibody derived from rat_CD147_#110, SEQ ID NO: 11 in the sequence listing a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 462 of SEQ ID NO:2; A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 463 of sequence number 114. or an amino acid sequence consisting of amino acid residues 20 to 463 of SEQ ID NO: 116. and a heavy chain having an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:110. Examples of antibodies include antibodies consisting of a light chain having a sequence.

[0072] As an example of a chimeric antibody derived from rat_CD147_#131, SEQ ID NO: 12 in the sequence listing A heavy chain having an amino acid sequence consisting of amino acid residues 20 to 464 of a heavy chain having an amino acid sequence consisting of amino acid residues 20 to 465 of number 122; and and having an amino acid sequence consisting of amino acid residues 21 to 234 of SEQ ID NO:118. Examples include antibodies consisting of light chains.

[0073] Humanized antibodies include antibodies in which only the CDRs have been incorporated into a human antibody (Nature 1986) 321, pp. 522-525), the CDR grafting method is used to graft the CDR sequences. In addition, some of the amino acid residues in the framework were also transplanted into a human antibody (International Publication No. WO9 (Pamphlet No. 0 / 07861).

[0074] The humanized antibody derived from rat_CD147_#84 antibody is rat_CD147_# 84, has binding activity to CD147, and The antibody of the present invention includes any antibody that activates rat_CD147. The heavy chain variable region of antibody #84 has a CDR consisting of the amino acid sequence shown in SEQ ID NO:55. H1, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO:56, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO:57 It has a CDRH3 consisting of the amino acid sequence shown in rat_CD147_# The light chain variable region of the antibody 84 comprises CDRL1 consisting of the amino acid sequence shown in SEQ ID NO:52; CDRL2 consisting of the amino acid sequence shown in SEQ ID NO:53, and The rat_CD147_#84 antibody has a CDRL3 consisting of the amino acid sequence Amino acid and nucleotide sequences of the heavy chain variable region and the heavy chain variable region, and amino acid sequences of the CDRs Columns are also illustrated in Figures 33-1 and 33-2.

[0075] The humanized antibody derived from rat_CD147_#101 antibody is rat_CD147_ The antibody has all six CDR sequences of #101 and has binding activity to CD147, As long as the antibody activates CD147, it is included in the antibody of the present invention. The heavy chain variable region of the 147_#101 antibody consists of the amino acid sequence shown in SEQ ID NO:65. CDRH1, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO:66, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO:6 7. It also has a CDRH3 consisting of the amino acid sequence shown in rat_CD14. The light chain variable region of antibody #101 is a CD4 antibody having the amino acid sequence shown in SEQ ID NO:62. RL1, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO:63, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO:64. It has a CDRL3 consisting of the amino acid sequence shown. The amino acid sequence and nucleotide sequence of the light chain variable region or heavy chain variable region of the antibody, CDR The amino acid sequences are also shown in Figures 34-1 and 34-2.

[0076] The humanized antibody derived from rat_CD147_#110 antibody is rat_CD147_ The antibody has all six CDR sequences of #110 and has binding activity to CD147, As long as the antibody activates CD147, it is included in the antibody of the present invention. The heavy chain variable region of the 147_#110 antibody consists of the amino acid sequence shown in SEQ ID NO:75. CDRH1, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO:76, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO:7 7. It also has a CDRH3 consisting of the amino acid sequence shown in rat_CD14. The light chain variable region of antibody #110 is a CD4 antibody having the amino acid sequence shown in SEQ ID NO:72. RL1, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 73, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 74. It has a CDRL3 consisting of the amino acid sequence shown. The amino acid sequence and nucleotide sequence of the light chain variable region or heavy chain variable region of antibody 0, The amino acid sequences are also set forth in Figures 35-1 and 35-2.

[0077] The humanized antibody derived from rat_CD147_#131 antibody is rat_CD147_ The antibody has all six CDR sequences of #131 and has binding activity to CD147, As long as the antibody activates CD147, it is included in the antibody of the present invention. The heavy chain variable region of the 147_#131 antibody consists of the amino acid sequence shown in SEQ ID NO:85. CDRH1, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 86, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 8 7. It also has a CDRH3 consisting of the amino acid sequence shown in rat_CD14. The light chain variable region of antibody #131 is a CD4 antibody having the amino acid sequence shown in SEQ ID NO:82. RL1, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 83, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 84. It has a CDRL3 consisting of the amino acid sequence shown. The amino acid sequence and nucleotide sequence of the light chain variable region or heavy chain variable region of the antibody, CDR The amino acid sequences are also set forth in Figures 36-1 and 36-2.

[0078] In addition, CDRs in which 1 to 3 amino acid residues in each CDR are replaced with other amino acid residues are also available. The DR-modified humanized antibody also has binding activity to CD147 and activates CD147. As long as the antibody is capable of expressing the above function, it is included in the antibody of the present invention. The humanized antibody of the present invention includes a human CD147 antibody or an antibody thereof having the following (a) and (b): Antigen-binding fragments of the body include: (a) a heavy chain selected from the group consisting of the following (a1) to (a4): Variable region: (a1) the 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 123 a heavy chain variable region consisting of (a2) the 20th to 140th amino acid residues of the amino acid sequence shown in SEQ ID NO: 125 a heavy chain variable region consisting of (a3) A framework region other than each CDR sequence in the sequence of (a1) or (a2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (a4) A sequence other than each CDR sequence in any one of (a1) to (a3). In the framework region sequence of The amino acid sequence, and (b) a light chain selected from the group consisting of (b1) to (b3) below: Variable region: (b1) the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO: 127 a light chain variable region consisting of (b2) A sequence of the framework region other than each CDR sequence in the sequence of (b1) an amino acid sequence having at least 95% sequence identity to the (b3) A framework region other than each CDR sequence in the sequence of (b1) or (b2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[0079] A preferred example of a humanized antibody derived from rat_CD147_#84 antibody is the antibody represented by SEQ ID NO: 1. A heavy chain variable region consisting of amino acid residues 20 to 140 of the amino acid sequence shown in 25. and consisting of the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO:127. or an antibody comprising a light chain variable region having 20 to 12 amino acid sequence as set forth in SEQ ID NO:123. A heavy chain variable region consisting of the 40th amino acid residue and the amino acid sequence shown in SEQ ID NO: 127 and an antibody comprising a light chain variable region consisting of amino acid residues 21 to 128 of the sequence.

[0080] A more preferred example of a humanized antibody derived from rat_CD147_#84 antibody is A heavy chain consisting of amino acid residues 20 to 467 of the amino acid sequence shown in No. 125, A light protein consisting of the 21st to 234th amino acid residues of the amino acid sequence shown in SEQ ID NO: 127. or an antibody comprising the 20th to 466th amino acid sequences of SEQ ID NO:123. and a heavy chain consisting of amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:127. Examples of antibodies include antibodies that contain a light chain consisting of amino acid residues of the same or similar order.

[0081] The humanized antibodies derived from the rat_CD147_#101 antibody are (e) and (f) below. ) a human CD147 antibody or an antigen-binding fragment thereof having the following structure: (e) A heavy chain selected from the group consisting of the following (e1) to (e4): Variable region: (e1) the 20th to 137th amino acid residues of the amino acid sequence shown in SEQ ID NO: 129 a heavy chain variable region consisting of (e2) the 20th to 137th amino acid residues of the amino acid sequence shown in SEQ ID NO: 131 a heavy chain variable region consisting of (e3) A framework region other than each CDR sequence in the sequence of (e1) or (e2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (e4) A sequence other than each CDR sequence in any one of (e1) to (e3). In the framework region sequence of The amino acid sequence, and (f) a light chain selected from the group consisting of (f1) to (f3) below: Variable region: (f1) the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO: 133 a light chain variable region consisting of (f2) A sequence of the framework region other than each CDR sequence in the sequence of (f1) an amino acid sequence having at least 95% sequence identity to the (f3) A framework region other than each CDR sequence in the sequence of (f1) or (f2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[0082] A preferred example of a humanized antibody derived from the rat_CD147_#101 antibody is represented by SEQ ID NO: The heavy chain variable region consists of the 20th to 137th amino acid residues of the amino acid sequence shown in and the amino acid sequence from 21 to 128 of SEQ ID NO:133 or an antibody comprising a light chain variable region consisting of 20 to 30 of the amino acid sequence set forth in SEQ ID NO: 131. A heavy chain variable region consisting of the 137th amino acid residue and the amino acid sequence shown in SEQ ID NO: 133 and an antibody having a light chain variable region consisting of amino acid residues 21 to 128 of the sequence .

[0083] A more preferred example of a humanized antibody derived from the rat_CD147_#101 antibody is A heavy chain consisting of amino acid residues 20 to 463 of the amino acid sequence shown in No. 129, and the 21st to 234th amino acid residues of the amino acid sequence shown in SEQ ID NO: 133. or an antibody comprising a light chain comprising amino acids 20 to 464 of the amino acid sequence set forth in SEQ ID NO:131. A heavy chain consisting of amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO: 133 An example of an antibody is an antibody having a light chain consisting of amino acid residues .

[0084] The humanized antibodies derived from the rat_CD147_#110 antibody are (c) and (d) below. ) a human CD147 antibody or an antigen-binding fragment thereof having the following structure: (c) a heavy chain selected from the group consisting of the following (c1) to (c4): Variable region: (c1) amino acid residues 20 to 136 of the amino acid sequence shown in SEQ ID NO: 135 a heavy chain variable region consisting of: (c2) from the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 147 a heavy chain variable region comprising (c3) A framework region other than each CDR sequence in the sequence of (c1) or (c2). an amino acid sequence having at least 95% sequence identity to the sequence of the region; and (c4) A sequence other than each CDR sequence in any one of (c1) to (c3). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. amino acid sequence, and (d) A light chain variable molecule selected from the group consisting of the following (d1) to (d5): Variable area: (d1) the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO: 137 a light chain variable region consisting of: (d2) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 149 a light chain variable region consisting of: (d3) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 151 a light chain variable region consisting of: (d4) In any one of the sequences (d1) to (d3), a sequence other than each CDR sequence Amino acids with at least 95% sequence identity to the framework region sequences Sequence; and (d5) A sequence other than each CDR sequence in any one of (d1) to (d4). An amino acid sequence in which one or several amino acids are deleted, substituted, or added in the framework region. Amino acid sequence.

[0085] A preferred example of a humanized antibody derived from the rat_CD147_#110 antibody is represented by SEQ ID NO: The heavy chain variable region consists of the 20th to 136th amino acid residues of the amino acid sequence shown in and the amino acid sequence from 21 to 128 of SEQ ID NO: 137 an antibody comprising a light chain variable region comprising the amino acid sequence from 20 to 136 of the amino acid sequence shown in SEQ ID NO:147; and a heavy chain variable region consisting of the amino acid residues shown in SEQ ID NO: 149. An antibody comprising a light chain variable region consisting of amino acid residues 1 to 128; or an antibody having SEQ ID NO: 147 A heavy chain variable region consisting of amino acid residues 20 to 136 of the amino acid sequence shown in A light chain consisting of amino acid residues 21 to 128 of the amino acid sequence shown in sequence number 151. Examples of antibodies include those that contain variable regions.

[0086] A more preferred example of a humanized antibody derived from the rat_CD147_#110 antibody is A heavy chain consisting of amino acid residues 20 to 463 of the amino acid sequence shown in No. 135, and the 21st to 234th amino acid residues of the amino acid sequence shown in SEQ ID NO: 137. An antibody comprising a light chain; the 20th to 463rd amino acids of the amino acid sequence shown in SEQ ID NO:147 and a heavy chain consisting of residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:149. an antibody comprising a light chain consisting of the amino acid residues of SEQ ID NO: 147; A heavy chain consisting of amino acid residues 20 to 463 and an amino acid sequence shown in SEQ ID NO: 151. Examples of such antibodies include antibodies having a light chain consisting of amino acid residues 21 to 234 of the amino acid sequence.

[0087] The humanized antibodies derived from rat_CD147_#131 antibody are (g) and (h) below. ) a human CD147 antibody or an antigen-binding fragment thereof having the following structure: (g) A heavy chain copolymer according to any one of the following (g1) to (g3): Variable area: (g1) amino acid residues 20 to 138 of the amino acid sequence shown in SEQ ID NO: 139 a heavy chain variable region consisting of: (g2) A sequence of the framework region other than each CDR sequence in the sequence of (g1) an amino acid sequence having at least 95% sequence identity to the (g3) A framework region other than each CDR sequence in the sequence of (g1) or (g2). an amino acid sequence in which one or several amino acids are deleted, substituted or added in the sequence of the region; To, (h) A light chain variable molecule selected from the group consisting of the following (h1) to (h3): Variable area: (h1) amino acid residues 21 to 128 of the amino acid sequence shown in SEQ ID NO: 141 a light chain variable region consisting of: (h2) A sequence of the framework region other than each CDR sequence in the sequence of (h1) an amino acid sequence having at least 95% sequence identity to the (h3) A framework region other than each CDR sequence in the sequence of (h1) or (h2). An amino acid sequence in which one or more amino acids are deleted, substituted or added in the sequence of the corresponding region.

[0088] A preferred example of a humanized antibody derived from the rat_CD147_#131 antibody is represented by SEQ ID NO: The heavy chain variable region consists of the 20th to 138th amino acid residues of the amino acid sequence shown in and the amino acid sequence from 21 to 128 of SEQ ID NO:141 The antibody includes a light chain variable region comprising:

[0089] A more preferred example of a humanized antibody derived from the rat_CD147_#131 antibody is A heavy chain consisting of amino acid residues 20 to 464 of the amino acid sequence shown in No. 139, and the amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:141. Examples include antibodies that contain a light chain.

[0090] Humanized antibody derived from the above rat_CD147_#84 antibody, rat_CD147_#1 Humanized antibody derived from 01 antibody, humanized antibody derived from rat_CD147_#110 antibody, or r The humanized antibody derived from the at_CD147_#131 antibody preferably inhibits CD147-mediated Activates p38MAPK signaling and / or SMAD4 signaling.

[0091] The antibody of the present invention further includes a human antibody. Anti-CD1 refers to a human antibody that has only the gene sequence of the antibody derived from a human chromosome. 47 Human antibodies, for example, have human chromosomal fragments that contain the genes for the heavy and light chains of a human antibody. Method using human antibody-producing mice (Tomizuka, K. et al., Nature Genetics(1997)16,p.133-143;Kuroiwa,Y.et .al.,Nucl.Acids Res.(1998)26,p.3447-3448 ;Yoshida,H.et.al.,Animal Cell Technology :Basic and Applied Aspects vol.10,p.69-7 3 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds. ), Kluwer Academic Publishers, 1999; Tomiz uka,K.et.al.,Proc.Natl.Acad.Sci.USA(2000 )97, pp.722-727, etc.) can be obtained by

[0092] Such human antibody-producing mice specifically have endogenous immunoglobulin heavy and light chains. The locus was destroyed and replaced by a human artificial chromosome. Mouse artificial chromosome (HAC) vectors and mouse artificial chromosomes Human immunoglobulin G (HIV) is delivered via vectors such as the cial chromosome (MAC) vector. A genetically modified animal into which the gene loci for heavy and light globulin chains have been introduced is called a knockout animal. and the creation of transgenic animals, and the creation of new strains of these animals by crossing them with each other. It can be brought out.

[0093] In addition, a human antibody encoding each of the heavy and light chains of the human antibody can be produced by genetic recombination technology. A eukaryotic cell is transformed with a cDNA, preferably a vector containing the cDNA, By culturing transformed cells that produce recombinant human monoclonal antibodies, can also be obtained from the culture supernatant. Here, the host may be, for example, a eukaryotic cell, preferably Mammalian cells such as CHO cells, lymphocytes and myeloma cells can be used.

[0094] In addition, we obtained human antibodies derived from phage display selected from a human antibody library. How to (Wormstone, IMet.al, Investigative O phthalmology & Visual Science.(2002)43(7 ),p.2301-2308;Carmen,S.et.al.,Briefings in Functional Genomics and Proteomics(20 02),1(2),p.189-203;Siriwardena,D.et.al., See Ophthalmology (2002) 109(3), p.427-431, etc. ) is also known.

[0095] For example, the variable region of a human antibody is expressed on the surface of a phage as a single chain antibody (scFv). The phage display method (Nature Bio technology (2005), 23, (9), p.1105-1116) By analyzing the genes of phages selected by binding to antigens, By using the DNA sequence encoding the variable region of a human antibody that binds to an antigen, it is possible to determine the DNA sequence encoding the variable region of the human antibody that binds to the antigen. Once the DNA sequence of the scFv that binds to the antigen is identified, an expression vector carrying the sequence can be prepared. A human antibody can be obtained by producing a human antibody vector and expressing the vector in an appropriate host. (WO92 / 01047, WO92 / 20791, WO93 / 06213, WO93 / 11236, WO93 / 19172, WO95 / 01438, WO95 / 15388, A nnu.Rev.Immunol(1994)12,p.433-455, Nature Biotechnology (2005)23(9), p.1105-1116).

[0096] The antibody of the present invention also includes an antibody having the same epitope as the antibody of the present invention. For example, LN22R8, 2P10F2, rat_CD147_#84, rat_CD147_ #101, rat_CD147_#110 or rat_CD147_#131 The present invention also includes antibodies having the same epitope as at least one of the above.

[0097] LN22R8 and 2P10F2 of the present invention bind to an epitope represented by mu3 in FIG. CD147v1: DALPGQKTEFKVDSDDQ (SEQ ID NO: 143), monkey CD1 47: DTLPGQKTDFEVDSDDL (SEQ ID NO: 144)). The antibody may include the sequence of SEQ ID NO:143 or SEQ ID NO:144, or the sequence of SEQ ID NO:143 or SEQ ID NO:1 In the sequence of 44, one or several, preferably one to three, more preferably one or two amines are Antibodies that recognize or bind to sequences containing amino acid sequences in which amino acids have been deleted, substituted or removed are also included. This antibody is preferred for activating signaling through CD147. I wish.

[0098] The antibody of the present invention also includes rat_CD147_#110, preferably humanized #11 This antibody recognizes the same epitope as 0H1L4. It is preferable that the humanized #110H1L4 activates signal transmission. The results are shown in Example 17.

[0099] A suitable antibody can be selected by evaluating its binding to an antigen, which is well known to those skilled in the art. The dissociation constant between the antibody and the antigen (CD147) is determined by using surface plasmon resonance (SPR) as a detection source. The Biacore T200 (GE Healthcare Bioscience) was used as a control. For example, a suitable antibody can be used to measure the antigen immobilized as a ligand. The antibody is reacted with the analyte at a specific concentration, and the binding and dissociation are measured. The binding rate constant ka1, the dissociation rate constant kd1 and the dissociation constant (KD; KD=kd1 / ka1 ) can be obtained.

[0100] The binding evaluation for CD147 is not limited to the use of Biacore T200, but can be performed using surface plasma The detection principle is spin-polarized spectroscopy (SPR), and the kinetic exclusion method (Kinetic Exclusion Method) is used. KinExA (Sapidyne Instrumentation Assay) is used as the detection principle. ruments), Bio-Layer Interferometry The detection principle is the BLItz system (Pall) or ELISA ( Enzyme-Linked ImmunoSorbent Assay is also possible.

[0101] Another index for comparing antibody properties is antibody stability. Differential scanning calorimetry (DSC) is a thermal analysis method that provides a good indicator of the relative structural stability of proteins. This method allows the denaturation midpoint (Tm) to be measured quickly and accurately. By measuring the Tm value and comparing the values, it is possible to compare the differences in thermal stability. It is known that the storage stability of antibodies shows a certain degree of correlation with their thermal stability. (Lori Burton,et.al.,Pharmaceutical Devel opment and Technology(2007)12,p.265-273) In addition, a suitable antibody can be selected based on its thermal stability. The targets are high yield in suitable host cells and low aggregation in aqueous solution. For example, the antibody with the highest yield does not necessarily exhibit the highest thermostability. Therefore, based on the above-mentioned criteria, a comprehensive judgment is made to select the most suitable antibody for administration to humans. You need to select the body.

[0102] Alternatively, the full-length sequences of the heavy and light chains of an antibody may be linked together using an appropriate linker to produce a single-chain immunoglobulin. Those who want to obtain single chain immunoglobulin The method is also known (Lee, HS, et. al., Molecular Immuno logy(1999)36,p.61-71;Shirrmann,T.et.al., mAbs (2010), 2, (1) p. 1-4). Such single-chain immunoglobulins are By dimerizing, it is possible to maintain a structure and activity similar to that of antibodies that are originally tetramers. In addition, the antibody of the present invention may have a single heavy chain variable region and no light chain sequence. Such antibodies may be single domain antibodies. These are called sdAb (single-stranded antibody) or nanobodies. It has been reported that this has actually been observed in camels and llamas, and that antigen-binding ability is maintained. (Muyldemans S.et.al., Protein Eng.(1994) 7(9),1129-35,Hamers-Casterman C.et.al.,N The above antibody is It can also be interpreted as a type of antigen-binding fragment of an antibody.

[0103] In addition, by regulating the sugar chain modification bound to the antibody of the present invention, antibody-dependent cellular It is possible to enhance the cytotoxicity of antibodies. No. 54342, WO2000 / 61739, WO2002 / 31140, etc. are known. , but is not limited to these.

[0104] When the antibody gene is isolated and then introduced into a suitable host to produce the antibody, a suitable Any combination of host and expression vector can be used.

[0105] Specific examples of antibody genes include genes encoding the heavy chain sequences of the antibodies described herein. The host cell may include a combination of genes encoding the low and high chain sequences. When transforming cells, the heavy and light chain sequence genes are inserted into the same expression vector. It is possible for the gene to be inserted into a single expression vector, or it may be inserted into a separate expression vector. When eukaryotic cells are used as hosts, animal cells, plant cells, and eukaryotic microorganisms can be used. As animal cells, mammalian cells, for example, monkey cells, COS cells (Gl uzman, Y. Cell (1981) 23, p. 175-182, ATCC CRL- 1650), mouse fibroblast NIH3T3 (ATCC No. CRL-1658) and Dihydrotestosterone-containing Chinese hamster ovary cells (CHO cells, ATCC CCL-61) Acid reductase-deficient strain (Urlaub, G. and Chasin, LA Proc. Na tl. Acad. Sci. USA (1980) 77, p. 4126-4220) In addition, when prokaryotic cells are used, examples thereof include Escherichia coli and Bacillus subtilis. The desired antibody gene can be introduced into these cells by transformation, and the transformed cells can be The transformed cells are cultured in vitro to obtain antibodies. In this case, the yield may vary depending on the antibody sequence, and it is difficult to select antibodies with the same binding activity. It is possible to select those that can be easily produced as medicines using the yield as an indicator.

[0106] The isotype of the antibody of the present invention is not limited, and may be, for example, IgG (IgG1, IgG2 , IgG3, IgG4), IgM, IgA (IgA1, IgA2), IgD or Ig Examples of the antibody include IgG and IgM, and more preferably IgG. Some examples include:

[0107] Human IgG1 is one of the five human IgG subclasses that is involved in complement fixation. It has very strong effector functions such as CDC activity and antibody-dependent cytotoxicity (Bru ggemann et al., J. Exp. Med., 1351-1361, 1987), effector function when targeting molecules highly expressed in cancer with therapeutic antibodies IgG form that shows therapeutic effects by promoting cell death of cancer cells through cytotoxicity via These drugs are used as anti-cancer drugs (trastuzumab, rituximab, etc.) that target HLA-DR. In the case of human IgG1 antibodies, the CDC activity of human IgG1 antibodies is dependent on the antibody's CDC activity after administration. It has been reported that cynomolgus monkeys died, and the compound targets a molecule that is also expressed in normal organs. There is concern that effector functions may cause serious side effects in antibody drugs (Tawa ra, T., J. Immunology, 2008, 2294-2298). When IgG1 is used as the isotype of the antibody of the present invention, the IgG1 antibody has a mutation. The effector function may be enhanced by substituting a part of the amino acid residues in the constant region. It is possible to adjust the function (WO88 / 007089, WO94 / 28027, WO 94 / 29351). IgG1 mutants with reduced effector function include I gG1 LALA (IgG1-L234A, L235A), 1gG1 LAGA (IgG 1-L235A, G237A) and the like.

[0108] Human IgG2 is one of the five human IgG subclasses that is unique in that it is the only one that binds complement. The effector functions such as CDC activity and antibody-dependent cytotoxicity are very weak (Bru ggemann et al., J. Exp. Med., 1351-1361, 1987 ), and when therapeutic antibodies target molecules expressed in normal organs, they act through effector functions. It is used as one of the IgG formats to avoid toxicity due to cytotoxicity (deno sumab, evolocumab, brodalumab).

[0109] Human IgG4 is one of the five human IgG subclasses that is involved in complement fixation. The effector functions such as CDC activity and antibody-dependent cytotoxicity are very weak (Bru ggemann et al., J. Exp. Med., 1351-1361, 1987 ), and when therapeutic antibodies target molecules expressed in normal organs, they act through effector functions. It is used as one of the IgG formats to avoid toxicity due to cytotoxicity (option When IgG4 is used as the isotype of the antibody of the present invention, the amino acid sequence of the constant region is By substituting some of the amino acid residues, the cleavage characteristic of IgG4 is suppressed, and the half-life is extended. (Molecular Immunology, 30, 1 105 -108(1993)).

[0110] When IgG4 is used as the isotype of the antibody of the present invention, the IgG4 antibody has a mutation. The IgG4 variant may be selected from the group consisting of IgG4 variants that have the EU index (Proc Natl A cad Sci US A.1969, 63(1), 78-85;Kabat et. al., Sequences of proteins of immunology cal interest, 1991 Fifth edition) Substitution of phenylalanine at position 234 with alanine (F234A) and leucine at position 235 to alanine (L235A) (Parekh et al., mA bs, 310-318, 2012). Such antibody mutations are called FALA mutations. IgG4PFALA binds to FcγRs (e.g., FcγRI, F Two amino acid residues necessary for interaction with FcγRII or FcγRIII, etc., are replaced with alanine. The effector function is further weakened by the substitution of In order to increase stability, the formation of SS bonds between antibody heavy chains is not stable. The mutations introduced are those that promote the formation of fusion proteins. Examples of such mutations include a serine to proline substitution at position 228 (S228P) (ANGAL et.al.,Molecular Immunology,105-108,199 3). This antibody mutation is called a Pro mutation. The constant region of the antibody of the present invention contains the above FA The LA mutation and the Pro mutation may be introduced simultaneously (Vafa et al., Me thods, 65, 114-126, 2014). IgG4 heavy chain with FALA mutation The IgG4 heavy chain with the Pro mutation is called the "IgG4FALA" type heavy chain, and the IgG4 heavy chain with the Pro mutation is called the "IgG4 IgG4 heavy chains with both FALA and Pro mutations, called "P" type heavy chains is referred to as an "IgG4PFALA" type heavy chain.

[0111] The antibody heavy chain constant region is composed of CH1, hinge, CH2 and CH3 regions. CH1 is Index 118 to 215, Hinge EU Index 216 to 230, CH2 EU index 231 to 340, CH3 is defined as EU index 341 to 446 Proline substituted for serine at position 228 as indicated by the EU index; Alanine substituted for phenylalanine at position 234 and leucine substituted for leucine at position 235 The alanines in the IgG4 chimeric rat CD147 #84 heavy chain are In SEQ ID NO: 100 showing the amino acid sequence of LA, the 248th proline and the 254th Alanine at position 1 and 255, human chimera rat_CD147_#101 In SEQ ID NO: 108 showing the amino acid sequence of IgG4PFALA, the 245th promoter Phosphorus, alanine at position 251 and alanine at position 252, human chimera rat_CD1 47_#110 The amino acid sequence of heavy chain IgG4PFALA in SEQ ID NO: 108 is Corresponding to proline at position 244, alanine at position 250, and alanine at position 251 .

[0112] Preferred isotypes of the antibody of the present invention include IgG1, IgG2, IgG4, and Ig G4P or IgG4PFALA, and particularly preferred are IgG2, IgG4P or More preferably, IgG2 or IgG4P is Some examples include:

[0113] The antibody of the present invention is an antigen-binding fragment of the antibody having an antigen-binding site or a modified fragment thereof. The antibody may be treated with proteolytic enzymes such as papain and pepsin, or the antibody may be By modifying the somatic gene by genetic engineering techniques and expressing it in appropriate cultured cells, Among such antibody fragments, those having a full-length antibody molecule can be obtained by the above-mentioned method. Fragments that retain all or some of the antibody's function can be referred to as antigen-binding fragments of an antibody. The function of an antibody can include activation of antigen-associated signal transduction.

[0114] CD147 is also expressed on blood cells, including erythrocytes, and in normal organs essential for survival. (Spring, et al., Eur. J. Immunol., 1997, 89 1-897), the antitumor effect using the effector function associated with the antibody has a low risk of side effects. In fact, red blood cells have the effector function (A) induced by antibody binding. It has been reported that the genus is susceptible to DCC, CDC, and ADCP (Flegel, W. ,Transfusion,2015,S47-S58), antibodies against red blood cells are produced in the body. It is known that an increase in this protein can lead to autoimmune hemolytic anemia (Gibson, J., Aust.NZJMed., 1988. 625-637). The antibody of the present invention is Therapeutic antibodies targeting CD147, which is also expressed on normal cells, are a cause of serious side effects Either or all of the ADCC activity, ADCP activity, and / or CDC activity are low. or is barely detectable.

[0115] The present inventors have demonstrated that CD147-mediated cell signaling is activated regardless of the effector function of the antibody. We have found for the first time a human CD147 antibody that exhibits antitumor activity when activated by CD147. The function of the antibody is to bind to and / or activate CD147. The antibody of the present invention preferably inhibits downstream related signaling molecules via CD147, For example, FAK, MEK, Erk, JAK / STAT, AKT or MAP kinase (MA The antibody of the present invention activates the PK or related downstream signaling molecules. More preferably, it activates MAPK or a molecule downstream of MAPK. Preferably, p38MAPK is used. As a signal molecule further downstream of MAPK, , e.g., HSP27, cxcl8, or SMAD (e.g., SMAD2, SMAD3, or SMAD4, preferably SMAD4). "Activation of CD147" includes For example, increased mRNA expression of p38MAPK, increased protein expression of p38MAPK In addition, phosphorylation of p38MAPK and phosphorylation of HSP27 (e.g., Ser8 of HSP27) phosphorylation of HSP27 or phosphorylation of Ser15 of HSP27), and expression of cxcl8 mRNA. Increase in the expression of cxcl8 protein or rhoB m through activation of SMAD signaling Increased expression of rhoB RNA or increased expression of rhoB protein. As the "activation," preferably, the increase in the protein expression level of p38MAPK, the phosphorylation of p38MAPK, phosphorylation of HSP27 (e.g., phosphorylation of Ser82 of HSP27 or phosphorylation of HSP27 phosphorylation of Ser15 of CXCL8, increased expression of CXCL8 mRNA or SMAD signaling activity SMAD2 or SMAD 3. When TGFβ binds to the TGFβ receptor (TGFBR1 / 2), It is phosphorylated by , forms a heterotrimer with SMAD4, translocates into the nucleus, and is expressed on chromosomes. The SMAD DNA binding element (Smad binding element: SBE) of It binds to the transcriptional regulatory region that regulates the mRNA expression of downstream genes positively or negatively. It is known (Miyazono, J. Geriatrics., 1999, 162-166). The presence of SMAD2 or SMAD3 is thought to be necessary for activation. MAD3 and SMAD4 negatively regulate the expression of KLF5 in a TGFβ-dependent manner (D avid et al.,Cell, 2016,164(5),1015-1030) In pancreatic cancer cells lacking SMAD4, the KLF5 gene is downregulated by SMAD2 and SMAD3. The inhibitory signal from SMAD4 is released, and the KLF5 protein is expressed. SMAD4 Loss of KLF5 inhibits TGFβ-dependent cell death signaling (SOX4-dependent It is known that the oxidative stress-dependent (targeted) pathway is suppressed (David et al., Cell, supra).

[0116] The present inventors have demonstrated that the human CD147 antibody of the present invention phosphorylates p38MAPK (Figure 21 ), phosphorylating HSP27 (Figure 20) and increasing the expression of cxcl8. (Figures 22(b) and 23(b)). Thus, the levels of these molecules were significantly increased before and after administration of the antibody of the present invention. At least one of the gene expression, protein expression, or phosphorylation state of By confirming whether the antibody of the present invention changes the expression of CD147, You can check whether it is.

[0117] Furthermore, the present inventors have found that the human CD147 antibody of the present invention is capable of inhibiting the expression of SMAD4 protein. The human CD147 antibody of the present invention shows efficacy against pancreatic cancer models (Figure 25); Pancreatic cancer tumors such as BxPC-3, which have genetic mutations in MAD4 and do not express SMAD4, In the present study, the antitumor effect was partial (~30%) (Figure 24); In tumors following treatment with a clear human CD147 antibody, SMAD2, SMAD3 and SMAD We found that the downstream molecule of 4 (rhoB, Fig. 22(c) and Fig. 23(c)) was induced. Therefore, the gene expression or protein expression of rhoB changes before and after administration of the antibody of the present invention. By confirming whether or not the antibody of the present invention activates CD147, In addition, the genomic sequence of SMAD4 in patient samples can be used to confirm whether Gene expression or protein expression is measured using methods known to those skilled in the art, and SMAD4 is expressed. A patient suffering from the disease is selected as a patient to whom the antibody of the present invention is to be administered, and the antibody of the present invention is administered. can be done.

[0118] In addition, KLF5 expression was found to be high in SMAD4-negative models such as BxPC-3. It is known (David et al., Cell, 2016, 164(5), 10 The human CD147 antibody of the present invention is a KLF5-expressing MIA Pa In the Ca-2 model, the sensitivity decreased from 91% to 20% (Example 26). We found that KLF5 expression suppresses SMAD2 and SMA expression induced by CD147 antibody. The present inventors believe that D3- and SMAD4-dependent cell death signals are suppressed. , ALL, lymphoma, gastrointestinal stromal tumor (GIST), skin cancer, sarcoma, AML, or kidney cancer Therefore, it is expected that many patients will respond to the human CD147 antibody of the present invention. In addition, the gene expression or protein expression of KLF5 in a patient sample can be analyzed by a method well known to those skilled in the art. The antibody of the present invention is administered to a patient having reduced or absent KLF5 expression. The antibody of the present invention can be administered to a patient selected from the group consisting of KLF and IL-1. 5 The degree of reduction in expression can be determined by methods well known to those skilled in the art and by conducting appropriate clinical trials. For example, the expression of KLF5 in patients who responded and those who did not respond can be examined. The current amount is compared and an appropriate threshold is set.

[0119] For example, antibody fragments include Fab, F(ab')2, Fv, or F(ab') of heavy and light chains. Single chain Fv (scFv) in which v is linked with an appropriate linker, diabody ( Examples of antibodies include diabodies, linear antibodies, and multispecific antibodies formed from antibody fragments. In addition, monovalent fragments of the variable region of an antibody obtained by treating F(ab')2 under reducing conditions can be obtained. The fragment Fab' is also included in the antibody fragments.

[0120] Furthermore, the antibody of the present invention is a multispecific antibody having specificity for at least two different antigens. Such molecules usually bind to two different antigens (i.e. That is, bispecific antibodies) "Multispecific antibodies" include antibodies that have specificity for more than one antigen (e.g., three types). It includes.

[0121] The multispecific antibodies of the present invention may be full-length antibodies or fragments of such antibodies (e.g., F (ab')2 bispecific antibodies) are also possible. Bispecific antibodies are antibodies that combine two different antibody heavy and light chains ( They can be made by combining two different antibodies (HL pairs) or by combining two different antibodies that produce different monoclonal antibodies. Bispecific antibody-producing hybridomas can also be fused to produce bispecific antibody-producing hybridomas. (Millstein et al., Nature (1983) 3 05, p.537-539).

[0122] The antibody of the present invention may be a single chain antibody (also referred to as scFv). A heavy chain variable region and a light chain variable region are linked with a polypeptide linker. (Pluckthun,The Pharmacology of Monoclona Antibodies, 113 (eds. Rosenberg and Moore, Springer, Ger Verlag, New York, p. 269-315 (1994), Natu re Biotechnology (2005), 23, p.1126-1136). In addition, a BiscFv fragment is prepared by linking two scFvs with a polypeptide linker. They may also be used as bispecific antibodies.

[0123] Methods for producing single chain antibodies are well known in the art (see, e.g., U.S. Pat. No. 4,633,663). No. 946,778, U.S. Pat. No. 5,260,203, U.S. Pat. No. 5,091,513 (See U.S. Patent No. 5,455,030, etc.) In this scFv, the heavy chain variable region and The light chain variable region is preferably linked to a linker, preferably a polypeptide linker, that does not form a conjugate. (Huston, J.S. et al., Proc. Natl. .Acad.Sci.USA(1988), 85, p.5879-5883). s The heavy and light chain variable regions in a cFv may be derived from the same antibody or may be derived from separate The polypeptide linker linking the variable regions may be derived from an antibody. Any single chain peptide of .about.19 residues can be used.

[0124] The DNA encoding the scFv is DNA encoding the heavy chain or heavy chain variable region of the antibody. and DNA encoding the light chain or the light chain variable region, The DNA portion encoding the desired amino acid sequence is used as a template, and primers are used to define both ends of the template. The pair is then amplified by PCR, and a polypeptide linker portion is then further amplified. The DNA is combined with a primer pair that specifies that both ends of the DNA are linked to the heavy and light chains, respectively. It is obtained by combining and amplifying the

[0125] In addition, once DNA encoding scFvs has been prepared, expression vectors containing them can be used. and a host transformed with the expression vector can be obtained by a conventional method. By using the host, scFv can be obtained according to a conventional method. The fragment can be produced by a host by obtaining and expressing the gene in the same manner as described above. do.

[0126] The antibody of the present invention may be polymerized to increase affinity for an antigen. A single antibody may recognize multiple epitopes of the same antigen. A method for multimerizing antibodies may be to combine IgG CH3 domains and Binding to two scFvs, binding to streptavidin, helix-turn-helix Examples include the introduction of a motif.

[0127] The antibody of the present invention is a mixture of multiple types of anti-CD147 antibodies with different amino acid sequences. The antibody may be a polyclonal antibody. An example of a polyclonal antibody is an antibody having different CDRs. Examples of such polyclonal antibodies include mixtures of multiple types of antibodies. by culturing a mixture of cells producing different antibodies and using antibodies purified from the cultures. This is possible (see WO2004 / 061104).

[0128] The antibody of the present invention has a heavy chain and / or a light chain which are 80% to 99% identical to those of the above-mentioned antibody. The antibody may have the same (or homologous) heavy chain amino acid sequence and the light chain amino acid sequence as described above. By combining sequences that show high homology with the amino acid sequence, it is possible to obtain antibodies equivalent to the above antibodies. Activation of CD147, preferably activation of MAPK, downstream signaling of MAPK It is possible to select antibodies that have the activity of a specific molecule. The homology is 80% or more, preferably 90% or more, more preferably 100% or more. Preferably, the homology is 95% or more, and most preferably 99% or more. The amino acid sequence of the main chain and / or the light chain is substituted, deleted and / or added with one or several amino acid residues. Combining the added amino acid sequences also exerts various functions equivalent to those of the above antibodies. It is possible to select an antibody having the following amino acid residues: The number is generally 10 amino acid residues or less, preferably 5 to 6 amino acid residues or less. More preferably, it is 2 to 3 amino acid residues or less, and most preferably, it is 1 amino acid residue. In addition, the lysine residue at the carboxyl terminal of the heavy chain of the antibody produced in cultured mammalian cells It is known that the nucleotide sequence is deleted (Tsubaki et al., Int. J. Biol. I. Macromol, 139-147, 2013). However, the deletion of these heavy chain sequences and modifications affect the antigen-binding ability and effector functions of antibodies (such as complement activation and antibody-dependent cellular cytotoxicity). Therefore, the present invention includes the modified antibody. , deletions of one or two amino acids at the heavy chain carboxyl terminus, and amidation The deleted form (e.g., a heavy chain in which the proline residue at the carboxyl terminal is amidated) However, antigen binding ability and related signal molecules downstream of CD147 are also included. The carboxyl-terminal deletion of the heavy chain of the antibody of the present invention may be omitted as long as the function of activating the antibody is maintained. The antibody is not limited to the above types. The two heavy chains constituting the antibody of the present invention may be full-length and and the deletion forms thereof, The ratio of the amounts of each deletion may be adjusted to produce the antibody of the present invention. Although the type of cultured mammalian cells and culture conditions may affect the antibody according to the present invention, For example, one amino acid residue is deleted from the carboxyl terminus of each of the two heavy chains. Some examples include:

[0129] The homology between two amino acid sequences was determined using the Blast algorithm version n 2.2.2(Altschul,Stephen F.,Thomas L.Mad den,Alejandro A.Schaffer,Jinghui Zhang,Z heng Zhang, Webb Miller, and David J. Lipma n (1997), “Gapped BLAST and PSI-BLAST: a ne w generation of protein database search Nucleic Acids Res. 25:3389-3402 ) can be determined using the default parameters of Blast. The algorithm is available on the Internet at www.ncbi.nlm.nih.gov It can also be accessed by accessing / blast. st algorithm to find Identity (or Identities) and Two types of percentage values ​​of Positivity (or Positivities) The former is calculated when there is a single amino acid residue between two amino acid sequences for which homology is to be determined. The latter value takes into account amino acid residues with similar chemical structures. In this specification, identity is defined as the difference between the amino acid residues. The value is taken as the homology value.

[0130] Antibodies conjugated with various molecules such as polyethylene glycol (PEG) as antibody modifications can also be used.

[0131] The antibodies of the present invention may further be conjugated with other drugs ( Examples of such antibodies include antibodies that are Examples include those bound to radioactive substances or compounds with pharmacological properties (Natur e Biotechnology (2005) 23, p. 1137-1146).

[0132] The obtained antibodies can be purified to homogeneity. Separation and purification of antibodies are performed in the same manner as for conventional proteins. For example, column chromatography, Filtration, ultrafiltration, salting out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric By appropriately selecting and combining techniques such as spot electrophoresis, antibodies can be separated and purified (Str ategies for Protein Purification and Cha racterization:A Laboratory Course Manual ,Daniel R.Marshak et al.eds.,Cold Spring Harbor Laboratory Press(1996);Antibodie s:A Laboratory Manual.Ed Harlow and Davi d Lane,Cold Spring Harbor Laboratory(198 8)) but is not limited to these.

[0133] Chromatography includes affinity chromatography, ion exchange chromatography, Chromatography, hydrophobic chromatography, gel filtration chromatography, reversed phase chromatography Examples of the methods include chromatography, adsorption chromatography, and the like.

[0134] These chromatography methods use liquid chromatography such as HPLC and FPLC. This can be done.

[0135] The columns used for affinity chromatography are protein A columns, An example of such a column is the Lotaine G column.

[0136] For example, columns using Protein A columns include Hyper D, POROS, and Se. pharose FF (GE Healthcare), etc.

[0137] Antibodies can also be purified by using antigen-immobilized carriers and utilizing their binding to antigens. It is possible.

[0138] (Drug containing anti-CD147 antibody) Anti-CD147 antibody obtained by the method described in the above section "Production of anti-CD147 antibody" The anti-CD147 antibody of the present invention can be obtained from the above. The antibodies of the present invention can be used as a therapeutic and / or preventive agent for tumors and / or cancers. The CD147 antibody has excellent antitumor activity and is useful as a therapeutic agent for tumors or cancer. The anti-CD147 antibody of the present invention is effective against gemcitabine-resistant cancer cells and sorafenib-low sensitive cancer cells. The anti-CD147 antibody of the present invention showed excellent antitumor effects in chronic myeloid leukemia cells. It showed significantly stronger efficacy than imatinib.

[0139] Tumors that can be treated with the anti-CD147 antibody of the present invention or a medicine containing said antibody include The tumor is not particularly limited as long as it expresses CD147, but is preferably a pancreatic cancer or liver cancer. , stomach cancer, colon cancer, kidney cancer, breast cancer, uterine cancer, ovarian cancer, lung cancer, thyroid cancer, skin cancer, head and neck cancer, meat tumors, prostate cancer, bladder cancer, brain tumors, gastrointestinal stromal tumors (GIST), leukemia (e.g., acute bone marrow tumors, Myeloid leukemia (AML), chronic myelogenous leukemia (CML), or chronic lymphocytic leukemia (CLL) ) or acute lymphocytic leukemia (ALL)), lymphoma or malignant lymphoma (e.g., B-cell lymphoma) lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma and pulmonary lymphoma (DLBCL), more preferably pancreatic cancer, liver cancer, stomach cancer, colon cancer, kidney cancer, leukemia, acute myeloid leukemia (AML), chronic bone marrow cancer, Myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL) , malignant lymphoma, B-cell lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma Examples include DLBCL.

[0140] In addition, examples of tumors that can be treated with the antibody of the present invention or a drug containing the antibody include S Tumors expressing MAD-positive CD147 are included, while tumors expressing SMAD-positive CD147 are included. Examples of tumors that can be treated include SMAD-positive CD147-expressing liver cancer and pancreatic cancer. The anti-CD147 antibody of the present invention or a drug containing the antibody preferably inhibits CD147. and / or SMAD expression is confirmed in patients. SMAD2, SMAD3 and / or SMAD4 are preferred, and SMA is more preferred. Preferably, in addition to confirming the expression of SMAD4, SMAD2 or S It is confirmed that at least one of the MAD3 genes is expressed.

[0141] Alternatively, tumors that can be treated with the antibody of the present invention or a drug containing the antibody include and tumors in which KLF5 expression is reduced or deleted. The tumors that were treated included liver cancer, ALL, lymphoma, gastrointestinal stromal tumor (GIST), skin cancer, and sarcoma. The anti-CD147 antibody of the present invention or the drug containing said antibody may be used as a treatment for cancer. is preferably administered to a patient in whom reduced or absent expression of KLF5 has been confirmed.

[0142] The anti-CD147 antibodies of the invention may be administered in combination with two, three or more other therapeutic agents, depending on the therapeutic objective. The other therapeutic agents can be administered by encapsulating them in the same formulation. The other therapeutic agent and the anti-CD147 antibody can be administered simultaneously in the same formulation. Alternatively, the anti-CD147 antibody and the other therapeutic agent can be administered simultaneously. They can also be packaged in separate formulations and administered simultaneously. The antibodies can also be administered separately, either before or after the other therapeutic agent. administering a therapeutic agent containing the D147 antibody or an antigen-binding fragment of said antibody as an active ingredient; Alternatively, a therapeutic agent containing an anti-CD147 antibody or an antigen-binding fragment of the antibody as an active ingredient is provided. This administration may be followed by administration of other therapeutic agents.

[0143] The present invention relates to a therapeutically and / or prophylactically effective amount of an anti-CD147 antibody and a pharma- ceutical acceptable dilution. Also provided are pharmaceutical compositions comprising the agent, carrier, solubilizer, emulsifier, preservative and / or adjuvant.

[0144] The present invention relates to a therapeutically and / or prophylactically effective amount of an anti-CD147 antibody and a therapeutically and / or prophylactic an effective amount of at least one antitumor therapeutic agent and a pharma- ceutically acceptable diluent, carrier, solubilizer; Pharmaceutical compositions containing emulsifiers, preservatives and / or adjuvants are also provided.

[0145] The substances used in the formulations acceptable for the pharmaceutical compositions of the present invention are preferably those having dosage and The concentrations administered are preferably non-toxic to those receiving the pharmaceutical composition.

[0146] The pharmaceutical composition of the present invention is characterized in terms of pH, osmolality, viscosity, transparency, color, isotonicity, sterility, stability, Contains formulation substances that modify or maintain dissolution rate, release rate, absorption rate, or permeability rate Formulation materials may include, but are not limited to: Not applicable: glycine, alanine, glutamine, asparagine, arginine or lysine Amino acids, antibacterial agents, ascorbic acid, sodium sulfate, sodium bisulfite, and other antioxidants Acidifiers, phosphoric acid, citric acid, borate buffer, sodium bicarbonate, Tris-HCl (Tr is-HCl) solution, bulking agents such as mannitol and glycine, ethylenediamine Chelating agents such as EDTA, caffeine, polyvinylpyrrolidine, β-cyclodextrin Complexing agents such as dextrin and hydroxypropyl-β-cyclodextrin, glucose, malic acid, bulking agents such as saccharides or dextrin, other carbohydrates such as monosaccharides and disaccharides, coloring agents, flavorings agents, diluents, emulsifiers, hydrophilic polymers such as polyvinylpyrrolidine, low molecular weight polypeptides, Salt forming counterions, benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenanthroline Netyl alcohol, methylparaben, propylparaben, chlorexidine, sorbic acid or Contains no preservatives such as hydrogen peroxide, glycerin, propylene glycol or polyethylene glycol. Solvents such as ethanol, sugar alcohols such as mannitol or sorbitol, suspending agents, sorbitan ethers, etc. Sterl, polysorbate 20, polysorbate 80, and other polysorbates, Triton (tr iton), tromethamine, lecithin or cholesterol Surfactants such as sucrose and sorbitol, stabilizing agents such as sodium chloride, potassium chloride, etc. Elasticity enhancers, transport agents, excipients, and / or pharmaceuticals such as sodium, mannitol, and sorbitol. The amount of these substances added for the formulation is 0.0 times the weight of the anti-CD147 antibody. It is preferable to add 1 to 100 times, particularly 0.1 to 10 times. The composition can be appropriately determined by those skilled in the art depending on the applicable disease, the applicable administration route, etc. .

[0147] In pharmaceutical compositions, excipients or carriers may be liquid or solid. Suitable excipients or carriers are It may be water, saline, artificial cerebrospinal fluid, or any other substance commonly used for parenteral administration. Physiological saline containing no active ingredient or saline containing serum albumin can also be used as a carrier. The composition includes Tris buffer, pH 7.0-8.5, acetate buffer, pH 4.0-5.5. These buffers may contain citrate buffers of pH 3.0-6.2. The pharmaceutical composition of the present invention may contain sorbitol or other compounds. Pharmaceutical compositions comprising an anti-CD147 antibody and an anti-CD147 antibody and at least one anti-tumor treatment - Patents.com The pharmaceutical composition of the present invention includes a pharmaceutical composition containing a selected composition and a necessary agent. It is available as a lyophilized or liquid preparation with high purity. and a pharmaceutical composition comprising an anti-CD147 antibody and at least one anti-cancer therapeutic agent. The composition may also be formulated as a lyophilizate using suitable excipients such as sucrose. Cut.

[0148] The pharmaceutical composition of the present invention can be prepared for parenteral administration, or can be absorbed orally through the gastrointestinal tract. The composition and concentration of the formulation can be determined depending on the administration method. When the antibody of the present invention is administered to a human, it is administered at a dose of about 0.1 to 100 mg / kg in 1 to 1 It may be administered once or multiple times over an 80-day period. However, the dosage and frequency of administration generally vary according to the individual patient. The decision should be made taking into consideration the patient's gender, weight, age, symptoms, severity, side effects, etc. The dosage and administration are not limited to those mentioned above.

[0149] The pharmaceutical composition of the present invention may be in the form of an injection, including a drip infusion, a suppository, a nasal agent, a sublingual agent, or a transdermal agent. The administration route is oral or parenteral, and parenteral Routes include, for example, intravenous, intraarterial, intramuscular, intrarectal, transmucosal, and intradermal. can be done.

[0150] The antibody or antigen-binding fragment of the antibody of the present invention, a drug conjugate containing the same, The bispecific antibodies and pharmaceutical compositions containing them are These antibodies and pharmaceutical compositions may be provided in combination with biomarkers for selection. The method may be provided as a kit in combination with a means for detecting the biomarker, The antibody or pharmaceutical composition and the biomarker may be provided separately. By using the antibody of the present invention, the antibody and pharmaceutical composition of the present invention can be expected to have a higher effect. The therapeutic agent may be administered to a patient population that is receiving the therapeutic

[0151] The present invention uses a biological sample derived from a cancer patient, and detects SMAD4 in the biological sample. The expression of SMAD4 or KLF5 was measured, and patients with SMAD4 or low KLF5 expression were Patients in whom a defect or deletion has been detected are treated with the antibody of the present invention or a functional fragment of the antibody, or the present invention. determining whether a patient is responsive to treatment of cancer with the pharmaceutical composition of the invention; A method for predicting response to cancer using a biological sample from a cancer patient, Patients in whom MAD4 expression or KLF5 expression was detected and SMAD4 or KLF5 expression was detected Patients in whom reduced expression or deletion of the antibody of the present invention has been detected are and selecting a subject for cancer treatment with the pharmaceutical composition of the present invention. A method for selecting a subject having a cancer using a biological sample derived from a cancer patient, the method comprising the steps of: Detecting the expression of SMAD4 or KLF5, and determining whether SMAD4 or KLF5 is present in the patient The antibody of the present invention or the function of said antibody is administered to patients in whom a decrease in expression or deletion of 5 is detected. a method for treating cancer comprising administering a therapeutically active fragment or a pharmaceutical composition of the present invention; Response to treatment of cancer with the disclosed antibody or functional fragment of said antibody or pharmaceutical composition of the present invention A kit for determining the expression or function of SMAD4 in a biological sample derived from a cancer patient, comprising: The present invention relates to a kit comprising at least a means for detecting the expression of KLF5.

[0152] As used herein, a "biological sample" refers to tissues, fluids, cells, and tissue samples isolated from an individual. This refers to a mixture of these fluids, such as tumor biopsies, cerebrospinal fluid, pleural fluid, abdominal fluid, lymphatic fluid, skin resection fluid, etc. tissues, blood, urine, feces, sputum, respiratory tract, intestinal tract, genitourinary tract, saliva, milk, digestive organs, and Examples of biological samples include, but are not limited to, cells obtained from a subject. " is preferably a sample containing cancer cells, more preferably obtained by resection or biopsy. Examples of the cells include tissues and cells derived from the pleural or peritoneal fluid. A suitable biological sample is a sample containing cancer cells or cancer tissue.

[0153] The detection or measurement of "SMAD4 expression" includes the detection or measurement of the genomic sequence, gene expression, or protein of SMAD4. Expression can be performed using methods well known to those of skill in the art, for example, RNA sequencing. , microarrays, genome sequencing, and immunoassays.

[0154] The detection or measurement of "KLF5 expression" refers to the genomic sequence, gene expression, or protein expression of KLF5. The expression can be detected using methods well known to those skilled in the art, for example, IHC, RNA sequencing, etc. These include sequencing, microarrays, genome sequencing, and immunoassays. "Decreased expression of" refers to a decrease in expression of a gene in a control (e.g., expression level in a healthy subject or in non-cancerous tissue of the same patient). Alternatively, the expression level of the antibody or the antibody of the present invention is lower than that of the antibody or the antibody of the present invention. The present invention relates to a method for determining whether a patient has a low level of KLF5 expression, which can be used to determine whether the patient is responsive to cancer treatment with a pharmaceutical composition. The degree of hypoxemia can be determined by those skilled in the art using known methods and by conducting appropriate clinical trials, e.g. For example, the expression levels of KLF5 in patients who responded to the treatment and those who did not respond to it were compared. Therefore, the "decreased expression of KLF5" refers to, for example, This means that the measured value is below the threshold value set by the EXAMPLES

[0155] The present invention will be described in detail with reference to the following examples, but the present invention is not limited thereto. Furthermore, these should not be interpreted in any restrictive manner. In the following examples, unless otherwise specified, each operation related to genetic manipulation was performed according to the method described in "Molecular "Molecular Cloning" (Sambrook, J. ., Fritsch, E.F. and Maniatis, T., Cold Spring (published by Harbor Laboratory Press in 1989) The method may be performed according to the methods described in the experimental manuals or other documents used by those skilled in the art, or may be performed using commercially available reagents and kits. When using a commercially available product, the procedure was carried out according to the instructions provided with the product. The free reagents, solvents and starting materials are readily available from commercial sources. The human pancreatic cell line MIA PaCa-2 was purchased from ATCC, Cat. CRL-1420. The human pancreatic cancer cell line PANC-1 was obtained from ATCC, Cat. CRL-1469. Ta.

[0156] Example 1: Preparation of mouse and rat antibodies by cellular immunization 1)-1 Construction of CD147 expression vector A commercially available clone of the human CD147 gene (BSG variant 2 / CD147v2) IOH3378 (Invitrogen) and mammalian cell expression vector pcDNA-DE ST40 (Invitrogen) was reacted with Gateway LR clonase. A human CD147v2 expression vector (pcDNA-DEST40-CD147v2) was constructed. Made.

[0157] Commercially available mammalian CD147 gene (BSG variant 1 / CD147v1) Cell expression vector pCMV6-XL5-hBSGv1 (Origene, Cat.S C303059) was purchased and used as a human CD147v1 expression vector.

[0158] The cynomolgus monkey CD147 expression vector was pCMV3-cynoBSG (Sino The 10-μg / mL 100-ng / mL lysine monophosphate buffer was purchased from Sigma-Aldrich Co., Ltd. (Cat. CG90636-UT, Sigma-Aldrich Co., Ltd.).

[0159] The mouse CD147v2 expression vector was pCMV3-mBSGv2 (Sino B The 10-μm-thick ...

[0160] 1)-2 Preparation of mouse hybridomas BALB / cAnNCrlCrlj mice (4-6 weeks old, Charles River, Japan) On days 0, 7, 15, and 24, Versene (Thermo Fis) was used. Her Scientific) peeled off 5 x 10 6 LNCaP cells (ATCC , CRL-1740) was suspended in PBS and administered subcutaneously to the back of the mouse. ×10 6 The spleen was harvested on the same day and used for hybridoma production. Usmieloma P3X63Ag8U.1 cells (ATCC, CRL-1597) and PEG Hybridomas were produced by cell fusion using the 4000 (IBL Co., Ltd.). For isolation and culture, ClonaCell-HY Medium D (STEMCELL TE CHNOLOGIES), ClonaCell-HY MediumE (STEMCE) LL TECHNOLOGIES) was used.

[0161] 1)-3 Preparation of rat hybridomas Seven-week-old WKY / Izm (Japan SLC Co., Ltd.) human pancreatic cancer cell line was used. PANC-1 1×10 7Each animal was immunized in the buttocks, and 13 days later, iliac lymph node cells were collected and used for hybridization. Rat spleen cells and mouse myeloma SP2 / 0-Ag14 cells ( ATCC, CRL-1581) was cultured using the LF301 cell fusion device (Vex Co., Ltd.). Hybridomas were isolated and cultured using Clona. Cell-HY MediumD (STEMCELL TECHNOLOGIES), ClonaCell-HY MediumE(STEMCELL TECHNOLOGI ES Co.) was used.

[0162] 1)-4 Antigen Identification by ELISA Human CD147Fc fusion protein (Sino Biological, Cat.101 86-H02H) and mouse CD147Fc fusion protein (Sino Biological The human CD147Fc fusion protein and mouse CD147Fc fusion protein were used. CD147Fc fusion protein was dissolved in PBS buffer on ice and adjusted to 1 μg / ml. The protein solution was placed in a 96-well plate (NUNC, Cat. 442404). and stored at 4° C. overnight to coat the wells with the CD147Fc fusion protein. Except for the protein solution, 1% BSA (Research Organics, Cat. The wells were blocked with PBS buffer containing 0.05% T Wash the wells with PBS buffer containing Ween 20 (ATTO, Cat. WSE-7235). After washing three times, the hybridoma culture supernatants prepared in Examples 1)-2 and 1)-3 were added to PB The solution was diluted 20-fold with S buffer, added to each well, and incubated at room temperature for 1 hour. Wash the wells three times with PBS buffer containing 20 (ATTO, Cat. WSE-7235). After that, anti-rat-F was diluted 50,000 times with PBS buffer containing 1% BSA. ab2-igG-HRP (Jackson ImmunoResearch, Cat. 112-036-072) was added in an amount of 100 μl and the mixture was shaken at room temperature for 30 minutes. Wash the wells with PBS buffer containing een20 (ATTO, Cat. WSE-7235) for 5 min. After washing twice, 100 μl of HRP enzyme coloring reagent (eBioscience, Supe r AquaBlue ELISA substrate, Cat.00-4203) Add the mixture, warm it at room temperature for 10 to 20 minutes, and then read it on a plate reader (Envision, PerkinElmer, The absorbance at 405 nm was measured using a chromatograph (Marr Co., Ltd.). The average absorbance values ​​of 2 to 3 wells were calculated. The value was calculated, and the antibody that showed an absorbance value that was more than twice the value measured in the control well without the primary antibody was selected. The results are summarized in Table 1. LN22R8, 2P1A6, 2P3A9, 2P3G8, 2P8C12, 2P10F 2. Culture supernatants of 2P2D7, 2P2D10, and 2P1B7 were analyzed using human CD147Fc fusion Specific color development was confirmed in the fusion protein-coated wells. LN24R7, 2P5F5, 2P6A2 For 2P3G8, human and mouse CD147Fc fusion protein-coated wells were specifically The color development was confirmed.

[0163] [Table 1]

[0164] 1)-5 Preparation of monoclonal antibodies and determination of antibody isotype The hybridomas confirmed to produce anti-human CD147 antibodies in Example 1)-4 were stably For culturable cells, a commercially available isotyping kit was used to identify the The isotypes of the antibodies were determined and are shown in Table 2. These hybridomas were cultured using a ELISA kit (Dickinson & Company) to produce monoclonal antibodies. Antibody-containing hybridoma culture supernatant was prepared.

[0165] [Table 2]

[0166] 1)-6 Purification of monoclonal antibodies The antibody was purified from the culture supernatant prepared in Example 1)-5. For clonal antibodies, rProtein A affinity chromatography ( The product was purified in a single step at 4-6°C using rProtein A affinity chromatography. The buffer replacement step after purification was carried out at 4 to 6°C. First, the culture supernatant was diluted with PBS. Equilibrated MabSelectSuRe (GE Healthcare Biosciences After the culture medium was completely filled into the column, The column was washed with PBS at least twice the volume of the column. Then, 2 M arginine hydrochloride solution (pH The antibody was eluted with 4.0 ml of hexane and the fractions containing the antibody were collected. ientific, Slide-A-Lyzer Dialysis Cassett e) was added to HBSor (25 mM Histidine / 5% Sorbitol / pH The liquid was replaced with Centrifugal UF Filter Devi 6.0. ce VIVASPIN20 (molecular weight cutoff UF10K, Sartorius, 4℃) The IgG concentration was adjusted to 4.9 mg / ml using Minisart-Pl. The mixture was filtered through a Sartorius filter (Sartorius) to obtain a purified sample.

[0167] For anti-human CD147 rat monoclonal antibody, use Protein G affinity chromatography. Protein G was purified in a single step by ice chromatography (at 4-6°C). The buffer replacement step after affinity chromatography purification was carried out at 4 to 6°C. First, Protein G (GE Healthcare Bios) was equilibrated with PBS. The hybridoma culture supernatant was applied to a column filled with IgG1 (Cypress Biosciences). After the entire supernatant had been loaded into the column, the column was washed with PBS having a volume at least twice that of the column. The antibody was eluted with 0.1M glycine / HCl solution (pH 2.7) and the fractions containing the antibody were collected. The collected fractions were adjusted to pH 7.0-7.5 by adding 1M Tris-HCl (pH 9.0). After adjustment, Centrifugal UF Filter Device VIVA SPIN20 (molecular weight cutoff UF30K, Sartorius, 4-6°C) was used for the analysis of HBS. or buffered to (25mM Histidine / 5% Sorbitol / pH6.0) The antibody concentration was adjusted to 1 mg / mL or more by performing a phasor exchange and concentration. Filtered through Minisart-Plus filter (Sartorius) and purified. It was simple.

[0168] 1)-7 Antibody screening by in vivo antitumor activity measurement 1×10 7The human pancreatic line PANC-1 was suspended in PBS and then transferred to NOD-scid mice ( Charles River Japan, NOD.CB17-Prkdc <scid> / J) axillary region The mice were subcutaneously transplanted. They were divided into groups based on the tumor volume, and 27, 34, and 41 days after transplantation, mouse antibodies were administered. CD147 antibody (LN22R8), rat anti-CD147 antibody (2P1A6, 2P1B7, 2P3G8, 2P2D10, 2P8C12, and 2P10F2) were administered at 10 mg / kg to tumor-bearing mice. The rat anti-CD147 antibody (2 P2D6) was administered intraperitoneally at 10 mg / kg to tumor-bearing mice (n=6). The diameter and minor diameter were measured twice a week using an electronic digital caliper (manufactured by Mitutoyo Corporation). The tumor volume was calculated using the formula shown below.

[0169] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 1(a)-(c). The graphs show the mean and standard deviations of the changes in tumor volume. The mean error is also shown. Results for 2P2D6 antibody, 2P3G8 antibody, and 2P2D10 antibody The tumor growth inhibition rate at the final measurement day, 48 days after transplantation, was 10 The rates were 10%, 45%, and 40% in the 22 mg / kg group, respectively. The results for the 2P1A6 antibody and the 2P1B7 antibody are shown in Figure 1(b). The tumor growth inhibition rates 48 days after implantation were 50% and 20%, respectively, in the 10 mg / kg administration group. The results for the 2P8C12 and 2P10F2 antibodies are shown in Figure 1(c). The tumor growth inhibition rate at 48 days after transplantation, which was the final measurement day, was 10 mg / kg. The rates were -2% and 62% in the control and control groups, respectively.

[0170] 1)-8 Analysis of species cross-reactivity of CD147 antibody Lipofectamine 200 for CHO-K1 cells (ATCC, CCL-61) 0(Thermofishers Scientific, Cat.11668-01 9), pcDNA-DEST40-CD147v2 prepared in Example 1)-1, or pCMV3-cynoBSG was introduced, and one day later, mouse anti-human CD147 antibody (LN 22R8), or rat anti-human CD147 antibodies (2P1A6, 2P1B7, 2P3G8, 2P2D10, 2P8C12, 2P10F2, 2P2D6), 10μg / ml. Anti-mouse IgG-FITC (MP Biomedical, Cat.554936) or Anti-rat IgG-PE (BD Biosciences, Cat. 550767) The binding of each antibody to CD147-expressing CHO-K1 cells was made fluorescently detectable using CH. Human and cynomolgus CD147 expression in O-K1 cells was detected using a commercially available anti-CD147 antibody (MEM -M6 / 1, Ab Serotec, Cat. MCA28822) The above cells were detected using a flow cytometer (Canto II, BD The results are summarized in Figures 2-1 to 2-3. The horizontal axis indicates the cell number, and the horizontal axis indicates the intensity of the fluorescent signal.

[0171] Commercially available anti-CD147 antibody (MEM-M6 / 1), mouse anti-human CD147 antibody (LN2 2R8), rat anti-CD147 antibody (2P1A6, 2P1B7, 2P3G8, 2P2D1 0, 2P8C12, 2P10F2, and 2P2D6), all of the anti-CD147 antibodies bind to human CD The antibody showed binding to 147-expressing CHO-K1 cells (Figures 2-1 to 2-3).

[0172] The commercially available anti-CD147 antibody (MEM-M6 / 1) is derived from cynomolgus monkey CD147-expressing CHO- The mouse anti-human CD147 antibody (LN22R8) and rat anti- Human CD147 antibodies (2P1A6, 2P1B7, 2P3G8, 2P2D10, 2P8C1 2, 2P10F2, and 2P2D6), all of the CD147 antibodies expressed CD147 in cynomolgus monkeys. No binding was observed to current CHO-K1 cells (Figures 2-1 to 2-3).

[0173] All of the anti-CD147 antibodies showed no binding to mouse CD147-expressing CHO-K1 cells. (data not shown).

[0174] 1)-9 Epitope Analysis Construction of human CD147 variant expression vectors for epitope analysis The amino acid sequences of cynomolgus monkey and human CD147 were identified using BLAST search (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) and 81 % identical, with limited amino acid differences that affect epitope recognition for CD147 antibody binding. Assuming that this is a direct effect, we used a mutant in which the amino acid sequence differing between species was partially transplanted. We decided to proceed with the prediction of the anti-tumor epitope of hCD147v1 and v2. We compared the amino acid sequences of CD147 from cynomolgus monkeys and humans. The amino acid regions that differ between CD147 and CD147 are classified into nine regions, mu1 to mu9 (Figure 3). A human FLAG sequence was introduced into the N-terminus to construct a mutant expression vector and confirm its expression on the cell membrane. The cDNA sequence of CD147 variant 2 was artificially synthesized and expressed in the pcDNA3.1 vector. The plasmid introduced into the vector, Signal-N-Flag-hCD147v2_pcDNA3 .1 (produced by Genscript Co., Ltd.). DNA substitutions were made in 7 genes for the amino acid sequence mu1 to mu9 of CD147 from cynomolgus monkeys. Human-cynomolgus monkey chimeric CD147 expression vector with amino acid substitution mutations introduced by -9 species, hCD147-mu1_pcDNA3.1, hCD147-mu2_pcDNA 3.1, hCD147-mu3_pcDNA3.1, hCD147-mu4_pcDNA 3.1, hCD147-mu5_pcDNA3.1, hCD147-mu6_pcDNA 3.1, hCD147-mu7_pcDNA3.1, hCD147-mu8_pcDNA 3.1. hCD147-mu9_pcDNA3.1 was prepared (Genscript (Manufactured).

[0175] 1)-10 Identification of antitumor epitope regions using mutants Human CD147, cynomolgus monkey CD147, or human-cynomolgus monkey chimeric CD147 Expression vectors Nine types of expression vectors were transfected into CHO-K1 cells (ATCC, CCL-61). pofectamine 2000 (Thermo Scientific, Cat. 1166 8-019), and one day later, anti-human CD147 mouse antibody (LN22R8) , rat anti-human CD147 antibodies (2P1A6, 2P1B7, 2P3G8, 2P2D10, 2P8C12, 2P10F2, 2P2D6), 10μg / ml, and anti-mouse IgG -PE (DAKO, Cat. R480), anti-rat IgG-PE (BD, #5507 67) was used to examine the binding of anti-CD147 antibodies to CD147-expressing CHO-K1 cells. The expression of CD147 protein was measured using a commercially available anti-FLAG antibody (anti-Flag M2, SI The results were confirmed using a flow cytometer (GMA, Cat. F4049-.2MG). The results are summarized in Table 3. Compared to control cells not treated with primary antibody, a 10-fold increase in fluorescent signal was observed. Samples were scored as positive for binding (+). Samples in which the binding was observed were judged to be weakly positive (±). Samples that did not show an increase in the fluorescent signal compared to cells were considered to be negative for binding (- ) was determined.

[0176] Antibodies 2P3G8 and 2P10F2 in which an antitumor effect of 40% or more was observed in Example 1)-7 The antibodies 2P2D10 and LN22R8 all bind to CD147 with the mu3 mutation. The binding was lost. It was suggested that the epitope important for the antitumor effect was the m3 region. .

[0177] [Table 3]

[0178] 1)-11 Cloning of cDNAs encoding the variable regions of LN22R8 and 2P10F2 antibodies Determination of nucleotide sequence 1)-11-1 Nucleotide sequence of cDNA encoding the variable region of LN22R8 antibody Determining columns 1)-11-1-1 Preparation of total RNA from LN22R8 antibody-producing hybridoma Manufacturing To amplify cDNA encoding the variable region of the LN22R8 antibody, From the producing hybridoma, TRIzol Reagent (Ambion) was used to tal RNA was prepared.

[0179] 1)-11-1-2 Light chain variable region of LN22R8 antibody by 5'-RACE PCR Amplification and sequence determination of cDNA encoding The cDNA encoding the light chain variable region was amplified using the t Approximately 1 μg of total RNA was used with the SMARTer RACE 5' / 3' Kit (Cl The variable region of the light chain gene of the LN22R8 antibody was encoded by a chromatin-converting enzyme (Agilent Technologies, Inc.). The primers used to amplify the cDNA corresponding to the nucleotide sequence were UPM (Universal Primer 1). Primer A Mix: Included in the SMARTer RACE 5' / 3' Kit ), and a primer designed from the known sequence of the mouse light chain constant region was used.

[0180] The cDNA encoding the light chain variable region amplified by 5'-RACE PCR was inserted into the plasmid The nucleotide sequence of the cDNA encoding the light chain variable region is then sequenced. A sequence analysis was performed.

[0181] The nucleotide sequence of the cDNA encoding the variable region of the light chain of the LN22R8 antibody was determined. The sequence is shown in SEQ ID NO: 7 and the amino acid sequence is shown in SEQ ID NO: 8. The regions CDRL1, CDRL2 and CDRL3 are set forth in SEQ ID NOs: 11, 12 and 13, respectively. Shown in 3.

[0182] 1)-11-1-3 Heavy chain variable region of LN22R8 antibody by 5'-RACE PCR Amplification and sequence determination of cDNA encoding The cDNA encoding the heavy chain variable region was amplified using the t Approximately 1 μg of total RNA was used with the SMARTer RACE 5' / 3' Kit (Clo The heavy chain gene encoding the variable region of the LN22R8 antibody was The primers used to amplify the cDNA were Universal Primer (UPM). Primer A Mix: included in the SMARTer RACE 5' / 3' Kit), Primers designed from the known sequence of the constant region of mouse heavy chain were used.

[0183] The cDNA encoding the heavy chain variable region amplified by 5'-RACE PCR was inserted into the plasmid The cDNA encoding the heavy chain variable region is then cloned into A sequence analysis was performed.

[0184] The nucleotide sequence of the cDNA encoding the heavy chain variable region of the LN22R8 antibody was determined. The sequence of the heavy chain of the LN22R8 antibody is shown in SEQ ID NO: 9, and the amino acid sequence is shown in SEQ ID NO: 10. The variable regions CDRH1, CDRH2 and CDRH3 are set forth as SEQ ID NOs: 14, 15 and 16, respectively. Shown in Figure 16.

[0185] 1)-11-2 Nucleotide sequence of cDNA encoding the variable region of 2P10F2 antibody Determining columns The procedure was the same as in Example 1)-11-1. However, the variable region of the light chain gene was not encoded. The primers used to amplify the cDNA to be cloned were UPM (Universal Primer 1). Primer A Mix: Included in the SMARTer RACE 5' / 3' Kit ), and primers designed from the known sequences of the constant regions of rat light chains were used to generate the heavy chain genes. The primers used to amplify the cDNA encoding the variable region of Universal Primer A Mix:SMARTer RACE 5' / 3 The primers were designed based on the known sequence of the constant region of the rat heavy chain. Used.

[0186] The nucleotide sequence of the cDNA encoding the light chain variable region of the 2P10F2 antibody has been determined. The sequence is shown in SEQ ID NO: 17 and the amino acid sequence is shown in SEQ ID NO: 18. Light chain of 2P10F2 antibody The variable regions CDRL1, CDRL2 and CDRL3 are represented by SEQ ID NOs: 21, 22 and 23, respectively. The nucleotide sequence of the cDNA encoding the heavy chain variable region is shown in SEQ ID NO: 19. and the amino acid sequence is shown in SEQ ID NO: 20. CDRs of the heavy chain variable region of the 2P10F2 antibody H1, CDRH2 and CDRH3 are shown in SEQ ID NOs: 24, 25 and 26, respectively.

[0187] 1)-12 Construction of human chimeric antibody expression vector for LN22R8 1)-12-1 Construction of human chimeric and humanized light chain expression vector pCMA-LK Restriction of the plasmid pcDNA3.3-TOPO / LacZ (Invitrogen) A fragment of about 5.4 kb obtained by digestion with the enzymes XbaI and PmeI and the sequence of SEQ ID NO: D containing a DNA sequence encoding the human light chain signal sequence and the human κ chain constant region shown in The NA fragment was cloning using the In-Fusion HD PCR Cloning Kit (Clontech, ) to generate pcDNA3.3 / LK.

[0188] pCMA was created by removing the neomycin expression unit from pcDNA3.3 / LK. -LK was constructed.

[0189] 1)-12-2 Human chimeric and humanized IgG1 type heavy chain expression vector pCMA-G Construction of 1 pCMA-LK was digested with XbaI and PmeI to extract the light chain signal sequence and the human kappa chain constant sequence. A DNA fragment from which the region has been removed, a human heavy chain signal sequence shown in SEQ ID NO:28, and a human A DNA fragment containing a DNA sequence encoding the amino acid of the IgG1 constant region was The PCR products were ligated using the on HD PCR cloning kit (Clontech) to create pC MA-G1 was constructed.

[0190] 1)-12-3 Human chimeric and humanized IgG2 type heavy chain expression vector pCMA-G Construction 2 The amino acid sequence of the human heavy chain signal sequence and the human IgG2 constant region shown in SEQ ID NO:29 Using a DNA fragment containing the coding DNA sequence, the same method as in Example 1)-12-2 was used. pCMA-G2 was constructed using the above plasmid.

[0191] 1)-12-4 Construction of human chimeric LN22R8 light chain expression vector Example 1)-11-1-2: cDNA encoding the variable region of the light chain of LN22R8 NA was used as a template and primers designed for in-fusion cloning were used. A DNA fragment containing the cDNA encoding the light chain variable region was amplified by PCR. pCMA-LK was cut with the restriction enzyme BsiWI, and the In-Fusion HD The amplified DNA fragment was inserted using a PCR cloning kit (Clontech). A human chimeric LN22R8 light chain expression vector was constructed by inserting the human chimeric LN22R8 light chain The nucleotide sequence of the light chain of N22R8 and the amino acid sequence of the light chain are shown in SEQ ID NO: 30 and SEQ ID NO: 31. These are shown in column number 31.

[0192] 1)-12-5 Construction of human chimeric LN22R8 IgG1 type heavy chain expression vector 1) The cDNA encoding the variable region of the LN22R8 heavy chain obtained in -11-1-3 was used as a template. As a template, PCR was performed using primers designed for in-fusion cloning. A DNA fragment containing a cDNA encoding the heavy chain variable region was amplified by carrying out the above steps. MA-G1 was digested with the restriction enzyme BlpI and then ligated with In-Fusion HD PCR clone. Insert the amplified DNA fragment using a Cloning Kit (Clontech). The human chimeric LN22R8 IgG1 type heavy chain expression vector was constructed by the above procedure. The nucleotide sequence of the IgG1 type heavy chain of LN22R8 and the amino acid sequence of the heavy chain are shown below. These are shown in SEQ ID NO:32 and SEQ ID NO:33, respectively.

[0193] 1)-12-6 Construction of an expression vector for the IgG2 type heavy chain of human chimeric LN22R8 cDNA encoding the variable region of the LN22R8 heavy chain obtained in Example 1)-11-1-3 Using A as a template, P was generated using primers designed for in-fusion cloning. A DNA fragment containing cDNA encoding the heavy chain variable region was amplified by PCR. pCMA-G2 was cut with the restriction enzyme BlpI and the In-Fusion HD P The amplified DNA fragment was inserted using the CR cloning kit (Clontech). By this procedure, an expression vector for the human chimeric LN22R8 IgG2 type heavy chain was constructed. The nucleotide sequence of the IgG2-type heavy chain of the chimera LN22R8 and the amino acid sequence of the heavy chain The sequences are shown in SEQ ID NO:34 and SEQ ID NO:35, respectively.

[0194] 1)-12-7 Construction of human chimeric LN22R8 IgG4P type heavy chain expression vector The amino acid sequence of the IgG4P-type heavy chain of human chimeric LN22R8 shown in SEQ ID NO: 36 A DNA fragment containing the coding DNA sequence was synthesized (GENEART). Using the A fragment, human chimeric LN22R8 Ig was isolated in the same manner as in Example 1)-12-2. A vector expressing the IgG4P type heavy chain was constructed. The amino acid sequence of the heavy chain is shown in SEQ ID NO:37.

[0195] 1)-13 Construction of expression vector for human chimeric antibody 2P10F2 1)-13-1 Human chimeric and humanized IgG1LALA type heavy chain expression vector pC Construction of MA-G1LALA The human heavy chain signal sequence shown in SEQ ID NO: 38 and the human IgG1LALA constant region A DNA fragment containing a DNA sequence encoding amino acid was used to carry out the same procedure as in Example 1)-12-2. pCMA-G1LALA was constructed in a similar manner.

[0196] 1)-13-2 Human chimeric and humanized IgG4P type heavy chain expression vector pCMA- Construction of G4P The amino acid sequence of the human heavy chain signal sequence and the human IgG4P constant region shown in SEQ ID NO: 39 Using a DNA fragment containing the coding DNA sequence, the same method as in Example 1)-12-2 was used. pCMA-G4P was constructed using the above plasmid.

[0197] 1)-13-3 Construction of human chimeric 2P10F2 light chain expression vector cDNA encoding the variable region of the light chain of 2P10F2 obtained in Example 1)-11-2 As a template, human chimeric 2P1 was synthesized in the same manner as in Example 1)-12-4. A light chain expression vector for human chimeric 2P10F2 was constructed. The amino acid sequence of the light chain and the amino acid sequence of the light chain are shown in SEQ ID NO:40 and SEQ ID NO:41, respectively.

[0198] 1)-13-4 Human chimeric 2P10F2 IgG1LALA type heavy chain expression vector Construction cDNA encoding the heavy chain variable region of 2P10F2 obtained in Example 1)-11-2 As a template, primers designed for in-fusion cloning were used. PCR was performed on the 100-kDa DNA fragment containing the cDNA encoding the heavy chain variable region. pCMA-G1LALA was digested with the restriction enzyme BlpI, and the In-Fusi The amplified DNA was analyzed using the on HD PCR cloning kit (Clontech). Expression of IgG1LALA type heavy chain of human chimera 2P10F2 by inserting A fragment A vector was constructed. The nucleotide sequence of the IgG1LALA type heavy chain of human chimeric 2P10F2 was The peptide sequence and the amino acid sequence of the heavy chain are shown in SEQ ID NO: 42 and SEQ ID NO: 43, respectively.

[0199] 1)-13-5 Construction of an expression vector for the IgG2 type heavy chain of human chimeric 2P10F2 cDNA encoding the heavy chain variable region of 2P10F2 obtained in Example 1)-11-2 As a template, human chimeric 2P1 was synthesized in the same manner as in Example 1)-12-6. An expression vector for the IgG2 type heavy chain of human chimera 2P10F2 was constructed. The nucleotide sequences of the two types of heavy chains and the amino acid sequences of the heavy chains are shown in SEQ ID NO: 44 and SEQ ID NO: They are shown in No. 45 respectively.

[0200] 1)-13-6 Construction of human chimeric 2P10F2 IgG4P type heavy chain expression vector cDNA encoding the heavy chain variable region of 2P10F2 obtained in Example 1)-11-2 As a template, primers designed for in-fusion cloning were used. PCR was performed on the 100-kDa DNA fragment containing the cDNA encoding the heavy chain variable region. pCMA-G4P was cut with the restriction enzyme BlpI and the In-Fusion DNA fragments amplified using HD PCR cloning kit (Clontech) The human chimeric 2P10F2 IgG4P type heavy chain expression vector was constructed by inserting The nucleotide sequence of the IgG4P-type heavy chain of human chimeric 2P10F2 and the heavy chain The amino acid sequences of are shown in SEQ ID NO: 46 and SEQ ID NO: 47, respectively.

[0201] 1)-14 Production and preparation of human chimeric antibodies of LN22R8 and 2P10F2 1)-14-1 Production of human chimeric antibodies against LN22R8 and 2P10F2 FreeStyle 293F cells (Invitrogen) were cultured according to the manufacturer's instructions. Subculture and culture were performed. 1.2 × 10 9 FreeStyle 293 F cells (Invitrogen) were cultured in 3L Fernbach Erlenmeyer Flask (CORNING) was seeded with FreeStyle293 express ion medium (Invitrogen) to 2.0 × 10 6 cells / m The volume was adjusted to 40 L. 0.24 mg of heavy chain expression vector, 0.36 mg of light chain expression vector, and 1.8 mg of Po Add lyethyleneimine (Polyscience #24765) and gently The mixture was stirred gently and left for another 5 minutes before being added to the FreeStyle 293F cells. After 4 hours of shaking culture at 90 rpm in a 37℃, 8% CO2 incubator, L EX-CELL VPRO medium (SAFC Biosciences), 18 mL GlutaMAX I (GIBCO), and 30 mL of Yeastolate Ul Trafiltrate (GIBCO) was added and the cells were incubated in a 37℃, 8% CO2 incubator. The culture supernatant obtained by shaking the culture medium at 90 rpm for 7 days was placed in Disposable C Filtration with apsule filter (Advantec #CCS-045-E1H) did.

[0202] Human chimeric LN22R8 IgG1 type heavy chain expression vector and human chimeric LN22R8 The human chimeric antibody LN22R8 obtained by combining the light chain expression vectors is called "LN22 The human chimeric LN22R8 IgG2 type heavy chain expression vector was named “R8chIgG1”. LN22R8 obtained by combining the target and human chimeric LN22R8 light chain expression vectors The human chimeric antibody was named "LN22R8chIgG2". A combination of the IgG4P type heavy chain expression vector and the human chimeric LN22R8 light chain expression vector The human chimeric antibody of LN22R8 obtained by combining these antibodies was named "LN22R8chIgG4P". The human chimeric 2P10F2 IgG1LALA type heavy chain expression vector and human chimeric Human chimera of L2P10F2 obtained by combining the light chain expression vector of mer2P10F2 The antibody was named "2P10F2chIgG1LALA." Combination of IgG2 type heavy chain expression vector and human chimeric 2P10F2 light chain expression vector The human chimeric antibody against L2P10F2 obtained by the combination was named "2P10F2chIgG2." The human chimeric 2P10F2 IgG4P type heavy chain expression vector and the human chimeric 2P1 The human chimeric antibody L2P10F2 obtained by combining the light chain expression vector of 0F2 is called " The antibody was named "2P10F2chIgG4P".

[0203] 1)-14-2 Purification of human chimeric antibodies LN22R8 and 2P10F2 The antibody was isolated from the culture supernatant obtained in Example 1)-14-1 using rProtein A affinity chromatography. The culture supernatant was equilibrated with PBS and purified by a single step of chromatography. SelectSuRe packed columns (GE Healthcare Biosciences) After applying the sample to a column (Ence), the column was washed with PBS that was at least twice the column volume. Next, the antibody was eluted with 2M arginine hydrochloride solution (pH 4.0) and the fractions containing the antibody were collected. The fraction was dialyzed (Thermo Scientific, Slide-A-Lys). The dialysis cassette was used to dialyze HBS or (25 mM histidine). The buffer was replaced with 100% Centrifugal Separator (pH 6.0) and 100% Centrifugal Separator (pH 6.0). gal UF Filter Device VIVASPIN20 (molecular weight cutoff UF1 Concentrate the antibody using 0K (Sartorius) to adjust the IgG concentration to 1 mg / mL or more. Finally, we filtered the water with a Minisart-Plus filter (Sartorius). This was filtered to obtain a purified sample.

[0204] 1)-15 ADCC activity of human chimeric antibodies ADCC activity of human chimeric antibodies using human peripheral blood mononuclear cells as effector cells (PBMC), and the human pancreatic cell line MIA PaCa-2 was used as the ADCC target cell. Radioisotopes 51 Cr-labeled MIA PaCa-2 cells and mouse antibody (LN22 R8), rat antibody (2P10F2), or human chimeric antibody (LN22R8chIgG 1, LN22R8chIgG2, LN22R8chIgG4P, 2P10F2chIgG 1LALA, 2P10F2chIgG4P) at a concentration of 0.5 or 5 μg / ml for 4°C. After 0 min of treatment, PBMCs isolated from human peripheral blood were incubated with MIA PaCa-2 cells for 2 h. The mixture was incubated at 37°C for 4 hours in the presence of 5% CO2. 51 Cr was measured using TopCount NXT v2.53 and the total rele ase values ​​were obtained. 51 Cr-labeled MIA PaCa-2 cells were incubated with Triton-100 Treated and released 51 The measured value of Cr is the Maximamu release value, PBM Released from antibody-treated cells without C 51 Cr measurement value Spontane The ous release value is calculated by the following formula: % specific release The values ​​of e were calculated and summarized in Figure 6. As a negative control sample, human IgG (hIgG,Chr omPure Human IgG, Jackson ImmunoResearch Laboratories, Cat. 009-000-003) The measurements were performed in triplicate, and the average and standard deviation were calculated. I took it out and showed it together.

[0205] % specific release=(Total release-Spont aneous release) / Maximamu release Human IgG (hIgG) and the mouse antibody LN22R8 did not show ADCC activity. In contrast, LN22R8chIgG1 was 17.4% at 0.5 μg / ml and 17.4% at 5 μg / ml. The ADCC activity was 18.1%. The ADCC activity of G4P was lower than that of LN22R8chIgG1, and both were The figures were 3.0% and 2.2%.

[0206] The 2P10F2 rat antibody showed 4.8% at 0.5 μg / ml and 8.4% at 5 μg / ml. 2P10F2chIgG1LALA showed ADCC activity at 0.5μg / ml. At 5μg / ml, the ADCC activity was 2.9%. , 3.4% at 0.5 μg / ml, 1.1% at 5 μg / ml and 2P10F2 rat antibody, 2 The ADCC activity of P10F2chIgG1LALA was lower than that of P10F2chIgG1LALA. mann et al., J. Exp. Med., 1351-1361, 1987) Report As shown in Fig. 1, human chimeric antibodies using the IgG1 subtype showed the highest ADCC activity. Ta.

[0207] 1)-16 CDC activity of human chimeric antibodies Complement-dependent cell killing (CDC) activity of anti-human CD147 antibody against target cells The evaluation was performed using the human pancreatic cell line MIA PaCa-2. w Tox-M Rabbit Complement, CEDARLANE LABO RATORIES LIMITED, Cat.CL3051) was used. Anti-human CD14 7. The antibody may be a mouse antibody (LN22R8), a rat antibody (2P10F2), or a human antibody. Chimeric antibodies (LN22R8chIgG1, LN22R8chIgG2, LN22R8ch IgG4P, 2P10F2chIgG1LALA, 2P10F2chIgG4P) Human IgG (hIgG, ChromPure Human) was used as a control antibody with negative CDC activity. man IgG,Jackson ImmunoResearch Laborator The above antibodies were used at 0, 0.1, 1 or After treatment with 10 μg / ml of 1 h at 4°C, rabbit complement was added to a final concentration of 7.5%. After heating for 3 hours at 37°C in the presence of 5% CO2, the intracellular ATP CellTiter-Glo Lumimescent Cell Viabi The measurement was performed using a City Assay (Promega, Cat. G7572). ellTiter-Glo Lumimescent Cell Viability The luminescence signal obtained using the EnVision 2104 M Assay was Quantification was performed using an Ultilabel Reader (Perkin Elmer). Measurements were performed in triplicate, and the average and standard deviation were calculated. The signal was taken as 100%, and the antibody- and complement-dependent decrease in luminescence signal was taken as the CDC activity. , summarized in Figure 7.

[0208] Only the mouse antibody (LN22R8) and rat antibody (2P10F2) showed a negative control hIg Concentration-dependent CDC activity was observed against G, with a maximum at 10 μg / ml in LN22R8. The viable cell count decreased to 41.1%. For 2P10F2, the maximum was 53.5% at 10 μg / ml. The number of live cells decreased to %.

[0209] Human chimeric antibodies (LN22R8chIgG1, LN22R8chIgG2, LN22R 8chIgG4P, 2P10F2chIgG1LALA, 2P10F2chIgG4P) No clear CDC activity was observed against the negative control hIgG.

[0210] 1)-17 ADCP activity of human chimeric antibodies Human IgG antibodies mediate antibody-dependent activation of monocytes and lymphocytes through interaction with mouse Fcγ receptors. It exerts cytotoxic activity against cancer cells by inducing phagocytosis by erythropoietin (ADCP). It has been reported that the immunology, 1-9, 2012). ADCP activity of human chimeric antibodies was investigated using RAW264.7 (ATCC, TIB-71) as effector cells, ADCP target cells The human pancreatic cell line PANC-1 or MIA PaCa-2 was used as a model for evaluation. Green Fluorescent Cell Linker Mini Kit for General Cell Membrane Labeling(SIGMA , Cat.MINI67-1KIT) labeled ADCP target cells and human chimeric antibody (L N22R8chIgG1, LN22R8chIgG2, LN22R8chIgG4P) After treatment at 20μg / ml for 1 hour at 4℃, PKH26 Red Fluores cent Cell Linker Lit for General Cell Me Labeled with mbrane labeling (SIGMA, Cat.PKH26GL-1KT) The RAW264.7 cells were added to the ADCP target cells in a volume of 5 times that of the normal cells, and incubated at 37°C for 3 hours in a 5% CO2-free environment. The cells were heated in the presence of CO2. The percentage of PKH26 positive cells that transitioned to PKH67 signal positivity through phagocytosis was measured. As a negative control sample, human IgG (hIgG, ChromPure Human IgG, Jackson ImmunoResearch Laboratories The same measurements were performed on samples treated with 1,2-dichlorophenyl ether (Cat. No. 009-000-003). The measurements were performed in triplicate, and the average value and standard deviation were calculated. , and Figure 8(b) show the results for MIA PaCa-2, respectively.

[0211] When PANC-1 cells were targeted with ADCP, LN22R8chIgG1 inhibited 9.2% LN22R8chIgG4P showed a high AD rate of 9.0% compared to human IgG (5.5%). LN22R8chIgG2 showed 5.9% ADCP activity and was negative. there were.

[0212] A similar trend was observed when MIA PaCa-2 cells were targeted with ADCP, and LN2 2R8chIgG1 was 6.6%, and LN22R8chIgG4P was 6.1%, indicating that human IgG ( 3.6%). LN22R8chIgG2 showed high ADCP activity against 3.6 %, and ADCP activity was negative.

[0213] 1)-18 In vivo antitumor activity of human chimeric antibodies 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS, and 4-5 week old female N OD-scid mice (NOD.CB17-Prkdc <scid> / J, Japan Charles The mice were transplanted subcutaneously into the axilla of mice (purchased from River Valley Cancer Center, Calif.). Groups were determined based on tumor volume 5 to 7 days after transplantation. The mouse antibody (LN22R8) of the anti-human CD147 antibody LN22R8 was used. Three chimeric antibodies (LN22R8chIgG1, LN22R8chIgG2, LN22R8 chIgG4P) was administered intraperitoneally to tumor-bearing mice at 1 mg / kg, 3 mg / kg, or 10 mg / kg. The rat antibody against the anti-human CD147 antibody 2P10F2 (2P10F2 ), and two types of human chimeric antibodies (2P10F2chIgG2, 2P10F2chIgG4P). The drug was administered intraperitoneally at 10 mg / kg to tumor-bearing mice (n=5-6). The diameter was measured twice a week using an electronic digital caliper (manufactured by Mitutoyo Corporation) and the following calculations were performed: Tumor volume was calculated using a formula.

[0214] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 9-1(a) to (d) and Figure 9-2(e) to (g). The changes in the products are reported along with the mean and standard error.

[0215] LN22R8, a mouse antibody, and three human chimeric antibodies showed dose-dependent antitumor effects. In the group administered 10 mg / kg of the human chimeric antibody LN22R8chIgG4P, Complete regression of tumors was observed in 5 out of 5 mice after 8 days, and the experiment was terminated 41 days after implantation. In the other LN22R8 antibody-treated groups, tumor regrowth was not observed in part or in all of the Tumor regrowth was observed in all mice.

[0216] 2P10F2 was confirmed to have antitumor effects as a rat antibody and two types of human chimeric antibodies. In the 10F2chIgG4P 10mg / kg administration group, 6 out of 6 mice died 21 days after transplantation. Complete regression of the tumor was observed.

[0217] The mouse antibody LN22R8, an anti-human CD147 antibody that recognizes the same epitope, The rat antibody 2P10F2 inhibits the ADCC, ADCP, and CDC activities of the mouse immune system. Human chimeric antibody chIgG1 with effector function dependent on IgG1 and ADCP activity Not only the human chimeric antibody chIgG4P, which is a IgG4 antibody, but also the human chimeric antibody chIgG4P, which is a IgG4 antibody, showed almost no effector function. The human chimeric antibody chIgG2 retains more than 90% of its antitumor effect. The antitumor effect of this antibody was independent of mouse immune system and was mediated by a novel mechanism of action that targets CD147. It has been suggested that this is indicative.

[0218] 1)-19 Antitumor effect of CD147 human chimeric antibody in NOG mice In NOG (NOD / Shi-scid, IL-2Rγnull) mice, mouse T A common cytokine receptor domain was identified in NOD-scid mice lacking thymocytes and B cells. By combining the IL-2 receptor γ chain knockout gene with the IL-2 receptor γ chain knockout gene, In addition to the immune system, they lacked NK cells and complement activity, and the function of macrophages and dendritic cells was reduced. and are in a severely immunocompromised state (Ito, Blood, 3175-3182, In these mice with severe immune deficiencies, the antitumor effect of CD147 antibodies was impaired. We investigated whether the effect of the endothelial cell graft on the cerebral cortex was significantly different from that of the MIA PaCa-2 subcutaneous implant model.

[0219] 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS, and 7-week-old female NOG Mouse (NOD / Shi-scid, IL-2RγKO Jic, In-Vivo Sc The mice were subcutaneously transplanted into the axilla of mice (purchased from Iience). Six days after transplantation, the mice were divided into groups based on the tumor volume. The anti-CD147 human chimeric antibody (LN22R8chIgG4P) was administered at 10 mg / mL. The tumor was then measured twice a week by electrophysiology. The tumor was measured using a digital caliper (manufactured by Mitutoyo Corporation) and calculated using the following formula: The volume was calculated.

[0220] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 10. The graph shows the mean and standard error for the change in tumor volume. He wrote:

[0221] The results of human chimeric antibody LN22R8chIgG4P shown in Figure 10 were obtained 17 days after transplantation. The tumor growth inhibition rate in the 10 mg / kg group was 99 %, with 3 out of 5 mice receiving the drug. Complete regression of the tumor was observed.

[0222] Anti-CD147 human chimeric antibody (LN22R8chIgG4P) binds to mouse T and B cells. In addition, it was also effective against pancreatic cancer tumors formed in NOG mice that lack NK cells and complement activity. The strong antitumor effect was observed, suggesting that the antitumor effect may be independent of mouse immune cells. Sex was suggested.

[0223] (Example 2) Preparation of monkey cross-reactive rat antibodies by immunization with CD147 protein The anti-human CD147 antibody exhibiting a strong antitumor effect obtained in Example 1 was The antibody obtained in Example 1 did not show cross-reactivity with CD147 in cynomolgus monkeys. We attempted to obtain a CD147 antibody that shows cross-reactivity with meropenem CD147.

[0224] 2)-1 Immunity Female WKY / Izm rats (Japan SLC) were used for immunization. inant Human BSG, His tagged(CREATIVE BIO MART) antigen protein and Freund's Complete Adjuvant ( The rats were administered a mixture of 100 mg / kg of 1000 mg ... This was used to produce hybridomas.

[0225] 2)-2 Generation of hybridomas Lymph node cells or spleen cells and mouse myeloma SP2 / 0-ag14 cells (ATC C, No. CRL-1581) and LF301 Cell Fusion Unit (B Then, electrofusion was performed using the ClonaCell-HY Selection Dilute in Medium D (StemCell Technologies) and culture. The hybridoma colonies that emerged were harvested to produce monoclonal hybridomas. Each of the collected hybridoma colonies was cultured, and the resulting hybridoma cultures The supernatant was used to screen for anti-CD147 antibody-producing hybridomas.

[0226] 2)-3 Antibody screening by flow cytometry An antibody that binds to human cancer cells and exhibits binding affinity to human CD147 and cynomolgus monkey CD147 Antibody-binding screen using a flow cytometer to select producing hybridomas We performed screening of human cancer cells using the CD147-positive human pancreatic cell line MIA PaCa- 2 was used. As in Example 1)-8, human or cynomolgus monkey CD147 was expressed. CHO-K1 cells (CHO-K1-hCD147v2, CHO-K1-cynoCD14 7) was used to confirm binding to human or cynomolgus monkey CD147. 2. CHO-K1-hCD147v2 and CHO-K1-cynoCD147 suspensions were An equal volume of hybridoma culture supernatant was added, and the mixture was incubated at 4°C for 1 hour or more. The cells were washed with PBS and incubated with anti-rat IgG-PE (BD Biosciences, Ca The binding of each antibody to the cells was made fluorescently detectable using a flow cytometer. The fluorescent signals of the cells were measured using a fluorometer (CantoII, BD Bioscience). The results were compared against a negative control sample (cells without hybridoma culture medium). The ratio of the fluorescent signals was calculated, and some of the results are summarized in Table 2.

[0227] A commercially available rat antibody isotyping kit (Bio-Rad Laboratories) was used. Using RMT1 (ES), we determined the isotype of the antibody contained in the culture supernatant. , as shown in Table 4.

[0228] 2P10F2 obtained in Example 1 was synthesized using MIA PaCa-2, CHO-K1-hCD1 It showed binding to 47v2, but not to CHO-K1-cynoCD147. rat_CD147_#84 (sometimes referred to as r#84 in this specification), rat _CD147_#131 (sometimes referred to as r#131 in this specification), rat_C D147_#110 (sometimes referred to as r#110 in this specification), rat_CD1 47_#101 (sometimes referred to as r#101 in this specification) is MIA PaCa -2, CHO-K1-hCD147v2, and CHO-K1-cynoCD147 We were able to obtain an anti-human CD147 rat antibody that shows cross-reactivity with cynomolgus monkeys.

[0229] [Table 4]

[0230] 2)-4 Preparation of rat monoclonal antibodies using low IgG serum The anti-human CD147 monoclonal antibody, which shows cross-reactivity with cynomolgus monkeys, was developed in hybridoma culture. First, the antibody-producing hybridoma rat_CD147_#131 was purified from the culture supernatant. Grow to sufficient volume in ClonaCell-HY Selection Medium E After incubation, the cells were incubated with Ultra Low IgG FBS (Life Technologies Hybridoma SFM (Life Technologies, Inc.) containing 20% The medium was replaced with fresh medium (company S) and cultured for 7 days. The culture supernatant was collected and filtered through a 0.45 μm filter. It was sterilized through.

[0231] 2)-5 Preparation of rat monoclonal antibodies by high-density culture Using a CL-1000 flask (Becton Dickinson and Company), rats were cultured in a CL-1000 flask (Becton Dickinson and Company). _CD147_#84, rat_CD147_#101, rat_CD147_#110 The hybridoma was cultured to prepare a hybridoma culture supernatant containing a monoclonal antibody. .

[0232] 2)-6 Purification of monoclonal antibodies The culture supernatants prepared in Examples 2)-4 and 2)-5 were subjected to the same procedure as in Example 1)-6. The antibody was purified by the method.

[0233] 2)-7 Antibody screening by in vivo antitumor activity measurement 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS containing 5-week-old female NO D-scid mice (NOD.CB17-Prkdc <scid> / J, Charles Japan The mice were subcutaneously transplanted into the axilla of mice (purchased from Rivers Biosciences, Inc.). Six to eight days after transplantation, the mice were divided into groups based on the tumor volume. The cynomolgus monkey cross-reactive anti-CD147 rat antibodies #84, #101, or #110 were used. was administered intraperitoneally at 10 mg / kg to tumor-bearing mice 8 and 15 days after transplantation (n=5 ) Mice in the control group were similarly intraperitoneally administered PBS. 147 Rat antibody #131 was administered intraperitoneally at 10 mg / kg to tumor-bearing mice 6 days after transplantation. The major and minor diameters of the transplanted tumors were measured twice a week using an electronic digital caliper (Michigan Corporation). The tumor volume was measured using a CT scanner (Tsutoyo Corporation) and the tumor volume was calculated using the following formula.

[0234] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 11 (a) to (d). The graphs show the changes in tumor volume as average values ​​and The standard error is also shown. r#84 showed a tumor growth inhibition rate of 10 The rate of r#101 was 95% in the 20 mg / kg group (Figure 11(a)). The tumor growth inhibition rate in the 10 mg / kg group was 37%, but the tumor The regrowth of tumor cells was observed (Figure 11(b)). r#110 suppressed tumor growth 15 days after transplantation. The tumor suppression rate was 51% in the 10 mg / kg group, but tumor regrowth was observed 28 days after implantation. (Figure 11(c)). The tumor growth inhibition rate of r#131 was 10 The tumor growth rate of MIA PaCa-2 was 50% in the 200 mg / kg group (Fig. 11(d)). Strongly inhibiting rat antibody, r#84, partially inhibiting r#101, r#110, and r# The result was 131.

[0235] The results are shown in Figure 11 (a) to (d). The graphs show the changes in tumor volume as average values ​​and The standard error is also shown. r#84 showed a tumor growth inhibition rate of 10m after 28 days from transplantation. The rate of r#101 was 95% in the 15-day post-implantation group (Fig. 11(a)). The tumor growth inhibition rate was 37% in the 10 mg / kg group, but the tumor Regrowth was observed (Figure 11(b)). r#110 suppressed tumor growth 15 days after transplantation. The tumor regrowth rate was 51% in the 10 mg / kg group, but tumor regrowth was observed 28 days after implantation. The tumor growth inhibition rate of r#131 was 10 mg / kg / day after the transplantation (Fig. 11(c)). The rate was 50% in the 100-kg administration group (Figure 11(d)).

[0236] 2)-8 Epitope analysis: 2P10F2-competitive ELISA To analyze the epitope of the rat CD147 antibody that cross-reacts with monkeys, 2P10F2chI The binding of gG4P to recombinant CD147 protein was inhibited by competitive ELISA. Human CD147-Fc fusion protein (Sino Biological Inc.) was used. 10186-H02H) was dissolved in PBS, adjusted to 20 μg / ml, and placed on a 96-well plate. Add 50 μl to a plate (Thermofisher, Cat. 43454) and store at 4℃. The protein solution was removed, 300 μl of 1% BSA-containing PBS was added, and the mixture was incubated at room temperature for 1 hour. 25 μl of 20 or 60 μg / ml CD4+ was diluted in PBS containing 1% BSA. 147 Rat antibody r#84, r#101, r#110, r#131 or 2P10F2, or 1% BSA in PBS was added to a 96-well plate as a competing antibody and incubated at room temperature for 2 hours. 20 ng / ml of 2P10F2chIgG diluted in PBS containing 1% BSA was used. 25 μl of 4P was added to a 96-well plate and incubated at room temperature for 2 hours. twice in PBS containing een 20 (BIO RAD, Cat. 170-6531), The wells were washed. Mouse monocytes diluted 2000-fold in PBS containing 1% BSA were added. oclonal HP6025 Anti-Human IgG4 Fc(HRP)(a Add 50 μl of 10 ... The mixture was incubated for 1 hour. 0.05% Tween 20 (BIO RAD, Cat. 170-6 The 96-well plate was washed three times with PBS containing 50 μl of Super Aqua. Blue ELISA Substrate (eBioscience, 00-42 03-58) was added to a 96-well plate and incubated at room temperature for 20 minutes. 2104 Multilabel Reader (Perkin Elmer) The absorbance of the 96-well plate was measured at 405 nm. The absorbance reduction caused by the competing antibody was calculated as a percentage using a constant value as a control and is shown in FIG. was performed in three wells, and the average value is shown.

[0237] r#84, r#101, and r#131 are similar to the 2P10F2 rat antibody. Inhibits the binding of chIgG4P by 90% or more, and the antibody recognition site is close to that of 2P10F2 This suggests that r#110 did not inhibit the binding of the 2P10F2 rat antibody. The recognition site is either distant from 2P10F2 or has weak binding affinity, so the 2P10F2 label It was considered possible that the binding of the IgG antibody could not be inhibited.

[0238] Example 3: Cloning of monkey cross-reactive rat antibodies and preparation of human chimeric antibodies 3)-1 Cloning of cDNA encoding the variable region of rat anti-CD147 antibody Determination of nucleotide sequence 3)-1-1 Cloning of the cDNA encoding the variable region of the rat_CD147_#84 antibody Determination of nucleotide sequence The same procedure as in Example 1)-11-2 was carried out. Determined rat_CD147_#8 The nucleotide sequence of the cDNA encoding the variable region of the light chain of antibody 4 is shown in SEQ ID NO:48. The amino acid sequence is shown in SEQ ID NO: 49. The nucleotide sequence of the cDNA encoding the heavy chain variable region The peptide sequence is shown in SEQ ID NO: 50, and the amino acid sequence is shown in SEQ ID NO: 51. rat_CD14 CDRL1, CDRL2, and CDRL3 of the light chain variable region of antibody #84 are The heavy chain variable region of the rat_CD147_#84 antibody is shown in SEQ ID NOs: 52, 53, and 54. CDRH1, CDRH2 and CDRH3 are shown in SEQ ID NOs: 55, 56 and 57, respectively. vinegar.

[0239] 3)-1-2 cDNA encoding the variable region of rat_CD147_#101 antibody Nucleotide sequence determination The same procedure as in Example 1)-11-2 was carried out. Determined rat_CD147_#1 The nucleotide sequence of the cDNA encoding the variable region of the light chain of antibody 01 is shown in SEQ ID NO:58. The amino acid sequence is shown in SEQ ID NO: 59. The nucleotide sequence is shown in SEQ ID NO: 60, and the amino acid sequence is shown in SEQ ID NO: 61. rat_CD1 CDRL1, CDRL2, and CDRL3 of the light chain variable region of antibody 47_#101 are The heavy chain variable regions of the rat_CD147_#101 antibody are shown in SEQ ID NOs: 62, 63, and 64. The regions CDRH1, CDRH2 and CDRH3 are represented by SEQ ID NOs: 65, 66 and 67, respectively. Shown in Figure 7.

[0240] 3)-1-3 cDNA encoding the variable region of rat_CD147_#110 antibody Nucleotide sequence determination The same procedure as in Example 1)-11-2 was carried out. Determined rat_CD147_#1 The nucleotide sequence of the cDNA encoding the variable region of the light chain of antibody 10 is shown in SEQ ID NO:68. The amino acid sequence is shown in SEQ ID NO: 69. The nucleotide sequence is shown in SEQ ID NO: 70, and the amino acid sequence is shown in SEQ ID NO: 71. rat_CD1 CDRL1, CDRL2, and CDRL3 of the light chain variable region of antibody 47_#110 are The heavy chain variable regions of the rat_CD147_#110 antibody are shown in SEQ ID NOs: 72, 73, and 74. The regions CDRH1, CDRH2 and CDRH3 are set forth as SEQ ID NOs: 75, 76 and 77, respectively. Shown in Figure 7.

[0241] 3)-1-4 cDNA encoding the variable region of rat_CD147_#131 antibody Nucleotide sequence determination The same procedure as in Example 1)-11-2 was carried out. Determined rat_CD147_#1 The nucleotide sequence of the cDNA encoding the variable region of the light chain of antibody 31 is shown in SEQ ID NO:78. The amino acid sequence is shown in SEQ ID NO: 79. The nucleotide sequence is shown in SEQ ID NO: 80, and the amino acid sequence is shown in SEQ ID NO: 81. rat_CD1 CDRL1, CDRL2, and CDRL3 of the light chain variable region of antibody 47_#131 are The heavy chain variable regions of the rat_CD147_#131 antibody are shown in SEQ ID NOs: 82, 83, and 84. The regions CDRH1, CDRH2 and CDRH3 are set forth as SEQ ID NOs: 85, 86 and 87, respectively. Shown in Figure 7.

[0242] 3)-2 Construction of human chimeric antibody expression vector 3)-2-1 Construction of expression vector for human chimeric antibody of rat_CD147_#84 3)-2-1-1 Human chimeric and humanized IgG4 PFALA type heavy chain expression vector Construction of pCMA-G4PFALA The human heavy chain signal sequence shown in SEQ ID NO: 88 and the human IgG4 PFALA constant region Using a DNA fragment containing a DNA sequence encoding an amino acid, pCMA-G4PFALA was constructed in a similar manner.

[0243] 3)-2-1-2 Construction of light chain expression vector for human chimeric rat_CD147_#84 The variable region of the light chain of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, human IgG1 gene was synthesized in the same manner as in Example 1)-12-4. A light chain expression vector for chimeric rat_CD147_#84 was constructed. The nucleotide sequence of the light chain of CD147_#84 and the amino acid sequence of the light chain are shown in SEQ ID NO:8. 9 and SEQ ID NO:90, respectively.

[0244] 3)-2-1-3 Expression of IgG1 type heavy chain of human chimera rat_CD147_#84 Vector construction The heavy chain variable region of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, a method similar to that of Example 1)-12-5 was performed. An IgG1 type heavy chain expression vector for chimeric rat_CD147_#84 was constructed. The nucleotide sequence of the IgG1 type heavy chain of chimeric rat_CD147_#84 and the heavy chain The amino acid sequences of are shown in SEQ ID NO:91 and SEQ ID NO:92, respectively.

[0245] 3)-2-1-4 IgG2 type heavy chain expression of human chimeric rat_CD147_#84 Vector construction The heavy chain variable region of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, human IgG1 gene was synthesized in the same manner as in Example 1)-12-6. An IgG2 type heavy chain expression vector for chimeric rat_CD147_#84 was constructed. The nucleotide sequence of the IgG2 type heavy chain of chimeric rat_CD147_#84 and the heavy chain The amino acid sequences of are shown in SEQ ID NO:93 and SEQ ID NO:94, respectively.

[0246] 3)-2-1-5 Expression of IgG4P type heavy chain of human chimera rat_CD147_#84 Construction of the current vector The heavy chain variable region of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, human IgG1 gene was synthesized in the same manner as in Example 1)-13-6. A chimeric rat_CD147_#84 IgG4P type heavy chain expression vector was constructed. The nucleotide sequence of the IgG4P type heavy chain of the rat chimera rat_CD147_#84 and The amino acid sequences of the heavy chains are shown in SEQ ID NO:95 and SEQ ID NO:96, respectively.

[0247] 3)-2-1-6 Human chimera rat_CD147_#84 IgG1LALA type Construction of heavy chain expression vector The heavy chain variable region of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, human IgG1 gene was synthesized in the same manner as in Example 1)-13-4. A chimeric rat CD147 #84 IgG1LALA type heavy chain expression vector was constructed. The nucleotide sequence of the IgG1LALA type heavy chain of human chimera rat_CD147_#84 was The code sequence and the amino acid sequence of the heavy chain are shown in SEQ ID NO:97 and SEQ ID NO:98, respectively.

[0248] 3)-2-1-7 Human chimera rat_CD147_#84 IgG4PFALA type Construction of heavy chain expression vector The heavy chain variable region of rat_CD147_#84 obtained in Example 3)-1-1 is encoded Designed for in-fusion cloning using the cDNA of interest as a template PCR was performed using the primers to obtain a cDNA encoding the heavy chain variable region. The NA fragment was amplified. pCMA-G4PFALA was cut with the restriction enzyme BlpI, Using the In-Fusion HD PCR cloning kit (Clontech), 1. Preparation of human chimera rat_CD147_#84 by inserting the amplified DNA fragment A gG4PFALA type heavy chain expression vector was constructed. The nucleotide sequence of the IgG4 PFALA type heavy chain of #84 and the amino acid sequence of the heavy chain are shown below. , SEQ ID NO: 99 and SEQ ID NO: 100, respectively.

[0249] 3)-2-2 Construction of expression vector for human chimeric antibody of rat_CD147_#101 3)-2-2-1 Construction of the light chain expression vector for human chimeric rat_CD147_#101 Construction The variable region of the light chain of rat_CD147_#101 obtained in Example 3)-1-2 was encoded Using the cDNA to be cloned as a template, the humanized polypeptide was cloned in the same manner as in Example 1)-12-4. A light chain expression vector for human chimera rat_CD147_#101 was constructed. The nucleotide sequence and amino acid sequence of the light chain of t_CD147_#101 are shown in the sequence They are shown in sequence numbers 101 and 102, respectively.

[0250] 3)-2-2-2 Expression of IgG2 type heavy chain of human chimera rat_CD147_#101 Construction of the current vector The heavy chain variable region of rat_CD147_#101 obtained in Example 3)-1-2 was encoded Using the cDNA to be cloned as a template, the humanized mutant was cloned in the same manner as in Example 1)-12-6. An IgG2 type heavy chain expression vector for the rat chimera rat_CD147_#101 was constructed. Nucleotide sequence of the IgG2 type heavy chain of human chimera rat_CD147_#101 and The amino acid sequences of the heavy chains are shown in SEQ ID NO:103 and SEQ ID NO:104, respectively.

[0251] 3)-2-2-3 IgG4P type heavy chain of human chimera rat_CD147_#101 Construction of expression vectors The heavy chain variable region of rat_CD147_#101 obtained in Example 3)-1-2 was encoded Using the cDNA to be cloned as a template, the humanized polypeptide was cloned in the same manner as in Example 1)-13-6. We constructed an IgG4P type heavy chain expression vector for the chimera rat_CD147_#101. Nucleotide sequence of the IgG4P type heavy chain of human chimera rat_CD147_#101 and the amino acid sequence of the heavy chain are shown in SEQ ID NO: 105 and SEQ ID NO: 106, respectively.

[0252] 3)-2-2-4 IgG4PFALA tag of human chimera rat_CD147_#101 Construction of IPP heavy chain expression vector The heavy chain variable region of rat_CD147_#101 obtained in Example 3)-1-2 was encoded The cDNA to be cloned was used as a template in the same manner as in Example 3)-2-1-7. Human chimeric rat_CD147_#101 IgG4PFALA type heavy chain expression vector The human chimeric rat_CD147_#101 IgG4PFALA type heavy chain was constructed. The nucleotide sequence of the heavy chain and the amino acid sequence of the heavy chain are set forth in SEQ ID NO:107 and SEQ ID NO:108. Each is shown.

[0253] 3)-2-3 Construction of expression vector for human chimeric antibody of rat_CD147_#110 3)-2-3-1 Construction of the light chain expression vector for human chimeric rat_CD147_#110 Construction The variable region of the light chain of rat_CD147_#110 obtained in Example 3)-1-3 is encoded Using the cDNA corresponding to the human IgG1 gene as a template, human IgG1 gene was synthesized in the same manner as in Example 1)-12-4. A light chain expression vector for chimeric rat_CD147_#110 was constructed. The nucleotide sequence of the light chain of CD147 #110 and the amino acid sequence of the light chain are shown in SEQ ID NO: No. 109 and No. 110, respectively.

[0254] 3)-2-3-2 Expression of IgG2 type heavy chain of human chimera rat_CD147_#110 Construction of the current vector The heavy chain variable region of rat_CD147_#110 obtained in Example 3)-1-3 was encoded Using the cDNA to be cloned as a template, the humanized mutant was cloned in the same manner as in Example 1)-12-6. An IgG2 type heavy chain expression vector for the rat chimera rat_CD147_#110 was constructed. Nucleotide sequence of the IgG2 type heavy chain of human chimeric rat_CD147_#110 and The amino acid sequences of the heavy chains are shown in SEQ ID NO:111 and SEQ ID NO:112, respectively.

[0255] 3)-2-3-3 IgG4P type heavy chain of human chimeric rat_CD147_#110 Construction of expression vectors The heavy chain variable region of rat_CD147_#110 obtained in Example 3)-1-3 was encoded Using the cDNA to be cloned as a template, the humanized polypeptide was cloned in the same manner as in Example 1)-13-6. We constructed an IgG4P type heavy chain expression vector for the chimeric rat CD147 #110. Nucleotide sequence of the IgG4P-type heavy chain of human chimera rat_CD147_#110 and the amino acid sequence of the heavy chain are shown in SEQ ID NO:113 and SEQ ID NO:114, respectively.

[0256] 3)-2-3-4 IgG4PFALA tag of human chimeric rat_CD147_#110 Construction of IPP heavy chain expression vector The heavy chain variable region of rat_CD147_#110 obtained in Example 3)-1-3 was encoded The cDNA to be cloned was used as a template in the same manner as in Example 3)-2-1-7. Human chimeric rat_CD147_#110 IgG4PFALA type heavy chain expression vector The human chimeric rat_CD147_#110 IgG4PFALA type heavy chain was constructed. The nucleotide sequence of the heavy chain and the amino acid sequence of the heavy chain are set forth in SEQ ID NO:115 and SEQ ID NO:116. Each is shown.

[0257] 3)-2-4 Construction of expression vector for human chimeric antibody of rat_CD147_#131 3)-2-4-1 Construction of the light chain expression vector for human chimeric rat_CD147_#131 Construction The variable region of the light chain of rat_CD147_#131 obtained in Example 3)-1-4 was encoded Using the cDNA to be cloned as a template, the humanized polypeptide was cloned in the same manner as in Example 1)-12-4. A light chain expression vector for human chimera rat_CD147_#131 was constructed. The nucleotide sequence and amino acid sequence of the light chain of t_CD147_#131 are shown in the sequence They are shown in sequence numbers 117 and 118, respectively.

[0258] 3)-2-4-2 Expression of IgG2 type heavy chain of human chimera rat_CD147_#131 Construction of the current vector The heavy chain variable region of rat_CD147_#131 obtained in Example 3)-1-4 was encoded Using the cDNA to be cloned as a template, the humanized mutant was cloned in the same manner as in Example 1)-12-6. An IgG2 type heavy chain expression vector for the rat chimera rat_CD147_#131 was constructed. Nucleotide sequence of the IgG2 type heavy chain of human chimera rat_CD147_#131 and The amino acid sequences of the heavy chains are shown in SEQ ID NO:119 and SEQ ID NO:120, respectively.

[0259] 3)-2-4-3 IgG4P type heavy chain of human chimera rat_CD147_#131 Construction of expression vectors The heavy chain variable region of rat_CD147_#131 obtained in Example 3)-1-4 was encoded Using the cDNA to be cloned as a template, the humanized polypeptide was cloned in the same manner as in Example 1)-13-6. We constructed an IgG4P type heavy chain expression vector for the chimeric rat CD147 #131. Nucleotide sequence of the IgG4P type heavy chain of human chimera rat_CD147_#131 and the amino acid sequence of the heavy chain are shown in SEQ ID NO:121 and SEQ ID NO:122, respectively.

[0260] 3)-3 Preparation of human chimeric antibodies 3)-3-1 Production of human chimeric antibodies of monkey cross-reactive rat antibodies Produced in the same manner as in Example 1)-14-1.

[0261] Human chimera rat_CD147_#84 IgG1 type heavy chain expression vector and human chimera Rat_CD147_#84 light chain expression vector combination The human chimeric antibody 147_#84 was named "#84chIgG1". IgG2 type heavy chain expression vector of t_CD147_#84 and human chimeric rat_CD1 The rat_CD147_#84 light chain expression vector was obtained by combining the rat_CD147_#84 light chain expression vectors. The human chimeric antibody was named "#84chIgG2". Human chimeric rat_CD147_ #84 IgG4P type heavy chain expression vector and human chimeric rat_CD147_#84 Human chimeric antibody of rat_CD147_#84 obtained by combining light chain expression vectors The antibody was named "#84chIgG4P". G1LALA type heavy chain expression vector and human chimeric rat_CD147_#84 light chain expression vector The human chimeric antibody rat_CD147_#84 obtained using the current vector combination is called "# The antibody was named "84chIgG1LALA". G4PFALA type heavy chain expression vector and human chimeric rat_CD147_#84 light chain The human chimeric antibody rat_CD147_#84 obtained by combining expression vectors is called " It was named "#84chIgG4PFALA".

[0262] Human chimera rat_CD147_#101 IgG2 type heavy chain expression vector and human Rat_ obtained by combining the light chain expression vectors of Mela rat_CD147_#101 The human chimeric antibody of CD147_#101 was named "#101chIgG2." IgG4P type heavy chain expression vector and human chimeric rat_CD147_#101 rat_CD1 obtained by combining the light chain expression vectors of at_CD147_#101 47_The human chimeric antibody #101 was named "#101chIgG4P". Human chimera IgG4PFALA type heavy chain expression vector of rat_CD147_#101 and human chimera Rat_C obtained by combining the light chain expression vectors of rat_CD147_#101 The human chimeric antibody D147_#101 was named "#101chIgG4PFALA." .

[0263] Human chimeric rat_CD147_#110 IgG2 type heavy chain expression vector and human chimeric Rat_ obtained by combining the light chain expression vector of Mela rat_CD147_#110 The human chimeric antibody of CD147_#110 was named "#110chIgG2." IgG4P type heavy chain expression vector and human chimeric rat_CD147_#110 rat_CD1 obtained by combining at_CD147_#110 light chain expression vectors 47_The human chimeric antibody #110 was named "#110chIgG4P". Human chimera IgG4PFALA type heavy chain expression vector of rat_CD147_#110 and human chimera Rat_C obtained by combining rat_CD147_#110 light chain expression vectors The human chimeric antibody D147_#110 was named "#110chIgG4PFALA." .

[0264] Human chimeric rat_CD147_#131 IgG2 type heavy chain expression vector and human chimera Rat_ obtained by combining the light chain expression vectors of Mela rat_CD147_#131 The human chimeric antibody of CD147_#131 was named "#131chIgG2." IgG4P type heavy chain expression vector of human chimeric rat_CD147_#131 rat_CD1 obtained by combining the light chain expression vectors of at_CD147_#131 47_The human chimeric antibody #131 was named "#131chIgG4P."

[0265] 3)-3-2 Purification of human chimeric antibodies of monkey cross-reactive rat antibodies The culture supernatant obtained in Example 3)-3-1 was purified in the same manner as in Example 1)-14-2. Made.

[0266] Example 4: In vivo antitumor activity of human chimeric antibodies 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS, and 5-6 week old female N OD-scid mice (NOD.CB17-Prkdc <scid> / J, Japan Charles The mice were transplanted subcutaneously into the axilla of mice (purchased from River Valley, California). Groups were determined based on tumor volume 5-6 days after transplantation. The cynomolgus monkey cross-reactive anti-CD147 human chimeric antibody (#84chIgG1, #84chIgG1LALA, #84chIgG2, #84chIgG4P, #84ch On the day of group division, tumor-bearing mice were intraperitoneally injected with IgG4PFALA at 1, 3, or 10 mg / kg. The cynomolgus monkey cross-reactive anti-CD147 human chimeric antibody (#101 chIgG2, #101chIgG4P, #101chIgG4PFALA, #110c hIgG2, #110chIgG4P, #110chIgG4PFALA, #131ch On the day of group allocation, tumor-bearing mice were administered 3 or 10 mg / kg of IgG2 or IgG4P. The major and minor diameters of the transplanted tumors were measured twice weekly using an electronic digital recorder. The tumor volume was measured using a GIS (Mitutoyo Corporation) and calculated using the following formula: Ta.

[0267] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figures 13-1(a)-(d), 13-2(e)-(h), and 13-3(i)-( The graphs show the changes in tumor volume, with the mean Values ​​and standard errors are shown.

[0268] Human chimeric antibody #84 showed dose-dependent antitumor effects for both IgG subtypes. The strongest antitumor effect was observed in the #84chIgG4P 10mg / kg administration group. In the study, complete regression of tumors was observed in five out of five mice 20 days after implantation.

[0269] Human chimeric antibody #101 showed dose-dependent antitumor effects for both IgG subtypes. The strongest antitumor effect was confirmed with 101chIgG4P administered at 10mg / kg. In the group, complete tumor regression was observed in four out of five mice 20 days after implantation.

[0270] Human chimeric antibody #110 showed dose-dependent antitumor effects for both IgG subtypes. The strongest antitumor effect was observed with 110chIgG4P administered at 10mg / kg. In the group, complete tumor regression was observed in three out of five mice 22 days after implantation.

[0271] Human chimeric antibody #131 showed dose-dependent antitumor effects in the IgG4P subtype #131chIgG2 showed antitumor effects in the 3mg / kg and 10mg / kg groups. There was no difference in the results.

[0272] All human chimeric antibodies were tested at 10 mg / kg, regardless of the human IgG subtype of the antibody. At a dose of 100 mg / kg, the tumor growth was inhibited by 68-100%. For the anti-human CD147 human chimeric antibodies #084, #101, #110, and #131, As well as anti-human CD147 antibodies, LN22R8 and 2P10F2, obtained from cell immunization, Antitumor effects are independent of the mouse immune system and are mediated by a novel mechanism of action that targets CD147. It has been suggested that this is indicative.

[0273] (Example 5) Evaluation of CD147 binding ability of human chimeric antibodies #84chIgG1, #84chIgG2, and #84chIgG1 prepared in Example 3)-3-1 IgG4P, #84chIgG1LALA, #84chIgG4PFALA, #101c The dissociation constants of hIgG4P and #110chIgG4P for human CD147 were measured using Bi We used acore T200 (GE Healthcare Bioscience). The Human Antibody Capture Kit (GE Healthcare) was used. Anti-Human Ig antibody immobilized using IgG antibodies (manufactured by IgG Biosciences, Inc.) The G(Fc)antibody captures the antibody as a ligand and binds the antigen. The measurement was performed using the capture method, in which the amount of nalyte was measured. HBS was used as the running buffer. -EP+ (GE Healthcare Bioscience), sensor chip CM5 (GE Healthcare Bioscience) was used as the Add 1μg / mL or 2μg / mL of human chimeric antibody onto the tip at 10μL / min for 60 seconds. After that, a dilution series of CD147 protein was used as an antigen (#131 for chIgG4P). 0.25~4μg / mL, #84chIgG1, #84chIgG2, #84chIgG 4P, #84chIgG1LALA, #84chIgG4PFALA, #101chIg G4P, 0.5-8 μg / mL for #110chIgG4P) at a flow rate of 30 μL / min. Add for 120 seconds, then monitor the dissociation phase for 120 seconds, 300 seconds, or 600 seconds. Here, CD147 protein was expressed in Escherichia coli and was shown to inhibit Ni affinity, S EC was purified in two steps, and the tag was cleaved and purified. magnesium chloride(GE Healthcare Biosci) A 1:1 binding model was used for data analysis. The binding rate constant ka, the dissociation rate constant kd, and the dissociation constant (KD; KD = kd / The results are shown in Table 5.

[0274] [Table 5]

[0275] Example 6: Preparation of humanized antibodies 6)-1 Design of humanized antibodies 6)-1-1 Molecular modeling of variable regions Methods in Enzyme Science y, 203, 121-153, (1991)). Using the analysis program Discovery Studio (Dassault Systèmes), , and the Protein Data Bank (Nu c. The structure registered in Acids Res. 35, D301-D303 (2007) The hit heavy chain, light chain, and heavy-light chain interface structures were used as templates to search for structures. A three-dimensional model was created.

[0276] 6)-1-2 Methods for designing humanized antibodies CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10 The rat_CD147_#84 fragment was humanized by the National Institute of Integrative Medicine (IIT) in collaboration with the National Institute of Integrative Medicine (IIT). The framework region was determined by the method described in KABAT et al. (Sequences of Proteins). eins of Immunological Interest,5th Ed.Pu blic Health Service National Institutes of Health, Bethesda, MD. (1991) The consensus sequence of kappa chain subgroup 1 and human gamma chain subgroup 3 Since they have high homology to the consensus sequence, they were identified as rat_CD147_#84 The light and heavy chains of rat_CD147_#101 were selected as acceptors, respectively. The framework regions are the human kappa chain sequences as defined in KABAT et al. The consensus sequence of subgroup 1 and the human gamma chain subgroup 3 and IMGT ( THE INTERNATIONAL IMMUNOGENETICS INFORMA IGHV of human gamma chain defined in the TION SYSTEM® Since 3-30*05 and IGHJ3*01 have high homology, they were identified as rat_ The rat_C was selected as an acceptor for the light and heavy chains of CD147_#101, respectively. The framework region of D147_#110 is a human kappa a chain IGKV1-39*01 and IGKJ4*01, and human gamma chain IGHV1- Since 2*02 and IGHJ6*01 have high homology, they are likely to be related to rat_CD1 These were selected as acceptors for the light and heavy chains of 47_#110, respectively. rat_CD14 The framework region of 7_#131 is the same as that of the human kappa chain as defined by IMGT. IGKV1-39*01 and IGKJ2*01, and the human gamma chain IGHV3-30* 05 and IGHJ6*01, rat_CD147_#13 The donor to be transferred onto the acceptor was selected as the light chain and heavy chain acceptor of 1, respectively. -residues are as described by Queen et al. (Proc. Natl. Acad. Sci. USA 86,10029-10033(1989)) It was selected by analyzing the three-dimensional model.

[0277] 6)-1-3 Humanization of rat_CD147_#84 heavy chain The acceptor shown in Figure 14(a) was used for the variable region of the heavy chain of rat_CD147_#84. The variable region of the humanized antibody heavy chain #84H1h was designed by transferring amino acid residues.

[0278] The gamma chain constant regions of human IgG2 and IgG4P were linked to the engineered variable regions. The humanized antibody heavy chains #84H1hIgG2 and #84H1hIgG The full-length amino acid sequence of #84H1hIgG2 is set forth in SEQ ID NO:123. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:123 is set forth in SEQ ID NO:124. The full length amino acid sequence of #84H1hIgG4P is set forth in SEQ ID NO: 125. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:125 is set forth in SEQ ID NO:126.

[0279] 6)-1-4 Humanization of rat_CD147_#84 light chain The acceptor shown in Figure 14(b) was used for the variable region of the rat_CD147_#84 light chain. The variable region of the humanized antibody light chain #84L2h was designed by transferring amino acid residues.

[0280] A humanized antibody light chain is designed by connecting a human κ chain constant region to the designed variable region, The full-length amino acid sequence of the light chain of #84L2h is shown in SEQ ID NO:127. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:127 is set forth in SEQ ID NO:128. Write down.

[0281] 6)-1-5 #84 humanized antibody The heavy chain #84H1hIgG2 and the light chain #84L2h designed above were combined to produce a human We also designed the antibody #84H1L2hIgG2. #84L2h was combined to design the humanized antibody #84H1L2hIgG4P.

[0282] 6)-1-6 Humanization of rat_CD147_#101 heavy chain The acceptor shown in Figure 15(a) was used for the variable region of the rat_CD147_#101 heavy chain. The variable region of the humanized antibody heavy chain #101H1h was designed by transferring the following amino acid residues: Ta. The gamma chain constant regions of human IgG2 and IgG4P were ligated to the designed variable regions. The humanized antibody heavy chains #101H1hIgG2 and #101H1hIg were designed with the same sequence. The full-length amino acid sequence of #101H1hIgG2 is shown in SEQ ID NO:129. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:129 is set forth in SEQ ID NO:130. The full-length amino acid sequence of #101H1hIgG4P is set forth in SEQ ID NO:131. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:131 is set forth in SEQ ID NO:132. do.

[0283] 6)-1-7 Humanization of rat_CD147_#101 light chain The acceptor shown in Figure 15(b) was used for the variable region of the rat_CD147_#101 light chain. The variable region of the humanized antibody light chain #101L2h was designed by transferring the following amino acid residues: Ta. A humanized antibody light chain was designed by connecting a human κ chain constant region to the designed variable region. The full-length amino acid sequence of the light chain of #101L2h is shown in SEQ ID NO:133. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:133 is shown in SEQ ID NO:134. Please refer to the following.

[0284] 6)-1-8 #101 humanized antibody The heavy chain #101H1hIgG2 and the light chain #101L2h designed above were combined, We designed a humanized antibody, #101H1L2hIgG2. We also designed the heavy chain, #101H1hIgG4 P and light chain #101L2h were combined to design humanized antibody #101H1L2hIgG4P did.

[0285] 6)-1-9 Humanization of rat_CD147_#110 heavy chain The activity of the rat_CD147_#110 heavy chain variable region was determined using the activities shown in Figure 16(a) and (b). The humanized antibody heavy chains #110H1h and #110H1 were created by transferring amino acid residues from the septa. The variable region of 3h was designed.

[0286] A humanized antibody heavy chain consisting of a designed variable region and the gamma chain constant region of IgG4P. The chains were designed and named #110H1hIgG4P and #110H13hIgG4P, respectively. The full-length amino acid sequence of #110H1hIgG4P is shown in SEQ ID NO: 135. The full length amino acid sequence of hIgG4P is set forth in SEQ ID NO: 147. The nucleotide sequence encoding the amino acid sequence is shown in SEQ ID NO: 136 and the amino acid sequence is shown in SEQ ID NO: 147. The nucleotide sequence encoding this is set forth in SEQ ID NO:148.

[0287] 6)-1-10 Humanization of rat_CD147_#110 light chain For the variable region of the rat_CD147_#110 light chain, the following sequences are shown in Fig. 16(c), (d), and (e). The humanized antibody light chains #110L4h and #110L4h were obtained by introducing the amino acid residues of the acceptor shown in the figure. The variable regions #10L2h and #110L12h were designed.

[0288] A humanized antibody light chain is designed by connecting a human κ chain constant region to the designed variable region, They were named #110L4h, #110L2h, and #110L12h, respectively. #110L4 The full-length amino acid sequence of the light chain of #110L2h is SEQ ID NO: 137. The full-length amino acid sequence of the light chain of SEQ ID NO: 149 and #110L12h is set forth in SEQ ID NO: 151. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 137 is SEQ ID NO: 138, the sequence The nucleotide sequence encoding the amino acid sequence of No. 149 is SEQ ID NO: 150, SEQ ID NO: 1 The nucleotide sequence encoding the 51 amino acid sequence is set forth in SEQ ID NO:152.

[0289] 6)-1-11 #110 Humanized antibody The heavy chain #110H1hIgG4P and light chain #110L4h designed above were combined. We designed a humanized antibody #110H1L4hIgG4P. Combining IgG4P and light chain #110L2h, humanized antibody #110H13L2hIgG4 P was designed to combine the heavy chain #110H13hIgG4P and the light chain #110L12h to produce We designed a humanized antibody, #110H13L12hIgG4P.

[0290] 6)-1-12 Humanization of rat_CD147_#131 heavy chain The acceptor shown in Figure 17(a) was used for the variable region of the heavy chain of rat_CD147_#131. The variable region of the humanized antibody heavy chain #131H2h was designed by transferring the following amino acid residues: Ta.

[0291] A humanized antibody was created by connecting the gamma chain constant region of human IgG2 to the designed variable region. The heavy chain was designed and named #131H2hIgG2. The amino acid sequence is set forth in SEQ ID NO: 139. The nucleotide sequence is set forth in SEQ ID NO:140.

[0292] 6)-1-13 Humanization of rat_CD147_#131 light chain The acceptor shown in Figure 17(b) was used for the variable region of the rat_CD147_#131 light chain. The variable region of the humanized antibody light chain #131L2h was designed by transferring the following amino acid residues: Ta.

[0293] A humanized antibody light chain was designed by connecting the human κ chain constant region to the designed variable region. The full-length amino acid sequence of the light chain of #131L2h is shown in SEQ ID NO: 141. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO:141 is set forth in SEQ ID NO:1. Please refer to 42.

[0294] 6)-1-14 #131 humanized antibody The heavy chain #131H2hIgG2 and the light chain #131L2h designed above were combined, A humanized antibody, #131H2L2hIgG2, was designed.

[0295] 6)-2 Construction of humanized antibody light chain expression vector 6)-2-1 Construction of #84L2h expression vector Nucleotide numbers 37 to 4 of the nucleotide sequence of #84L2h shown in SEQ ID NO:128 The DNA fragment shown in Figure 02 was synthesized (GENEART). In-Fusion HD Using a PCR cloning kit (Clontech), pCMA-LK was cloned using restriction enzymes. The #84L2h gene was generated by inserting a synthetic DNA fragment into the BsiWI cleavage site. The current vector was constructed.

[0296] 6)-2-2 Construction of #101L2h expression vector The nucleotide sequence of #101L2h shown in SEQ ID NO:134 includes nucleotides 37 to 139. The DNA fragment shown in 402 was synthesized (GENEART). The #101L2h expression vector was constructed in the same manner.

[0297] 6)-2-3 #110L4h, #110L2h and #110L12h expression vectors construction #110L4h, #110L4h, and #110L4h shown in SEQ ID NO: 138, SEQ ID NO: 150, and SEQ ID NO: 152 The nucleotide sequence of #110L12h and #110L2h is shown in nucleotide numbers 37 to 402. The DNA fragment corresponding to the above was synthesized (GENEART Co., Ltd.) in the same manner as in Example 6)-2-1. The #110L4h, #110L2h and #110L12h expression vectors were constructed.

[0298] 6)-2-4 Construction of #131L2h expression vector The nucleotide sequence of #131L2h shown in SEQ ID NO:142 includes nucleotides 37 to 149. The DNA fragment shown in 402 was synthesized (GENEART). The #131L2h expression vector was constructed in the same manner.

[0299] 6)-3 Construction of humanized antibody heavy chain expression vector 6)-3-1 Construction of #84H1hIgG2 expression vector Nucleotide number 3 of the nucleotide sequence of #84H1hIgG2 shown in SEQ ID NO:124 The DNA fragment shown in 6 to 437 was synthesized (GENEART). Using the HD PCR cloning kit (Clontech), pCMA-G2 The synthetic DNA fragment was inserted into the site of the restriction enzyme BlpI. A 1hIgG2 expression vector was constructed.

[0300] 6)-3-2 Construction of #84H1hIgG4P expression vector Nucleotide numbers in the nucleotide sequence of #84H1hIgG4P shown in SEQ ID NO: 126 The DNA fragment shown in 36 to 437 was synthesized (GENEART). Using the on HD PCR cloning kit (Clontech), #8 was created by inserting a synthetic DNA fragment into the site of 4P cut with the restriction enzyme BlpI. A 4H1hIgG4P expression vector was constructed.

[0301] 6)-3-3 Construction of #101H1hIgG2 expression vector Nucleotide numbers in the nucleotide sequence of #101H1hIgG2 shown in SEQ ID NO:130 The DNA fragment shown in 36 to 428 was synthesized (GENEART). Example 6)-3 A #101H1hIgG2 expression vector was constructed in the same manner as in -1.

[0302] 6)-3-4 Construction of #101H1hIgG4P expression vector The nucleotide number of the nucleotide sequence of #101H1hIgG4P shown in SEQ ID NO: 132 The DNA fragments shown in Nos. 36 to 428 were synthesized (GENEART). The #101H1hIgG4P expression vector was constructed in the same manner as in 3-2.

[0303] 6)-3-5 #110H1hIgG4P and #110H13hIgG4P expression vectors Construction of #110H1hIgG4P and #110H1 shown in SEQ ID NO: 136 and SEQ ID NO: 148 The DNA shown in nucleotide numbers 36 to 425 of the nucleotide sequence of 3hIgG4P The fragment #110H1 was synthesized (GENEART). hIgG4P and #110H13hIgG4P expression vectors were constructed.

[0304] 6)-3-6 Construction of #131H2hIgG2 expression vector Nucleotide numbers in the nucleotide sequence of #131H2hIgG2 shown in SEQ ID NO:140 The DNA fragment shown in 36 to 431 was synthesized (GENEART). Example 6)-3 A #131H2hIgG2 expression vector was constructed in the same manner as in -1.

[0305] 6)-4 Preparation of humanized antibodies 6)-4-1 Production of humanized antibodies Produced in the same manner as in Example 1)-14-1. Example 6)-1-5, Example 6)-1 -8, Example 6)-1-11, and Example 6)-1-14. Various humanized antibodies can be obtained by combining H-chain expression vectors and L-chain expression vectors that correspond to the target sequence. I got it.

[0306] 6)-4-2 One-step purification of humanized antibodies The antibody was isolated from the culture supernatant obtained in Example 6)-4-1 by rProtein A affinity chromatography. The culture supernatant was equilibrated with PBS and purified by a single chromatography step. A column packed with ElectSuRe (GE Healthcare Biosciences) After applying the sample to a column (manufactured by nce), the column was washed with PBS that was at least twice the column volume. Next, the antibody was eluted with 2M arginine hydrochloride solution (pH 4.0) and the fractions containing the antibody were collected. The fraction was dialyzed (Thermo Scientific, Slide-A-Lyze The buffer was replaced with PBS using a Dialysis Cassette. Centrifugal UF Filter Device VIVASPIN20( The antibody was concentrated using a molecular weight cutoff of UF10K (Sartorius) to achieve an IgG concentration of 1 mg / mL. The solution was then diluted to 1 mL or more. The mixture was filtered using a filtration filter (IUS) to obtain a purified sample.

[0307] 6)-4-3 Two-step purification of humanized antibodies The culture supernatant obtained in Example 6)-4-1 was subjected to rProtein A affinity chromatography. The culture supernatant was purified in a two-step process using HPLC and ceramic hydroxyapatite. A column packed with MabSelectSuRe (GE Healthcare) equilibrated with PBS was After applying the solution to a column (Human Care Biosciences), the volume of the column was increased by more than twice the volume of the column. The column was washed with PBS. Then, the antibody was dissolved in 2 M arginine hydrochloride solution (pH 4.0). The antibody-containing fraction was dialyzed (Thermo Scientific, Slide Buffer to PBS using eA-Lyzer Dialysis Cassette -Replace with 5 mM sodium phosphate / 50 mM MES / pH 7.0 buffer. After dilution 5-fold with 5 mM NaPi / 50 mM MES / 30 mM NaCl A ceramic hydroxyapatite column (Japan) equilibrated with a pH 7.0 buffer was used. Bio-Rad Bio-Scale CHT Type-1 Hydroxyapat The solution was applied to a 100% cellulose column. A linear gradient elution with sodium chloride was performed. The fractions containing the antibodies were collected. Hic Slide-A-Lyzer Dialysis Cassette Buffer to BSor (25 mM histidine / 5% sorbitol, pH 6.0) Replacement was performed. Centrifugal UF Filter Device VIVA The antibodies were concentrated using SPIN20 (molecular weight cutoff UF10K, Sartorius), and the Ig The G concentration was adjusted to 25 mg / mL. The mixture was filtered through a Sartorius filter to obtain a purified sample.

[0308] Example 7: Measurement of humanized antibody activity 7)-1 Evaluation of CD147 antibody binding of humanized antibodies Humanized anti-human CD147 antibody #84H1L2hIgG2 prepared in Example 6)-4-3 , #84H1L2hIgG4P, #101H1L2hIgG2, #101H1L2hIg G4P, #110H1L4hIgG4P and #131H2L2hIgG2 with human CD14 The dissociation constant of 7 was measured using a Biacore T200 (GE Healthcare Bio Human Antibody Capture K A was immobilized using it (GE Healthcare Bioscience). Anti-Human IgG(Fc) antibody captures the antibody as a ligand ( The capture method was used, in which the antigen is measured as an analyte. HBS-EP+ (GE Healthcare Bioscience) was used as the mixing buffer. ce) as a sensor chip, and CM5 (GE Healthcare Biosciences) as a sensor chip. A humanized antibody (manufactured by Ixence) was applied to the chip at 1 μg / mL for 60 seconds at 10 μL / min. After adding the antigen dilution series used in Example 5 (#101H1L2hIgG2 and 0.0625-1μg / mL for #101H1L2hIgG4P, #84H1L2 hIgG2, #84H1L2hIgG4P, #110H1L4hIgG4P, #110H 13L2hIgG4P, #110H13L12hIgG4P and #131H2L2hIg G2) at a flow rate of 30 μL / min for 120 seconds, followed by The dissociation phase was monitored for 300 seconds. Chloride (GE Healthcare Bioscience) was added at a flow rate of 20 The data were analyzed using a 1:1 binding model with binding rate constants. The number ka, the dissociation rate constant kd and the dissociation constant (KD; KD=kd / ka) were calculated.

[0309] The results are shown in Table 6.

[0310] [Table 6]

[0311] 7)-2 Antitumor effect of humanized CD147 antibody in pancreatic cancer model 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS containing 4-week-old female NO D-scid mice (NOD.CB17-Prkdc <scid> / J, Charles Japan The mice were divided into groups based on tumor volume and were then transplanted subcutaneously into the axilla of mice (purchased from River Cells, Inc.). The humanized CD147 antibody (#84H1L2hIgG2, #84H1L2Ig4P, #101H1L2hIg2, #101H1L2hIg4P, # 110H1L4hIg4P, #131H2L2hIg2) at 3 mg / kg and 10 mg The drug was administered intraperitoneally to tumor-bearing mice at a dose of 100 mg / kg (n=5). Gemcitabine (purchased from Eli Lilly Japan) was administered at 400 mg / kg on days 7 and 14 after transplantation. The tumor was then measured twice a week by electrophysiology. The tumor was measured using a digital caliper (manufactured by Mitutoyo Corporation) and calculated using the following formula: The volume was calculated.

[0312] The results are shown in Figure 18 (a) to (d). The graphs show the changes in tumor volume as average values ​​and Standard errors are also shown.

[0313] The tumor growth inhibition rate of the control drug was 71%, whereas no disappearance of the tumor was observed. Both humanized CD147 antibodies were significantly superior to gemcitabine at 3 or 10 mg / kg doses. #84H1L2hIg4P and #101H1L2hIg showed superior antitumor effects to those of the control. 2. 10 mg / kg administration of #101H1L2hIg4P and #110H1L4hIg4P In the group, a strong antitumor effect was observed, accompanied by disappearance of the tumor.

[0314] (Example 8) Activation of p38MAPK signal by CD147 antibody in vitro 8)-1 p-cell proliferation by anti-human CD147 human chimeric antibody in pancreatic cancer cell PANC-1 38Induction of MAPK phosphorylation It has been reported that CD147 promotes phosphorylation of p38 MAPK upon activation ( Lim et al., FEBS Letters, 88-92, 1998) t.,al.J.Hepatology,1378-1389,2015). Antitumor effect To investigate the effect of anti-CD147, which expresses CD1 47 Human chimeric antibody LN22R8chIgG4P was treated at 10 μg / ml for 15 min. For PANC-1 cells, p38MAPK phosphorylation was analyzed using a Simple Western The results were evaluated using the Protein Simple assays method (Protein Simple Japan, Ltd., Wes). As a control sample, PANC-1 cells were incubated with human IgG (Jackson ImmunoR esearch, 009-000-003) 10 μg / ml was treated in the same manner and used for analysis. For detection of p38MAPK, p38 MAPK rabbit mAb (Cel Signaling Technology, Cat.#9212) was used. To detect phosphorylated p38 MAPK, P-p38 MAPK (T180 / Y182) (D3 F9)XP rabbit mAb(Cell signaling technology The phosphorylation of p38MAPK was detected by the The ratios of p38MAPK signals are shown in Figure 19. Antibody-treated samples were run in duplicate and the average The values ​​are shown in the figure.

[0315] In the LN22R8chIgG4P antibody-treated group, an increase in phosphorylated MAPK signal was observed. It was done.

[0316] 8)-2 HSP27, a downstream molecule of p38 signaling in vitro by CD147 antibody Phosphorylation of It has been reported that p38MAPK phosphorylates HSP27 upon activation ( Landry et al.,Biochem.Cell Biol.,703-707 , 1995). p38 phosphorylation induced by CD147-human chimeric antibody LN22R8 To confirm whether oxidation actually promotes p38 signal activation, we treated cells with 8)-1 antibody. The samples were analyzed for phosphorylation using Simple Western assays (Protein The evaluation was performed using the InSimple Japan Co., Ltd. (Wes). HSP27 antibody (R&D Systems, Cat. AF15801) was used. Phospho-HSP27 (Ser82)antibody was used to detect phosphorylated HSP27. ody (Cell signaling technology, 2401S), or Anti-HSP27 (phospho Ser15) antibody (abcam, Cat.a b76313) was used.

[0317] Ser82 or Ser15 phosphorylated HSP27 for detected HSP27 signals The signal ratios are shown in Figure 20(a) or (b), respectively. The measurements were performed in duplicate, and the average values ​​are shown in the figures.

[0318] In the LN22R8chIgG4P antibody-treated group, an increase in phosphorylated HSP27 signal was observed. The phosphorylation of p38 induced by CD147-human chimeric antibody was observed downstream The anti-human CD147 human chimera induced phosphorylation and activation of HSP27. Antibody LN22R8IgG4P was found to induce activation of p38MAPK signaling. In addition, in pancreatic cancer cells, MIA PaCa-2, p38MAPK signaling was also suppressed. Activation was confirmed.

[0319] (Example 9) Activation of p38 signaling in tumors by CD147 antibody observed in vitro The activation of p38MAPK signaling by CD147 antibody was observed in mice subcutaneously. We investigated whether the tumor growth also occurs in the subcutaneous tumor of MIA PaCa-2 mice. 6 Thin Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Cornin Five-week-old female NOD-scid mice were suspended in PBS containing 100 mM NaCl (Cat. No. 354230) and incubated for 1 h. S(NOD.CB17-Prkdc <scid> / J, purchased from Charles River Japan ) were subcutaneously transplanted into the axilla of mice. Five days after transplantation, mice were divided into groups based on tumor volume, and anti-human C D147 human chimeric antibody LN22R8chIgG4P was administered at 10mg / kg on the day of group allocation. The antibody was administered intraperitoneally to tumor-bearing mice. Tumors were sampled 6, 24, 48, and 72 hours after antibody administration. The samples were frozen on dry ice and then stored frozen. 3) gentleMACS Octo Dissociator with He The tumor lysate was treated with Simple Western assays (Protein Simple Japan, Ltd., Wes) The analysis was carried out using

[0320] The average values ​​of the detected p38MAPK signals are shown in FIG. 21(a) together with the standard error. The average phosphorylated p38 MAPK signal detected is shown in Figure 21(b) along with the standard error. The mean ratio of phosphorylated p38 MAPK signal to p38 MAPK signal is shown in The values ​​are shown in Figure 21(c) together with the standard error. LN22R8chIgG4P was Increased the proportion of phosphorylated p38MAPK from 24 hours to 72 hours. During the 6-hour period, p38MAPK increased, and the phosphorylated p38MAPK signal was The number of cases peaked at 100 and then decreased.

[0321] Administration of CD147 chimeric antibody also increased p38 phosphorylation and HS in subcutaneous tumors in mice. Increased phosphorylation of p27 was observed, indicating activation of p38 signaling. Ta.

[0322] (Example 10) Induction of CXCL8, a molecule downstream of p38MAPK Activation of p38MAPK induces CXCL8 mRNA stabilization (Hof fmann et al., J. Leukoc. Biol., 847-855, 2002 ), and activation of SMAD3 / 4 signaling has been reported (Leovonen et al. ., PLOS ONE, e57474, 2013). MIA PaCa-2 intratumoral So, is CXCL8 gene expression induced after antibody administration? Is it in mouse subcutaneous tumors after antibody administration? The RNA extracted from the cells was examined by quantitative PCR. The RHOB gene, which has been reported to be induced by ,FASEB Journal,891-905,2010) for CD147 antibody The importin (ipo8) gene was used as an endogenous control gene. and TATA box binding protein (tbp) gene expression. Anti-human CD147 human chimeric antibody was administered, and 72 hours later, MIA PaCa-2 tumor After sampling and processing with RNA later (QIAGEN, Cat. 76104), RNeasy Mini Kit (250) (QIAGEN, Cat. 74106) As the anti-human CD147 human chimeric antibody, Example 1)-1 was used to extract RNA. LN22R8chIgG1, LN22R8chIgG2 or LN22R8c prepared in 4 hIgG4P was used. EXPRESS One-Step was used for quantitative RT-PCR. SuperScript qRT-PCR kit Universal(Thermo Fisher Scientific, Cat. 11781-01K) was used to determine the gene As a quantitative probe, importin(ipo8) (Thermo Fisher Scientific scientific,Cat.Hs00183533_m1),TATA box bi nding protein(tbp)(Thermo Fisher Scienti fic,Cat.Hs00427621_m1),rashomolog family member B(rhoB)(Thermo Fisher Scientific ,Cat.hs00269660_s1),interleukin 8(Thermo Fisher Scientific, Cat.Hs00174103_m1) The increase in gene-specific fluorescent signal accompanying the PCR reaction was measured using the ABI Prism Measurements were performed using a 7500 (Applied Biosystems). Figure 22(a) shows the average expression ratio of ipo8 / tbp genes (n=3) along with the standard deviation. showed. Figure 22(b) shows the average expression ratio of cxcl8 / tbp genes (n=3) along with the standard deviation. It was shown. Figure 22(c) shows the average expression ratio of rhoB / tbp genes (n=3) along with the standard deviation. showed.

[0323] LN22R8chIgG1, LN22R8chIgG2 or LN22R8chIgG4 After P administration, ipo8 gene expression did not change, whereas anti-human CD147 human kinase Induction of cxcl8 and rhoB expression was confirmed in the group administered with the Mela antibody. The expression of B was induced in accordance with the strength of the antitumor effect of the human chimeric antibody shown in Example 1)-18. These results suggest that induction of expression of both genes may correlate with antitumor effects.

[0324] (Example 11) Enhancement of antitumor effect by conversion of anti-human CD147 rat antibody to human chimeric antibody Induction of cxcl8 and rhoB genes in strong The anti-human CD147 rat antibody rat_CD147_#110 was used in Examples 2 and 7. As shown, the antitumor effect was enhanced by human chimerization. Human chimeric antibody LN22R8 Tumors after administration of chIgG1, LN22R8chIgG2, or LN22R8chIgG4P The induction of cxcl8 and rhoB was observed in rat_CD 147_#110 was compared with chimeric antibody #110chIgG4P.

[0325] Figure 23(a) shows the average expression ratio of ipo8 / tbp genes (n=3) along with the standard deviation. It was shown.

[0326] Figure 23(b) shows the average expression ratio of cxcl8 / tbp genes (n=3) along with the standard deviation. The results are shown below.

[0327] Figure 23(c) shows the average expression ratio of rhoB / tbp genes (n=3) along with the standard deviation. It was shown.

[0328] The expression of the ipo8 gene did not change with antibody administration. The expression of oB gene was similar to that of the non-treated group after administration of rat_CD147_#110. No change was observed in cxcl8 and rhoB in #110chIgG4P. The induction of both genes was confirmed as a parameter correlated with the antitumor effect of CD147 antibody. It was suggested that this was a

[0329] (Example 12) Evaluation using SMAD4-negative pancreatic cancer tumor-bearing model The transcription factor SMAD4 is known to be one of the important molecules for activating SMAD signals. (Zang, et al., Current Biology, 270-276, 1997). In some pancreatic cancers, genetic deficiency of SMAD4 results in the suppression of SMAD signaling. It is known that the IL-1 gene is partially inhibited (Hahn, et al., Science ce, 350-353, 1996). SMAD4 is absent and SMAD signaling is partially For the pancreatic cancer cell line BxPC-3, which is inhibited (Yasutome et al., Clin. Exp. Metastasis, 461-473, 2005), CD147 anti- The results showed that the 2.5×10 6 Human pancreatic cell line BxPC-3 (ATC C,Cat.CRL-1687) to 100% Matrigel (Corning, Ca. The cells were suspended in PBS containing t.354234 and then transferred to 6-week-old female BALB / c-nu mice (CA nN.Cg-Foxn1nu / CrlCrlj (purchased from Charles River, Japan) The mice were subcutaneously transplanted into the cavity of the mouse. Eight days after transplantation, the mice were divided into groups based on the tumor volume. After 22 days, mouse anti-human CD147 antibody LN22R8R8 or rat anti-human CD14 7 Antibody 2P10F2 was administered intraperitoneally at 10 mg / kg to tumor-bearing mice (n=5). Gemcitabine (Eli Lilly Japan, Gemzar (Registered)), a drug used to treat pancreatic cancer, is Tumor-bearing mice were administered 200 mg / kg of 100 mg ... The major and minor axes of the transplanted tumors were measured twice a week using an electronic digital caliper (Mitsu Co., Ltd.). The tumor volume was measured using a CT scanner (manufactured by Toyo University) and calculated using the following formula.

[0330] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The graph shows the mean and standard error for the changes in tumor volume. BxPC-3 tumors were resistant to the LN22R8 and 2P10F2 antibodies and gemcitabine. It was sexual.

[0331] (Example 13) Acquisition of CD147 antibody sensitivity by introduction of SMAD4 SMAD signaling is restored by introduction of SMAD4 in multiple pancreatic cancer cell lines It has been reported that SMAD4-induced restoration of SMAD signaling promotes CD4 expression. We investigated whether the sensitivity of antibody 147 was increased.

[0332] 13)-1 Generation of SMAD4 stable expressing cells Retro-X TM Using the Q vector kit, we created a stable SMAD4-expressing BxPC-3 line. A retroviral vector (Takara Bio, Retro-X) was prepared. TM Q Ve The cloned vector of pQCXIP is included in the kit as a vector set (Cat. 631516). The artificially synthesized human SMAD4 gene was introduced into the targeting site, and SMAD4 expression was confirmed. Retrovirus vector. Retro-X Universal Packagi The ng System (Takara Bio, Cat. 631530) was used to A SMAD4 expression retroviral vector was introduced into the mice, and puromycin (Takara Bio , Cat. 631306), a retrovirus that integrates into the chromosome through viral infection. BxPC-3 cells that were rare, puromycin-resistant, and SMAD4-positive were selected and then subjected to SMAD4 immunofluorescence. AD4-positive BxPC-3 cells were designated BxPC-3-SMAD4. Retroviral vector BxPC-3 cells were similarly infected with pQCXIP and made puromycin resistant. The retroviral infection experiment was performed twice, and the BxPC-3-mock For BxPC-3-SMAD4, lot.1 and lot.2 were prepared.

[0333] 13)-2 Confirmation of CD147 and SMAD4 expression BxPC-3 (ATCC, Cat. CRL-1687), prepared in Example 13)-1 About BxPC-3-mock, BxPC-3-SMAD4, Simple West The analysis was performed using the ern assays method (Protein Simple Japan, Ltd., Wes) MIA PaCa-2 was used as a SMAD4 positive control sample. Anti-SMAD4 antibody (R&D systems, Cat. AF2097) was used to detect D4. For the detection of GAPDH, anti-GAPDH antibody (Abfrontier, Cat. LF-MA0026 was used. Anti-CD147 antibody (Abca m, Cat. Ab108317) was used.

[0334] The results are shown in Figure 25(a). MIA PaCa-2 cells were SMAD4 positive and CD147 positive. BxPC-3 was SMAD4 negative and CD147 positive. Mock showed no effect of retroviral infection, and was SMAD4 negative and CD147 positive. The SMAD4-expressing retroviral vector was introduced into BxPC-3-SMA D4 was positive for SMAD4 in both lot 1 and lot 2. Lot.2 was used as BxPC-3-SMAD4 for the subsequent experiments because it had high MAD4 expression. did.

[0335] 13)-3 CD147 human chimeric antibody against BxPC-3 tumors stably expressing SMAD4 Susceptibility to 2.5×10 6 Cells BxPC-3-mock or BxPC-3-SMAD4 were cultured at 10 Suspended in PBS containing 0% Matrigel (Corning, Cat. 354234) Five-week-old female BALB / c-nu mice (CAnN.Cg-Foxn1nu / CrlC The tumors were then subcutaneously transplanted into the axilla of mice (RLJ, purchased from Charles River, Japan). Six days after BxPC-3-mock transplantation, BxPC-3-SMAD4 group was treated with 100 mg / kg / day of transplantation. On the day of grouping, and 7, 14, 21, and 28 days later, human chimeric anti-human CD147 antibody LN22R8R8chIgG2 or LN22R8R8chIgG4P The drug was administered intraperitoneally to tumor-bearing mice at 10 mg / kg (n=5). Measure twice a week using an electronic digital caliper (manufactured by Mitutoyo Corporation) and use the following calculation formula: The tumor volume was calculated by the following method.

[0336] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 25(b) and Figure 25(c). The graphs show the changes in tumor volume on average. The mean and standard error are shown. BxPC-3-mock tumors were LN22R8R8c They were resistant or had low sensitivity to hIgG2 or LN22R8R8chIgG4P antibody. BxPC-3-SMAD4 tumors were treated with LN22R8R8chIgG2 or LN22R8R It showed partial sensitivity to 8chIgG4P antibody.

[0337] 13)-4 Changes in p38 signaling in tumors due to SMAD4 expression In SMAD4-negative pancreatic cancer cells, expression of SMAD4 inhibits p38 signaling. It has been reported that the nal is enhanced (Chen et al., BMC, 147 1-2407, 2014). p38MAPK and phosphorylation in BxPC-3-SMAD4 tumors For the p38MAPK antibody, anti-human CD147 human chimeric antibody was administered (72 hours after antibody administration). Regarding the variation due to the following, Simple Western a The results were analyzed using the Protein Simple assays method (Protein Simple Japan, Ltd.). As in Example 1)-18, LN22R8c was used as an anti-human CD147 human chimeric antibody. hIgG4P was administered at 10 mg / kg to mice bearing subcutaneous MIA PaCa-2 tumors. Samples from tumor tissues (n=3) were prepared using the gentleMACS Octo A Dissociator with Heaters (Miltenyi) was used.

[0338] Figure 26(a) shows the average p38 MAPK values ​​from three tumor samples. The values ​​and standard errors are shown in the graph. The values ​​are shown in the graph as the average and standard error of the measurements for three tumor samples. .

[0339] In BxPC-3-SMAD4 tumors, p38 and phosphorylated p38 were increased more than two-fold. At 72 hours after administration of CD147 human chimeric antibody, there was a partial decrease in p38, phosphorylation, and A partial increase in lysed p38 was observed.

[0340] In pancreatic cancer BxPC-3 tumors, SMAD4 expression increased p38 signaling. The CD147 human chimeric antibody LN22R8chIgG4P was found to be highly potent. It is possible that the increased sensitivity is due to the enhancement of p38 signaling mediated by SMAD4. do.

[0341] (Example 14) Antitumor effect of chimeric CD147 antibody in gemcitabine-resistant pancreatic cancer The antitumor effect of CD147 antibody was investigated in a gemcitabine-resistant pancreatic cancer tumor model. 10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Co The cells were suspended in PBS containing 100 mM NaCl (Borning, Cat. 354230) and cultured with 5-week-old female NOD-sc mice. id mice (NOD.CB17-Prkdc <scid> / J, Charles River, Japan Six days after transplantation, gemcitabine (Nihon Ikinen Co., Ltd.), a drug used to treat pancreatic cancer, was administered subcutaneously to the armpits of mice. (Lilly & Company) was administered intraperitoneally at 400 mg / kg, and proliferation was confirmed one week later. Mice with tabine-resistant tumors were divided into groups based on tumor size, and a control group (n= 5) Gemcitabine was administered at 400 mg / kg intraperitoneally on the 13th and 20th days after transplantation (the day of group allocation). The CD147 antibody and gemcitabine combination group (n=5) received gemcitabine. In addition, 400 mg / kg of riboflavin was administered intraperitoneally on the 13th day (grouping day) and the 20th day after transplantation. , CD147 human chimeric antibody LN22R8chIgG4P was administered on the 13th day after transplantation (day of group allocation). On the 20th day, 10 mg / kg of the tumor was administered intraperitoneally. The major and minor diameters of the transplanted tumors were measured twice a week using electronic data. The tumor volume was measured using a digital caliper (manufactured by Mitutoyo Corporation) and calculated using the following formula: was calculated.

[0342] The results are shown in the graph in Figure 27, which shows the average and standard error for the change in tumor volume. The non-treated group did not receive either gemcitabine or antibody. The tumor growth rate of the 5 patients was also reported (n=5).

[0343] In the control group treated with gemcitabine, the average tumor size was 1,269 mm 28 days after implantation. m 3 No tumor regression was observed, whereas CD147 human chimeric antibody LN2 The average tumor size in the 2R8chIgG4P-treated group was 15 mm 3 There are 5 cases Tumor regression was observed in three of the cases. Pancreatic cancer tumors have also been shown to be sensitive to CD147 antibodies.

[0344] Example 15: Antitumor effect of humanized CD147 antibody in liver cancer model 15)-1 Expression of CD147 and SMAD4 in Hep G2 cells In the same manner as in Example 13)-2, liver cancer cell line HepG2 cells (ATCC, Cat. HBsAg) were cultured in a 50-well platelet-free culture medium. We confirmed the expression of CD147 and SMAD4 in the CD147-positive control group ( The vectors were MIA PaCa-2 and BxPC-3 (ATCC, Cat. CRL-1687 ) was used as a control for SMAD4-positive MIA PaCa-2, SMAD4-negative As a control sample, BxPC-3 was used.

[0345] The signal ratios of the detected signals to GAPDH were calculated and summarized below. Hep G2 cells were found to be positive for CD147 and SMAD4.

[0346] CD147 / GAPDH signal ratio MIA PaCa-2 0.481 BxPC-3 0.481 Hep G2 2.944

[0347] SMAD4 / GAPDH signal ratio MIA PaCa-2 0.329 BxPC-3 0.003 Hep G2 0.723

[0348] 15)-2 Expression of CD147 in Hep G2 cells by flow cytometry confirmation CD14 expressed on the cell surface of HepG2 cells (ATCC, Cat. HB-8065) 7 was analyzed by flow cytometry. Anti-human CD147 mouse IgG1 antibody MEM labeled with APC as a CD147 antibody -M6 / 1-APC (Thermofisher, Cat. MA1-10104) mIgG1-AP was used as a mouse IgG1 isotype control antibody. C (Miltenyi Bio, Cat. 130-092-214) was used. To the cell suspension, 1 / 10 volume of MEM-M6 / 1-APC was added and incubated at 4°C for 30 minutes. After washing the cells with PBS buffer containing 5% FBS, the cells were analyzed using a flow cytometer (Cantonese). I, BD Biosciences) and the results are summarized in FIG. 28(a).

[0349] Hep G2 cells treated with MEM-M6 / 1-APC showed strong fluorescent signals. , and were found to express CD147.

[0350] 15)-3 p38 activation by humanized CD147 antibody in hepatocellular carcinoma cells The effect of anti-CD147 antibody on p38MAPK in liver cancer cell HepG2 To investigate this, anti-human CD147 human chimeric antibody (LN22R8chIgG4P) or Example 6)-4-2: Anti-human CD147 humanized antibody (#84H1L2hIgG2 , #84H1L2hIg4P, #101H1L2hIgG2, #101H1L2hIgG 4P, #110H1L4hIg4P, #131H2L2hIgG2) at 10 μg / ml HepG2 cells (ATCC, Cat. HB-8065) ​​treated for 15 minutes were 8. Phosphorylation was measured using Simple Western assays (Protein Simple As a control sample, HepG2 cells were used. hIgG (Jackson ImmunoResearch, 009-00 0-003) 10μg / ml were treated in the same manner and subjected to analysis. , p38 MAPK rabbit mAb(Cell signaling tech For the detection of phosphorylated p38MAPK, P-p38 MAPK(T180 / Y182)(D3F9)XP rabbit mAb (Cell signaling technology, #4511S) was used. The ratio of phosphorylated p38MAPK signal to detected p38MAPK signal is shown in Fig. 2. 8(b).

[0351] LN22R8chIgG4P, #84H1L2hIgG2, #84H1L2hIg4P , #101H1L2hIgG2, #101H1L2hIgG4P, #110H1L4hI Treatment with g4P or #131H2L2hIgG2 increased the IgG-related Increased phosphorylated p38 MAPK signaling was observed in liver cancer cells as well as pancreatic cancer cells. It was found that anti-human CD147 antibody induces phosphorylation of p38MAPK. I did.

[0352] 15)-4 Comparison of antitumor effects of humanized CD147 antibody and sorafenib in liver cancer CD147 and SMAD4 positive, and p38 phosphorylation confirmed by anti-human CD147 antibody The human liver cell line HepG2 (ATCC, Cat. HB-8065) ​​was treated with anti-human C The antitumor effects of D147 human chimeric and humanized antibodies were examined.

[0353] 5×10 6 Human liver cell line HepG2 was cultured in 50% Matrigel (Corning The cells were suspended in PBS containing 100% ethanol (Cat. 354234) and then transferred to 4-week-old female NOD-scid mice ( NOD.CB17-Prkdc <scid> / J, purchased from Charles River, Japan) The mice were subcutaneously transplanted into the axilla. Nine days after transplantation, the mice were divided into groups based on the tumor volume. D147 antibody (LN22R8chIgG4P), humanized C prepared in Example 6)-4-2 D147 antibody (#84H1L2hIgG2, #84H1L2hIg4P, #110H1L 4hIg4P) was administered intraperitoneally at 1 mg / kg or 10 mg / kg to tumor-bearing mice (n = 10). 5) The control drug was sorafenib (Nexavar tablets 200 mg, (Yell Pharmaceuticals Co., Ltd.) is a reference for the package insert of Nexavar tablets (Chang et.al .,Cancer Chem. Thera. Pharm., 2007) 5 Castor oil (Cremophor EL, Nacalai Tesque, Cat. 09727-14 ) Dissolved in ethanol solvent, 9, 10, 11, 12, 13, 16, 17, 18 days after transplantation The compound was orally administered at 30 mg / kg or 90 mg / kg to tumor-bearing mice (n=5). The major and minor diameters were measured twice a week using an electronic digital caliper (manufactured by Mitutoyo Corporation). The tumor volume was calculated using the formula below.

[0354] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Table 7 and Figures 29(a) to (d). The graphs show the changes in tumor volume. The mean values ​​and standard errors are also shown. Sorafenib administration was observed to partially inhibit tumor growth, but tumor disappearance was not observed. LN22R8chIgG4P, #84H1L2hIgG2, #84H1L2hI Both #110H1L4hIg4P and #110H1L4hIg4P showed excellent antitumor effects accompanied by tumor disappearance. showed.

[0355] [Table 7]

[0356] Example 16: Effect on T cells and PBMCs CD147 expression increases in CD4-positive and CD8-positive T cells upon T cell activation ( Hu et al.,J.Cell.Mol Med.,2132-2143,2010 ), some CD147 antibodies have been reported to have the effect of inhibiting T cell activation and proliferation. (Koch et al., Int. Immunology, 777-786, 1 999;Chiampanichayakul et al., Immunology 167-178, 2006). It exhibits strong antitumor effects independent of effector functions. We investigated the effect of anti-human CD147 antibody on peripheral blood lymphocytes (PBLs), including T cells. .

[0357] 16)-1 Increased expression of CD147 by CD3 / CD28 stimulation of PBMC We investigated whether CD147 expression increases upon T cell activation using human PBMCs. Human PBMCs were cultured in RPMI1640 medium containing 10% FBS at 37°C in the presence of 5% CO2. During the culture, Dynabeads Human T-Activator C D3 / CD28(CD3 / CD28 beads,Thermofishers sci Cell proliferation was induced by adding 100% erythrocytes (Centific, Cat. 1131D) and 4 days later, the cells were analyzed by flow cytometry. We performed cytochrome P450 assay to determine whether expression of CD147 was altered. For confirmation, a commercially available anti-human CD147 antibody, APC-labeled anti-human CD147 mouse IgG1 antibody MEM-M6 / 1-APC (CD147-APC, Thermofish Mouse IgG1 isotype codon (Cat.MA1-10104) was used. As an ntrol antibody, mIgG1-APC (Miltenyi Bio, Cat. 130-09 2-214) was used to detect CD3, CD4, and CD8 of T cells contained in human PBMC. In order to do so, APC / Fire TM 750 anti-human CD3 Anti body (BioLegend, Cat. 344840), PerCP / Cy5.5 anti-human CD4 (BioLegend, Cat. 344608), Brilliant Violet 510 anti-human CD8(BioL egend, Cat. 344732) was used.

[0358] CD147-APC in CD3, CD4 positive cells and CD3, CD8 positive cells The binding of CD3, CD4 positive cells and CD3, CD8 positive cells is summarized in Figure 30. In this study, the expression of CD147 was increased when stimulated with CD3 / CD28 beads. It was confirmed that expression of CD147 on the T cell membrane surface increases with T cell activation. Ta.

[0359] 16)-2 Evaluation of the effect of anti-human CD147 antibody on the proliferation of human peripheral blood mononuclear cells The effect of anti-human CD147 antibody on the proliferation of human peripheral blood mononuclear cells (PBMC) was analyzed. The anti-human CD147 antibody used was 2P10F2chIgG4P. Claret Far Red Fluorescent Cell Linker K PBMCs were fluorescently labeled using it (Sigma, Cat. MIDCLARET-1KT). After that, the cells were incubated in RPMI1640 medium containing 10% FBS at 37℃ in the presence of 5% CO2. During the culture, IL-2, Dynabeads Human T-Activator tor CD3 / CD28(CD3 / CD28 beads,Thermofisher Scientific, Cat. 1131D) was added to induce proliferation of 2P1 0F2chIgG4P (10 μg / ml) was added to examine the effect on proliferation. On day 5, the PBMC cell fluorescence signal was measured by flow cytometry, which was reduced by cell division. Measurement was performed using a chromatograph (Canto II, BD Biosciences), and the results shown in FIG. The results are summarized in.

[0360] By adding CD3 / CD28 beads, the PBMC cells that were reduced by cell division were Cellular fluorescence signals were observed after 3 and 5 days of culture. IL-2, 2P10F2chIg When G4P or IL-2 and 2P10F2chIgG4P were added during culture, the fluorescence No change was observed in the reduction of signal. Anti-human CD147 chimeric antibody 2P10F2 showed strong antitumor effects in tumor models It was suggested that chIgG4P did not affect the proliferation of PBMCs.

[0361] 16)-3 Effect of anti-human CD147 antibody on cytokine production in human peripheral blood lymphocytes evaluation As anti-human CD147 antibodies, human chimeric antibodies #84chIgG1 and #84chIgG 2, #84chIgG4P, #84chIgG1LALA, #84chIgG4PFAL A, #101chIgG4P or #110chIgG4P was used. PB was administered using coll-Paque PLUS (GE Healthcare Japan, Ltd.). A 96-well plate was coated with 10 μg / ml of human chimeric antibody. Human IgG (hIgG, Jackson ImmunoRe) was used as a control antibody. Search, Inc., 009-000-003), induces T cell activation and cytokine induction Dynabeads Human T-Activat or CD3 / CD28(CD3 / CD28-beads, Thermofishers Scientific, Cat. 1131D) was used. 1x10 6 After 24 hours, the cytokines in the medium (IL2, TNFα, INFγ) was measured using Dynabeads Human T-Activator C D3 / CD28 was added directly to the wells containing PBLs, and after 24 hours, Cytokines (IL2, TNFα, INFγ) were measured. tikine ELISA Human IL-2(R&D systems,Cat. Amersham TNF-α Human Immunosorbent Assay Kit (D2050) was used to measure TNFα. n, Biotrak Easy ELISA (GE Healthcare Japan, Ltd., C At.RPN5967) was used. Human IFN-γ EL ISA development kit (MABTECH, Cat.3420-1H -6) was used. The measurements were carried out in triplicate, and the average and standard deviation of the detected absorbance were calculated. This is summarized in Figure 32.

[0362] The cytokines produced by the measured PBLs (IL2, TNFα, INFγ) were These results were also obtained by culturing in wells containing CD3 / CD28-beads, which serve as a positive control. The increase was confirmed only in the cultures coated with either anti-human CD147 human chimeric antibody. No increase in cytokines was observed in the rats fed the hIgG-treated control. Ta.

[0363] (Example 17) X-ray crystal structure analysis of humanized #110 Fab'-CD147 complex 17)-1 Crystallization of the complex Fab' obtained by cleaving humanized #110H1L4hIgG4P with Pepsin After reducing 2 with dithiothreitol, it was converted to 2 with iodoacetamide. The Fab' fragment was obtained by alkylating the Fab' fragment. The mixture of hCD147v2(22-205) was incubated with Superdex 10 / 300GL I Gel filtration chromatography using an ncrease column (GE Healthcare) The complex was then loaded onto an Amicon Ultra 15 MWCO 10K (Millipore) in a buffer solution (10 mM Tris HCl pH 7.5, 50 mM The complex solution was crystallized by vapor diffusion. 0.5 μL of the protein solution was diluted with a precipitant solution (0.1 M NaMalonate pH 7.0, 12% (w / v) Polyethylene Glycol 3350) The equal amounts of the solutions were placed in a sealed container containing 0.05 mL of precipitant solution so that the two solutions did not come into contact with each other. The sample was placed in a container and left to stand at 25°C. After about one week, the 0.15mm x 0.15mm x 0.02mm diameter sample was obtained. .3mm crystals were mixed with polyethylene glycol to make a 30% (w / v) solution. The samples were then immersed in a precipitant solution containing 400 mM sodium chloride and frozen in liquid nitrogen. X-ray diffraction data were collected at the beamline PF-BL17A at the University of Tokyo (Ibaraki, Japan). The diffraction images were analyzed using the software mosflm (CCP4: Collaborative Analysis). Diffraction intensities were calculated using the VE Computational Project No. 4) The crystal structure factor was calculated by quantifying the crystal. The crystal space group is P21, and the crystal unit cell is (a=64 .96Å, b=93.37Å, c=98.31Å, alpha=gamma=90, beta=90.89).

[0364] 17)-2 Structural analysis of the complex The homology model of the obtained structural elements and the Fab' fragment and the known structure of human CD147 The phase was determined by molecular replacement using the three-dimensional structure coordinates of (PDBID:3b5h). The calculations were performed using the software Phaser (CCP4: Collaborative Com The crystals were prepared using the 2-membered asymmetric unit. The software Refmac5 (CCP4: Collabora The structure was refined using the Interactive Computational Project No. The model was then refined using the software COOT. This process was repeated. The final R value was 23% and the free R value was 28% at 2.3 Å resolution. The Fab' fragments of humanized #110H1L4 and hCD147, which bind to each of them, are v2. The other hCD147v2 corresponds to amino acid residues 23-203. The electron density corresponding to domain 1 was clearly observed for the other one. Instead, only electron density corresponding to amino acid residues 103-202 was observed.

[0365] 17)-3 Identification of epitopes The Fab fragment of humanized #110H1L4 was commonly found in the two complexes contained in the asymmetric unit. The amino acid residues of hCD147v2 that are within 4 Å of the fragment binding interface are: :Arg106, Lys108, Ala109, Val110, Lys127, Ser1 28, Glu129, Ser130, Val131, Pro132, Pro133, Va l134, Gln164, Gly165. Figure 41 shows the ribbon model and surface of the entire complex. FIG. 42 shows the interaction between hCD147v2 and humanized #110H1L4.

[0366] (Example 18) Antitumor effect of humanized CD147 antibody in a gastric cancer model KATO I human gastric cancer cell line confirmed to be CD147 positive by flow cytometry II cells (ATCC, Cat. HTB-103), anti-human CD147 human chimera The antitumor effects of antibodies and humanized antibodies were examined.

[0367] 5×10 6 The human gastric cancer cell line KATO III was cultured in 100% Matrigel (Corn The cells were suspended in 100 mM NaCl (Cat. No. 354234) and then incubated with 5-week-old female NOD-scid mice (NO D.CB17-Prkdc <scid> / J, purchased from CLEA Japan) was implanted subcutaneously in the axilla. Based on the tumor volume, the mice were divided into groups 3 days after transplantation, and the mice were treated with human chimeric CD147 antibody (L N22R8chIgG4P), humanized CD147 antibody prepared in Example 6)-4-2 (# 110H1L4hIg4P) was administered intraperitoneally at 10 mg / kg to tumor-bearing mice 7 days after group allocation. The major and minor diameters of the transplanted tumors were measured twice a week using an electronic digital caliper ( The tumor volume was measured using a measuring device (manufactured by Mitutoyo Corporation) and the tumor volume was calculated using the following formula.

[0368] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 43. The graph shows the mean and standard error for the changes in tumor volume. He wrote: The mean tumor volume in untreated mice was 290 mm 24 days after implantation. 3 whereas In the LN22R8chIgG4p-treated group, the mean mean was 199 mm 3 , #110H1L4hIgG4 In the P-treated group, the mean mean was 134 mm. 3 The calculated antitumor effect was The rate was 31% in the G4p-administered group and 54% in the #110H1L4hIgG4P-administered group.

[0369] Example 19: Antitumor effect of humanized CD147 antibody in a chronic myeloid leukemia model Human chronic myeloid leukemia cell lines confirmed to be CD147 positive by flow cytometry For KU812 cells (ATCC, Cat. CRL-2099), anti-human CD147 antibody was used. The antitumor effects of the antibody were examined.

[0370] 5×10 6 Chronic myeloid leukemia cell line KU812 was cultured on 50% Matrigel (Co The mice were then suspended in PBS containing 100% ethanol (Borning, Cat. 354234) and cultured with 5-week-old female NOD-sc mice. id mice (NOD.CB17-Prkdc <scid> / J, purchased from Claire Japan) The mice were subcutaneously transplanted into the axilla. Three days after transplantation, the mice were divided into groups based on the tumor volume. The humanized CD147 antibody (#110H1L4hIg4P) prepared in 4-2 was administered at 10 mg / kg. The tumor-bearing mice were intraperitoneally administered 0.1 mg / kg every 7 days after grouping (n=5). Imatinib (ASTATECH, Cat.#63168), a drug used to treat myeloid leukemia The compound was prepared in distilled water at 9 mg / ml and orally administered to tumor-bearing mice at 90 mg / kg (Sat. Days off medication, 4, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 21 after transplantation The major and minor diameters of the transplanted tumors were measured twice a week using an electronic digital caliper. The tumor volume was calculated using the following formula: .

[0371] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 44. The graph shows the mean and standard error for the changes in tumor volume. He wrote: The mean tumor volume in untreated mice was 627 mm 25 days after implantation. 3 whereas In the imatinib group, the mean mean was 328 mm 3 In the #110H1L4hIgG4P administration group, 6mm 3 The calculated antitumor effect was 48% in the imatinib group and 49% in the #110H1L group. In the 4hIgG4P-administered group, the rate was 97%. Complete regression of the tumor was observed in four of the five cases.

[0372] Example 20: Antitumor effect of humanized CD147 antibody in a colon cancer model SW620 human colon cancer cell line confirmed to be CD147 positive by flow cytometry The antitumor effect of humanized antibodies was examined on cells (ATCC, Cat. CCL-227). Ta.

[0373] 5×10 6 The human colon cancer cell line SW620 was cultured in 100% Matrigel (Cornin The mixture was suspended in 1000 mM NaCl, Cat. 354234) and incubated in 5-week-old female NOD-scid mice (NOD. CB17-Prkdc <scid> / J, purchased from CLEA Japan) was implanted subcutaneously in the axilla. Based on the tumor volume, the mice were divided into groups 3 days after transplantation, and the mice were treated with human chimeric CD147 antibody (LN2 2R8chIgG4P), humanized CD147 antibody (#08 4H1L2hIg4P or #110H1L4hIg4P) at 10 mg / kg in tumor-bearing mice. The mice were intraperitoneally administered with 100 mg / kg of 1000 mg / kg every 7 days after group division (n=5). The major and minor diameters of the transplanted tumors were measured weekly. The measurements were taken twice using an electronic digital caliper (manufactured by Mitutoyo Corporation) and the following calculation formula was used: The tumor volume was calculated based on the above data.

[0374] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 45. The graph shows the mean and standard error for the changes in tumor volume. He wrote: The mean tumor volume in untreated mice was 1,302 mm 21 days after implantation. 3 Whereas In the #084H1L2hIg4P group, the mean tumor size was 709 mm 3 , #110H1L4hIgG In the 4P-administered group, the 3 The calculated antitumor effect was The rate was 46% in the Ig4P-administered group and 69% in the #110H1L4hIgG4P-administered group.

[0375] Example 21: Antitumor effect of humanized CD147 antibody in renal cancer 786-O model Flow cytometry confirmed that human renal cell carcinoma 786-O was CD147 positive. The antitumor effects of the humanized antibodies were then examined. 5×10 6 Human kidney cancer 786-O cells were cultured in 50% Matrigel (Corning, Cat.354234) were suspended in 5-week-old female NOD-scid mice (NOD.CB 17-Prkdc <scid>The tumor was then subcutaneously transplanted into the axilla of a mouse (J, purchased from CLEA Japan). Three days after transplantation, the tumors were divided into groups based on tumor volume, and the human chimeric CD147 antibody (LN22R 8chIgG4P), humanized CD147 antibody (#084H 1L2hIg4P or #110H1L4hIg4P) at 10mg / kg in tumor-bearing mice The mice were intraperitoneally injected with 100 mg / kg of 1000 mg once every 7 days for a total of 4 times (n=6). Measure twice a week using an electronic digital caliper (manufactured by Mitutoyo Corporation) and use the following calculation formula: The tumor volume was calculated by the following method.

[0376] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 46. The graph shows the mean and standard error for the changes in tumor volume. He wrote: The mean tumor volume in untreated mice was 918 mm 31 days after implantation. 3 whereas In the #084H1L2hIg4P group, the mean was 224 mm 3 , #110H1L4hIgG4 In the P-treated group, the mean age was 379 mm. 3 The calculated antitumor effect was #084H1L2hI The rate was 76% in the #110H1L4hIgG4P-administered group and 59% in the #110H1L4hIgG4P-administered group.

[0377] Example 22: Antibody-specific expression of humanized CD147 antibody in acute myeloid leukemia (AML) model Tumor effect Human AML cell line OCI-A confirmed to be CD147 positive by flow cytometry The antitumor effect of humanized antibodies on ML3 cells (DSMZ, Cat.ACC 582) was evaluated. I considered it.

[0378] 5×10 6 Human AML cell line OCI-AML3 cells were cultured at 50% GFR-Matr The mice were suspended in igel (Corning, Cat. 354230) and cultured with 5-week-old female NOD-s. cid mice (NOD.CB17-Prkdc <scid> / J, purchased from Claire Japan) The mice were subcutaneously transplanted into the axilla of each mouse. Three days after transplantation, the mice were divided into groups based on the tumor volume. - Humanized CD147 antibody (#110H1L4hIg4P) prepared in -4-2 was injected into the tail vein. The tumor-bearing mice were divided into groups and administered the drug at 10 mg / kg every 7 days (n=6). The major and minor diameters of the tumor were measured twice a week using electronic digital calipers (Mitutoyo Corporation). The tumor volume was calculated using the following formula.

[0379] Tumor volume (mm 3 ) = 1 / 2 x minor axis (mm) x minor axis (mm) x major axis (mm) The results are shown in Figure 47. The graph shows the mean and standard error for the changes in tumor volume. He wrote: The mean tumor volume in untreated mice was 1533 mm 21 days after implantation. 3 Whereas In the #110H1L4hIgG4P-administered group, the 3 and the calculated antitumor The tumor efficacy was 74% in the #110H1L4hIgG4P-administered group.

[0380] Example 23: Activity measurement of humanized anti-CD147 antibodies with different binding properties 5×10 6 Human pancreatic cell line MIA PaCa-2 was cultured in 50% GFR-Matrigel (Corning, Cat. 354230) was added to PBS and incubated at 4 weeks old female nude mice. e Armpit of mouse (BALB / c Slc-nu / nu, purchased from Japan SLC Co., Ltd.) The mice were divided into groups based on the tumor volume, and 7 days after the transplantation, We have developed three humanized CD147 antibodies (#110, #111, #112, #113, #114, #115, #116, #117, #118, #119, #120, #121, #122, #123, #124, #125, #126, #127, #128, #129, #130, #131, #132, H1L4hIgG4P, #110H13L02hIgG4P and #110H13L12h IgG4P (binding activity is shown in Table 6) was administered at 10 mg / kg into the tail vein of tumor-bearing mice ( (n=6). Gemcitabine (available from Eli Lilly Japan), a treatment for pancreatic cancer, was used as a control drug. (purchased from a third-party supplier) was administered at 400 mg / kg to the tail vein of tumor-bearing mice 3 and 10 days after transplantation (n= 6) The major and minor diameters of the transplanted tumors were measured twice a week using an electronic digital caliper (Mitutoyo Corporation). The tumor volume was calculated using the following formula.

[0381] The results are shown in Figure 48. The graph shows the mean and standard error for the changes in tumor volume. He wrote:

[0382] The tumor growth inhibition rate of the control drug gemcitabine was 66%, while that of both humanized The CD147 antibody also showed superior antitumor activity to gemcitabine at 10 mg / kg. did.

[0383] Example 24: Comparison of CD147 antibodies 24)-1 Evaluation of antigen binding of existing anti-CD147 antibodies As the competitive antibody, 4A5 and 5F6 antibodies of WO2010 / 036460, Purified antibodies were prepared based on the sequences described in the patent PPAT-082-03 of 061602. The dissociation constant with CD147 protein was measured using a Biacore T200 (GE Healthcare Human Antibody Ca (manufactured by Care Bioscience) was used. Using the Implant Kit (GE Healthcare Biosciences) The antibody was ligated to the immobilized anti-human IgG(Fc) antibody. The capture method captures the target substance as a target substance and measures the antigen as an analyte. The running buffer was HBS-EP+ (GE Healthcare B ioscience), and CM5 (GE Healthcare) as the sensor chip. A 10 μL competitive antibody (manufactured by Bioscience) was placed on the chip at 1 μg / mL. After addition at 1000μg / min for 60 seconds, the antigen dilution series (0.5 to 8μg) used in Example 2)-5 was added. (µg / mL) was added at a flow rate of 30 µL / min for 120 seconds, and the dissociation phase was then monitored for 300 seconds. The regeneration solution was 3M magnesium chloride (GE He (manufactured by Althcare Bioscience) was added at a flow rate of 20 μL / min for 30 seconds. The data were analyzed using a 1:1 binding model, with the association rate constant ka, dissociation rate constant kd, and The dissociation constant (KD; KD = kd / ka) was calculated. The dissociation constants of #1L2hIgG4P and #110H1L4hIgG4P are shown in Example 7. Calculated using the -1 method.

[0384] Table 8 shows the calculated dissociation constants, effector functions, and epitope region information. .

[0385] [Table 8]

[0386] 24)-2 Competitive ELISA with existing CD147 antibodies Humanized CD147 antibody (#084H1L2hIg4P) prepared in Example 6-4-2 Rui or #110H1L4hIg4P) was used to generate Recombinant Human CD 147 / Fc (Sino Biological Co., Ltd., Cat. 10186-H02H) The binding activity of was evaluated by competitive ELISA. The competing antibodies were 4A5, prepared in 24)-1, The 5F6 antibody and the PPAT-082-03 antibody were used. Human I was used as a competitive negative control antibody. As a competitive positive control antibody, #0 84H1L2hIg4P antibody, #84H1L2hIgG2 antibody, #110H1L4 Antibody #110chIgG2 was used against hIg4P.

[0387] PBS in a 96-well plate (Thermo Scientific, Cat. 43454) Recombinant Human CD147 / Fc diluted with 50 ul / well was added and stored at 4°C overnight. After removing the protein solution, 1% BSA 300 ul of PBS containing 100% ethanol was added and incubated at room temperature for 1 hour. The antibody solution (0, 0.2, 2, 20ug / ml) was added and incubated at room temperature for 2 hours. 25 ul of humanized CD147 antibody (#084H1L2hIg4P or #110H1L4hIg4P) was added to each well and incubated at room temperature for 2 hours. 2% Tween 20 (BIO RAD, Cat. 170-6531) in PBS After washing twice, 50 ul of anti-human IgG4 diluted 2000-fold with PBS containing 1% BSA was -HRP (Abcam, Cat. ab99823) was added and incubated at room temperature for 1 hour. PBS containing 0.05% Tween 20 (BIO RAD, Cat. 170-6531) After washing three times with 100 ml of ... at.00-4203-58) was added, and the mixture was incubated at room temperature for 15 to 20 minutes. The absorbance was measured using a plate reader (PerkinElmer, model name EnVision2104 ) was measured.

[0388] The results are shown in Table 8 and Figures 49(a) and (b).

[0389] #084H1L2hIg4P Recombinant Human CD147 / Binding to Fc was observed in the presence of hIgG and in the presence of existing CD147 antibodies at 1-10ug / ml. #110H1L4hIg4P Recombinant Human C Binding to CD147 / Fc was confirmed in the presence of hIgG and 0.1-10ug / ml of existing CD147 It was not inhibited in the presence of antibody, but was inhibited in the presence of #110chIgG2 antibody. The epitope of 1L2hIg4P is competed for by existing anti-CD147 antibodies. The epitope of #110H1L4hIg4P is not affected by the binding of existing anti-CD147 antibodies. It was found that this would not be possible. The epitope information of the H110H1L4h antibody shown in Example 17)-3 is shown in Table 8. Example 1) 2P10F, whose epitope was predicted by analysis using the CD147 mutant of -9 From the results of the binding competition test with the two antibodies (Example 2-8), it was found that the epitope of #084H1L2h The loop regions were predicted and are listed in Table 8.

[0390] 24)-3 ADCC evaluation of anti-CD147 antibodies The ADCC activity of the anti-CD147 antibody was evaluated according to the method of Example 1)-15. As a different condition from the method described in )-15, HepG2 cells (ATCC 61161) were used as ADCC target cells. HB-8065) ​​was used, and #110H1L4hIgG4 was used as the CD147 antibody. P, #084H1L2hIg4P, 4A5, 5F6, and PPAT-082-03 at 1μg / The evaluation was performed at a concentration of 1 ml. The measurements were carried out in triplicate, and the average value and standard deviation were calculated. Cellular 51 When Cr was detected, the result was considered to be ADCC positive (+). When Cr was less than 5%, the result was considered to be ADCC positive (+). The CC activity was determined to be negative (-). The results are shown in Table 8.

[0391] #110H1L4hIgG4P and #084H1L2hIg4P showed ADCC activity. The results were determined to be ADCC(-). 4A5, 5F6, and PPAT-082-03 showed a 5% More than 100 cells 51 Cr was detected and the result was ADCC positive (+). G4P, #084H1L2hIg4P, is ADCC negative and inhibits CD14 in vivo in humans. The possibility of inducing cell death in normal cells, such as blood cells, that express ADCC 7 It is predicted to be lower than the activity-positive 4A5, 5F6, and PPAT-082-03.

[0392] 24)-4 CDC evaluation of anti-CD147 antibodies According to the method of Example 1)-16, the complement-dependent cell killing activity ( The CDC activity was evaluated. As a condition different from that of the method of Example 1)-16, Human liver cell line HepG2 cells (ATCC, Cat. HB-8065) ​​were used, and anti-human CD1 47 antibodies: #110H1L4hIgG4P, #084H1L2hIg4P, 4A5 , 5F6 and PPAT-082-03 were used, and rabbit complement was added to a final concentration of 8%. The measurements were performed in triplicate, and the average and standard deviation were calculated. Antibodies that showed a CDC activity dependent on the antibody were recorded as CDC activity positive and were shown in the table as CDC(+ The results are shown in Table 8. Of the anti-human CD147 antibodies, only 4A5 showed positive CDC activity. #110H1L4hIgG4P, #084H1L2hIg4P, 5F6, P PAT-082-03 is CDC-negative and expresses CD147 in vivo in humans The possibility of inducing cell death in normal cells such as blood cells is higher than that of CDC-positive 4A5. It is expected to be lower than the 24)-5 ADCP evaluation of anti-CD147 antibody The ADCP activity of the anti-CD147 antibody was measured according to the method of Example 1)-17. As a different condition from the method of )-17, human liver line HepG2 cells (ATC C, Cat. HB-8065) ​​was used, and #110H1L4hIg was used as the anti-CD147 antibody. G4P, #084H1L2hIg4P, 4A5, 5F6, PPAT-082-03 at 1μ The labeled RAW264.7 cells were added at a concentration of 1 μg / ml, and the same amount of ADCP target cells were added. The ADCP activity was measured. The measurement was performed in triplicate, and the average value and standard deviation were calculated. A 10% or less increase in ADCP activity compared to the gG-treated group was considered weakly positive (±); The results are shown in Table 8 as positive (+).

[0393] The ADCP activity of #110H1L4hIgG4P was less than 10%, and the ADCC activity was ± The results were as follows: #084H1L2hIgG4P, 4A5, 5F6, PPAT-082-03 anti- The ADCP activity in the whole body was 10% or more, and the result was determined to be ADCP activity positive. #110H1L4hIgG4P, which recognizes CD147-D1, is a different CD147 ADCP was less active than the CD147 antibody. After this, the Fc portion of the antibody is bound to the Fcγ receptors expressed on macrophages and monocytes. However, the epitope of antibody #110 is close to the cell surface and is not a target for antigen recognition. The FC portion of the antibody that binds to CD147 is more specific than other antibodies that recognize CD147-D1. It is possible that the antibody is less likely to be recognized by Fcγ receptors and therefore has lower ADCP activity. H1L4hIgG4P, weakly positive for ADCP activity, expresses CD147 in vivo in humans ADCP activity positive cells may induce cell death in healthy cells such as blood cells. #084H1L2hIg4P, 4A5, 5F6, and PPAT-082-03 It is predicted that...

[0394] (Example 25) 25)-1 Hematological cell aggregation by anti-CD147 antibody Some anti-CD147 antibodies have been reported to induce aggregation of blood cells (Ka Sinrerk et al. Immunology 1999,96(2)p184-192). Aggregation of cytoplasmic cells can cause severe hematologic toxicity (Doll, C., et al., 1994, Curr. Opin. Oncol., 345-350), therapeutic antibodies These are undesirable properties for anti-CD147 antibodies. The CD147 antibodies #110H1L4hIgG4P and #084H1L2hIg 4P, 4A5, 5F6, and PPAT-082-03 were evaluated. Human IgG was used as a negative control antibody. IgG (hIgG, ChromPure Human IgG, Jackson Imm unoResearch Laboratories, Cat.009-000-00 3) was used. HEL92.1.7 cells (purchased from ATCC, Cat.#TIB-180 ) into a 96-well U-bottom plate (Sumitomo Bakelite Co., Ltd., Cat. MS-9096U). 1600 cells per well / 80 uL 10% FBS (Hyclone, Ca RPMI 1640 medium (Thermo Fisher Scientific) containing Tiffiq Co., Ltd., Cat. 11875-093) was added and incubated at 5% CO2 and humidity of 9% for 4 hours. The cells were incubated at 37°C with 5% CO. Each well was filled with 20 ul of anti-CD147 antibody solution (150 ul). The final concentrations were adjusted to 30 and 10 ug / ml. The cells were cultured for two days under conditions of 95% humidity and 37 degrees, and then observed under a microscope.

[0395] No cell accumulation was observed with the addition of human IgG, #110H1L4hIgG4P. In contrast, #084H1L2hIg4P, 4A5, 5F6, and PPAT-082-03 antibodies In the presence of the endothelial cells, the cells accumulated and a folded cell mass was observed in the center of the plate. #110H1L4hIgG4P, which recognizes D147-D2, binds to the CD147-D1 domain. Unlike other CD147 antibodies that recognize CD147, it was shown to have no blood cell agglutination activity. CD147 antibodies with cell agglutination activity, including #084, when administered to humans, It is not used to treat blood clots because it may cause toxici...

Claims

1. A human CD147 antibody or an antigen-binding fragment thereof, the heavy chain sequence comprises a variable region having a CDRH1, a CDRH2 and a CDRH3, said CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 75, said CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 76 and said CDRH3 consisting of the amino acid sequence set forth in SEQ ID NO: 77; and the light chain sequence comprises a variable region having CDRL1, CDRL2 and CDRL3, said CDRL1 consisting of the amino acid sequence set forth in SEQ ID NO:72, said CDRL2 consisting of the amino acid sequence set forth in SEQ ID NO:73 and said CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:74; The human CD147 antibody or an antigen-binding fragment of the antibody,

2. A human CD147 antibody or an antigen-binding fragment of said antibody described in claim 1, which activates signal transduction via CD147.

3. A human CD147 antibody or an antigen-binding fragment of said antibody described in claim 1, characterized in that it competes for binding to human CD147 with an antibody comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 71 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO:

69.

4. A human CD147 antibody or an antigen-binding fragment of said antibody according to claim 1, characterized in that it binds to an epitope to which an antibody comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 71 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 69 binds.

5. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, which has reduced or absent ADCC activity.

6. A human CD147 antibody or an antigen-binding fragment of said antibody according to any one of claims 1 to 5, which has reduced or absent CDC activity.

7. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, which has reduced or absent ADCP activity.

8. A human CD147 antibody or an antigen-binding fragment of said antibody according to any one of claims 1 to 7, which binds to an epitope comprising residues from arginine (Arg) at position 106 to glycine (Gly) at position 165 of SEQ ID NO:

3.

9. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, which binds to an epitope comprising the following residues in the amino acid sequence of SEQ ID NO:3: arginine (Arg) at position 106, lysine (Lys) at position 108, alanine (Ala) at position 109, valine (Val) at position 110, lysine (Lys) at position 127, serine (Ser) at position 128, glutamic acid (Glu) at position 129, serine (Ser) at position 130, valine (Val) at position 131, proline (Pro) at position 132, proline (Pro) at position 133, valine (Val) at position 134, glutamine (Gln) at position 164, and glycine (Gly) at position 165.

10. An antigen-binding fragment of the human CD147 antibody according to any one of claims 1 to 9, selected from the group consisting of Fab, F(ab')2, Fab' and Fv.

11. An antigen-binding fragment of a human CD147 antibody according to any one of claims 1 to 9, characterized in that it is an scFv.

12. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, characterized in that it is a chimeric antibody.

13. The human CD147 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 9, characterized in that it is humanized.

14. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, 12 and 13, wherein the heavy chain comprises a constant region of a human immunoglobulin G1 heavy chain, a human immunoglobulin G2 heavy chain or a human immunoglobulin G4 heavy chain, and the light chain comprises a constant region of a human immunoglobulin κ light chain.

15. The human CD147 antibody or antigen-binding fragment thereof described in claim 14, wherein the heavy chain comprises the constant region of a human immunoglobulin G4 heavy chain.

16. A human CD147 antibody or an antigen-binding fragment of said antibody according to claim 15, in which serine (Ser) at position 228 as indicated by the EU index in the constant region of the human immunoglobulin G4 heavy chain is replaced by proline (Pro).

17. A human CD147 antibody or an antigen-binding fragment of said antibody according to claim 15, in which in the constant region of the human immunoglobulin G4 heavy chain, phenylalanine (Phe) at position 234 as indicated by the EU index is replaced with alanine (Ala), and leucine (Leu) at position 235 is replaced with alanine (Ala).

18. A human CD147 antibody or an antigen-binding fragment of said antibody according to claim 15, in which in the constant region of the human immunoglobulin G4 heavy chain, serine (Ser) at position 228 as indicated by the EU index is replaced by proline (Pro), phenylalanine (Phe) at position 234 is replaced by alanine (Ala), and leucine (Leu) at position 235 is replaced by alanine (Ala).

19. The human CD147 antibody or antigen-binding fragment thereof described in claim 14, wherein the heavy chain comprises the constant region of a human immunoglobulin G2 heavy chain.

20. A human CD147 antibody or an antigen-binding fragment of the antibody, characterized in that it has the following (c) and (d): (c) A heavy chain variable region selected from the group consisting of the following (c1) to (c4): (c1) a heavy chain variable region consisting of amino acid residues 20 to 136 of the amino acid sequence set forth in SEQ ID NO: 135; (c2) a heavy chain variable region consisting of amino acid residues 20 to 136 of the amino acid sequence set forth in SEQ ID NO: 147; (c3) an amino acid sequence having at least 95% sequence identity to the sequence of a framework region other than each CDR sequence in the sequence of (c1) or (c2); and (c4) An amino acid sequence in which one or several amino acids are deleted, substituted or added in the sequence of a framework region other than each CDR sequence in any one of (c1) to (c3), and (d) A light chain variable region selected from the group consisting of the following (d1) to (d5): (d1) a light chain variable region consisting of amino acid residues 21 to 128 of the amino acid sequence set forth in SEQ ID NO: 137; (d2) a light chain variable region consisting of amino acid residues 21 to 128 of the amino acid sequence set forth in SEQ ID NO: 149; (d3) a light chain variable region consisting of amino acid residues 21 to 128 of the amino acid sequence set forth in SEQ ID NO: 151; (d4) an amino acid sequence having at least 95% sequence identity to the sequence of a framework region other than each CDR sequence in any one of (d1) to (d3); and (d5) An amino acid sequence in which one or several amino acids have been deleted, substituted or added in the sequence of a framework region other than each CDR sequence in any one of (d1) to (d4).

21. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain variable region consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 135, and a light chain variable region consisting of the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO:

137.

22. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain consisting of amino acid residues 20 to 463 of the amino acid sequence shown in SEQ ID NO: 135, and a light chain consisting of amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:

137.

23. 23. The human CD147 antibody of claim 22, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.

24. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain variable region consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 147, and a light chain variable region consisting of the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO:

149.

25. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain consisting of amino acid residues 20 to 463 of the amino acid sequence shown in SEQ ID NO: 147, and a light chain consisting of amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:

149.

26. 26. The human CD147 antibody of claim 25, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.

27. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain variable region consisting of the 20th to 136th amino acid residues of the amino acid sequence shown in SEQ ID NO: 147, and a light chain variable region consisting of the 21st to 128th amino acid residues of the amino acid sequence shown in SEQ ID NO:

151.

28. A human CD147 antibody or an antigen-binding fragment of said antibody, comprising a heavy chain consisting of amino acid residues 20 to 463 of the amino acid sequence shown in SEQ ID NO: 147, and a light chain consisting of amino acid residues 21 to 234 of the amino acid sequence shown in SEQ ID NO:

151.

29. 29. The human CD147 antibody of claim 28, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.

30. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 20 to 29, which has reduced or absent ADCC activity.

31. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 20 to 30, which has reduced or absent CDC activity.

32. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 20 to 31, which has reduced or absent ADCP activity.

33. The human CD147 antibody or antigen-binding fragment thereof according to any one of claims 2 and 5 to 19, wherein the activation of signal transduction mediated by CD147 is activation of p38 MAPK and / or activation of SMAD4.

34. The human CD147 antibody or antigen-binding fragment of said antibody according to claim 33, wherein the activation of p38MAPK and / or activation of SMAD4 is an increase in the expression level of p38MAPK, phosphorylation of p38MAPK, phosphorylation of HSP27, an increase in the expression level of CXCL8, an increase in the expression level of rhoB, a decrease in KLF5 mRNA or a decrease in the expression level of KLF5 protein.

35. An antibody-drug conjugate comprising a human CD147 antibody or an antigen-binding fragment of said antibody according to any one of claims 1 to 34 conjugated to another drug.

36. A bispecific antibody comprising an antigen-binding fragment of a human CD147 antibody described in any one of claims 1 to 34 and an antigen-binding fragment that binds to an antigen other than CD147.

37. A pharmaceutical composition comprising at least one of a human CD147 antibody, an antigen-binding fragment of the antibody, an antibody-drug conjugate, or a bispecific antibody according to any one of claims 1 to 36.

38. 38. The pharmaceutical composition of claim 37, which is an antitumor agent.

39. The pharmaceutical composition of claim 38, wherein the tumor is a tumor that expresses CD147.

40. The pharmaceutical composition according to claim 38 or 39, wherein the tumor is pancreatic cancer, liver cancer, gastric cancer, colon cancer, kidney cancer, breast cancer, uterine cancer, ovarian cancer, lung cancer, lymphoma, thyroid cancer, skin cancer, head and neck cancer, sarcoma, prostate cancer, bladder cancer, brain tumor, gastrointestinal stromal tumor (GIST), leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), malignant lymphoma, B-cell lymphoma, non-Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL).

41. The pharmaceutical composition according to any one of claims 38 to 40, wherein the tumor is pancreatic cancer, liver cancer, gastric cancer, colon cancer, renal cancer, leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), malignant lymphoma, B-cell lymphoma, non-Hodgkin's lymphoma, or diffuse large B-cell lymphoma (DLBCL).

42. The pharmaceutical composition according to any one of claims 38 to 41, wherein the tumor is a SMAD4-positive tumor or a tumor in which expression of KLF5 is reduced or deleted.

43. The pharmaceutical composition according to any one of claims 37 to 42, further comprising another antitumor agent.

44. The pharmaceutical composition according to any one of claims 37 to 42, which is administered simultaneously with another antitumor agent by being encapsulated in the same formulation, or which is administered separately from the other antitumor agent by being encapsulated in a different formulation at the same time or before or after the other antitumor agent.

45. A polynucleotide encoding a human CD147 antibody or an antigen-binding fragment of said antibody according to any one of claims 1 to 34.

46. The polynucleotide of claim 45, comprising a polynucleotide encoding a CDRH1 consisting of the amino acid sequence set forth in SEQ ID NO: 75, a CDRH2 consisting of the amino acid sequence set forth in SEQ ID NO: 76, and a CDRH3 consisting of the amino acid sequence set forth in SEQ ID NO: 77, and a polynucleotide encoding a CDRL1 consisting of the amino acid sequence set forth in SEQ ID NO: 72, a CDRL2 consisting of the amino acid sequence set forth in SEQ ID NO: 73, and a CDRL3 consisting of the amino acid sequence set forth in SEQ ID NO:

74.

47. 47. An expression vector containing the polynucleotide of claim 45 or 46.

48. A host cell transformed with the expression vector of claim 47.

49. A method for producing a human CD147 antibody or an antigen-binding fragment of the antibody described in any one of claims 1 to 34, comprising the steps of culturing the host cell described in claim 48 and collecting the target antibody or an antigen-binding fragment of the antibody from the culture product.

Citation Information

Patent Citations

  • Anti-CD147 antibody, method and use

    JP2012506369A

  • Anti-CD147 antibody

    JP7271424B2

  • CD147 binding molecules as therapeutics

    WO1999045031A2

  • Anti-CD147 antibodies, methods, and uses

    WO2010036460A2

  • Antibody capable of specifically binding to CD147 molecule, and use thereof

    WO2017061602A1